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A peptide is defined, as a molecule that contains less than fifty amino acids; anything 
larger is a protein.
1
 Peptides are important molecules because they have diverse uses. Peptides 
were utilized in two ways: 1) Peptide bioconjugates containing a fluorescent porphyrin or 
phthalocyanine macrocycle were designed and investigated, with or without a PEG moiety for 
selective targeting of the epidermal growth factor receptor (EGFR). 2) Amyloid aggregating 
mitigating peptides (AAMPs) was synthesized and investigated containing polar amino acids, 
MiniPEGs, and/or !!AAs that have the ability to inhibit and disrupt Amyloid Beta (A"). The 
peptide bioconjugates containing a porphyrin or phthalocyanine were able to selectively target 






INTRODUCTION TO PEPTIDE CHEMISTRY 
 
1.1 Introduction  
 
Amino acids are the building blocks of peptides and proteins. There are twenty essential 
amino acids that are DNA encoded along with unusual amino acids such as L and D amino acids, 
! and " amino acids, N-methylated amino acids, and #,#-disubstituted amino acids. These amino 
acids are used to generate various peptides and protein sequences. Peptides are mostly 
synthesized using standard Fmoc chemistry, other methods can be employed such as the acyl 
chloride method, acyl azide method, anhydrides, active esters, and coupling agents. Peptides 
have proven to be useful molecules for the treatment of different diseases, generation of 
nanofibers, and for chemical imaging. Peptides were utilized in two ways, 1)  Peptide 
bioconjugates were designed containing a fluorescent porphyrin or phthalocyanine macrocycle 
with or without a PEG moiety that selectively targets the epidermal growth factor receptor 
(EGFR). 2)  Peptides were designed to behave as amyloid aggregating mitigating peptides 
(AAMPs) that have the ability to inhibit and disrupt Amyloid Beta (A!). The peptide 
bioconjugates containing a porphyrin or phthalocyanine were able to selectively target EGFR 
and select AAMPs were able to inhibit and disrupt Amyloid Beta (A!). 
 
1.1.1 Amino Acids 
Amino acids are small molecules that contain an N-terminus, C-terminus, #-carbon, and 
side chain. They are the building blocks of peptides and proteins.
1
 There are different groups of 
amino acids including natural and unusual amino acids. There are twenty essential amino acids 
that are encoded by DNA. Each amino acid is different due to the nature of its side chain and is 
categorized into four groups based on the properties of their side chains: acidic, basic, uncharged 
 
 2 
polar, and nonpolar. Amino acids can be represented by a three-letter abbreviation or a one-letter 
abbreviation as shown in Table 1. Table 1 lists the 20 natural amino acids, their three-letter and 
one-letter abbreviations, and common protecting groups. The four different categories are color 
coded as acidic amino acids (blue), basic amino acids (red), uncharged polar amino acids (green) 
and nonpolar amino acids (purple).  
 
Table 1-1: Amino Acids 
# Category Name Symbol Code Common Protecting Group 
1 Acidic Aspartic Acid Asp D Fmoc-L-Asp 
2 Glutamic Acid Glu E Fmoc-L-Glu(Otbu)-OH 
3 Basic Lysine Lys K Fmoc-L-Lys(Boc)-OH 
4 Arginine Arg R Fmoc-L-Arg (Pbf)-OH 
5 Histidine His H Fmoc-L-His (Trt)-OH 
6 Uncharged 
Polar 
Asparagine Asn N Fmoc-L-Asn (Trt)-OH 
7 Glutamine Gln Q Fmoc-L-Gln (Trt)-OH 
8 Serine Ser S Fmoc-L-Ser(Otbu)-OH 
9 Threonine Thr T Fmoc-L-Thr (tBu)-OH 
10 Tyrosine Tyr Y Fmoc-L-Tyr (tBu)-OH 
11 Nonpolar Alanine Ala A Fmoc-L-Ala-OH 
12 Valine Val V Fmoc-L-Val-OH 
13 Methionine Met M Fmoc-L-Met-OH 
14 Tryptophan Trp W Fmoc-L-Trp (Boc)-OH 
15 Leucine Leu L Fmoc-L-Leu-OH 
16 Isoleucine Ile I Fmoc-L-Ile-OH 
17 Glycine Gly G Fmoc-Gly-OH 
18 Cysteine Cys C Fmoc-Cys(Trt)-OH 
19 Phenylalanine Phe F Fmoc-Phe-OH 
20 Proline Pro P Fmoc-L-Pro-OH 
 
 All natural amino acids, except glycine, have one chiral center that is located at the !-
carbon. Amino acids contain an N-terminus, C-terminus, !-carbon, and side chain as shown for 
Leu in Figure 1. The C-terminus of the amino acid has an acidic pKa range of 1.8 to 2.4 and the 
N-terminus of the amino acid has a basic pKa range of 9 to 10.8. Only seven amino acids (Arg, 
Asp, Cys, Gln, His, Lys, and Tyr) have a pKa range of 3.9 to 12.5 for the side chain. Amino 
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acids with an ! chiral center has two stereoisomers, the L and D enantiomers. The L-enantiomer 





Figure 1-1: Amino Acid: Leu. 
 
D-enantiomers, D-Ala and D-Glu, are found in polypeptides from select bacterial cell walls.
2
 The 
L and D enantiomers of Leu are shown in Figure 1-2. L and D isomers rotate the plane of 















There is an abundant source of unusual amino acids that are not DNA encoded. Examples 
consist of ornithine that is found in several antibiotics and hydroxyproline, which is a constituent 
found in collagen. Ornithine and hydroxyproline are similar in structure to Lys and Pro, 
respectively. Betaine is used as a methylating agent to synthesize methionine. !-amino acids and 
" amino acids are also unusual amino acids. These amino acids differ in the relative positioning 
of the amine and carboxylic acid groups. Figure 1-3 is an example of these unusual amino acids. 
 
 
Figure 1-3: Examples of (A) ! amino acids (B) " amino acids. 
 
N-methylated amino acids are unusual amino acids that are found in several natural peptides and 
proteins such as haliclamide, pseudomonas aeruginosa, pseudomonas, and staphylomycins.
3
 N-
methylated amino acids have been used to increase the liphophilicity and permeability of 
peptides.
3
 Figure 1-4 shows N-methylated Gly that is known as sarcosine.  
 
 



























!,!-Disubstituted amino acids (!!AAs) are important amino acids due to their stability toward 
racemization in vivo and restricted conformational flexibility.
4
 !!AAs are present in many 
biologically active compounds and some antibiotics, such as altemicidin.
4
 An example of an 
!!AAs (the !,!-dibenzylglycine, Dbzg) is shown in Figure 1-5. Dbzg is similar to phenylalanine 
except it has an additional benzyl functionality at the !-C of the amino acid.  
 
 
Figure 1-5: Structure of Dbzg. 
 
Amino acids are the building blocks of peptides because more than one amino acid can be joined 
through a peptide bond to form different molecules, depending on the sequence.
1
 A peptide bond 
is an amide bond that is formed when the C-terminus of one amino acid reacts with the N-
terminus of another amino acid.  
Peptides have resonance structures between the carbonyl carbon and the amine group, as 
shown in Figure 1-6.
1,5
 The partial negative charge is on the oxygen due to its electronegativity 
and the partial positive charge is on the nitrogen.   
 
 























1.1.2 Solution Ionization of Amino Acids 
Amino acids have various ionization properties due to the amine and carboxylic acid 
group that can accept and donate a proton. Each amino acid can behave as zwitterion when the 
amine is pronated and the carboxylic acid is deprotonated, at pH 7 (see Figure 1-7).
5
 These 
compounds are also known as amphoteric or ampholytes. The charge of the amino acid can 
affect its chemical behavior and its physical properties.
1
 Amino acids are involatile solids with 
high melting points due to its zwitterions forming strong ionic interactions between each other.
1
 
Amino acids also have isoelectric points, pI, that are obtained when the net charge of the amino 
acid is 0.  
 
 
Figure 1-7: Zwitterionic form of an amino acid. 
 
Amino acids have both hydrophobic (water hating) and hydrophilic (water loving) 
properties. Examples of hydrophobic and hydrophilic amino acids are valine, phenylalanine, 
tyrosine, and glutamic acid, serine, and lysine, respectively. The hydrophobic and hydrophilic 
character of a peptide can influence its behavior in biological systems. 
 
1.1.3 Peptides 
Peptides contain amino acids that are joined through amide bonds. A peptide is defined, 
as a molecule that contains less than fifty amino acids; larger is a protein. The amino acid 







of sequences. A peptide sequence is normally read from left to right, starting with the N-terminus 
and ending with the C-terminus.  
The C-terminus of the peptide has a free carboxylic acid or synthetically it can have an 
amide terminus. The functionality of the peptides C-terminus (carboxylic acid or amide) is 
determined by the resin. Resins are used as a solid support linkage for synthesizing peptides. 
Different types of resins are used for carboxylic acid functionality such as Wang resin, HMPA 
resin, and Rink Acid resin. Examples of resins for amide functionality on the C-terminus are 
Sieber resin, Fmoc-PAL-PEG resin, and Rink amide resin.  
 
1.1.4 Formation of Peptide Bonds 
The formation of a peptide bond can occur using two processes: stepwise elongation or 
fragment condensation. Stepwise elongation occurs by joining amino acids one amino acid at a 
time. Fragment condensation is the combination of two separate peptides to produce a larger 
peptide. Peptide bonding begins by activation of the carboxylic acid groups into acylating 
agents.
5
 The hydroxyl group is replaced by an electron withdrawing substituent, thus enhancing 
the polarization of the carbonyl group, making the carbonyl carbon a more electrophilic atom.
5
 
This will make the carbonyl carbon atom more susceptible to nucleophilic attack.
5
 Peptide bonds 
can be formed using the acyl chloride method, acyl azide method, anhydrides, active esters, and 
coupling agents.  
Emile Fischer proposed the use of acid chlorides in 1903 to form peptide bonds.
5,6
 
Different methods for preparing acid chlorides consist of but not limited to using phosphorous 
pentachloride, thionyl chloride, and acylamino acid chlorides.
5,6
 Scheme 1-1 shows the reaction 
of a Y protected amino acid with phosphorous pentachloride in order to generate an acid 
 
 8 
chloride. The chloride group is a good leaving group (weak base). The acid chloride formation 
conditions are harsh for complex or sensitive substrates.
5
 Acylamino acid chlorides can cyclize 
to produce oxazolones and racemic peptides.
5,6
 An improved method requires the use of Fmoc 
protected amino acid chlorides that are easy to prepare and have stable intermediates. 
 
 
Scheme 1-1: Carboxylic acid activation using an acid chloride method. 
 
Acyl azide formation was first introduced by Curtius in 1902.
5,6
 As shown in Scheme 1-2 
this method uses excess hydrazine hydrate to generate a diimine. This product is treated with 
nitrous acid to produce the azide. Due to the abundance of side reactions that can occur, this 
approach is not commonly used for the stepwise elongation of amino acids although it can be 





Scheme 1-2: Peptide bond formation using acyl azide method. 
 
Anhydrides can be employed in two ways to generate amide bonds using symmetrical 
and mixed anhydrides.
5,6
 Anhydrides are not as reactive as acid chlorides but they are more 
selective in their reaction. Symmetrical anhydrides can be obtained from !-amino acids protected 




with phosgene or with carbodiimides.
6


















































amino acids are very reactive intermediates for peptide bond formation.
6
 Scheme 1-3 shows the 
formation of a peptide bond between a symmetrical anhydride and a primary amine. A tripeptide 
is generated along with a protected amino acid. Mixed anhydrides can be employed using 
various methods: with carboxylic acids, carbonic acids, and with diphenylphosphinic acid.
6
 The 
method generally used is mixed anhydrides with carbonic acids. This involves the generation and 
aminolysis of a carboxylic-carbonic anhydride.  
 
 
Scheme 1-3: Formation of a peptide bond using symmetrical anhydrides.  
 
Scheme 1-4 shows that only one carbonyl component is activated in the intermediate. The 
presence of oxygen atoms and bulky R groups diminishes the other carbonyl reactivity.
6
 
Therefore, nucleophilic attack is directed towards the original carbonyl component.
6
 This 
approach is used in stepwise synthesis and is rarely used for fragment condensation. 
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N-Carboxyanhydrides (NCAs) also known as Leuchs’ anhydrides of !-amino acids can 
be obtained using different methods applying the use of phosgene with !-amino acids or by 
thermal decomposition of alkoxycarbonyl !-amino acid chlorides.
5,6
 NCAs are beneficial for 
peptide bond formation in two ways. First, a small amount of initiator in an organic solvent is 
added to NCA, this leads to successive ring opening and loss of carbon dioxide. This generates a 
new nucleophile that can attack another molecule of NCA (causing a repetitive cycle) leading to 
the formation of a homopolyamino acid as shown in Scheme 1-5. Second, under carefully 
controlled conditions NCAs are also used for rapid peptide synthesis in aqueous conditions. 
However, carbamic acids produced by NCAs are unstable and decarboxylation can occur before 
aminolysis is complete.
5,6
 Hence, the need for carefully designed conditions. 
 
 
Scheme 1-5: Formation of a peptide bond using NCAs.  
 
Active esters (AE) are typically prepared using DCCI- mediated coupling between a 
protected amino acid and the ester moiety.
5,6
















































reduced side reactions and are utilized for aqueous coupling reactions. Scheme 1-6 shows the 
formation of a peptide bond using ! Fmoc protected amino acids via an active ester HOPfp.  
 
  
Scheme 1-6: Formation of a peptide bond using active esters.  
 
N-hydroxysuccinimide is used for water-insoluble protected peptides and for stabilizing 
O’acylisourea intermediate generated for EDC coupling. For water-soluble products a 
halophenyl ester is used because halophenols are ether soluble. 
The most efficient method for peptide bond formation is the use of coupling agents and 
coupling additives.
5,6
 Different coupling agents can be used such as carbodiimide (see Figure 1-8 











































Each of these coupling agents has different coupling pathways in which they proceed. Coupling 
additives are used to reduce racemization. Examples of coupling additives are HOBT and C1-
HOBT, which are known as OBt active esters.  
 
 
Figure 1-9: Aminium coupling agents. 
 
The solid phase peptide synthesis is a method that is currently and commonly used to synthesize 
peptides using standard Fmoc chemistry, that was first proposed by Merrifield.
7a
 An automated 
synthesizer is used to swell the resin of choice with a polar aprotic solvent such as DMF.  
 
 
Figure 1-10: Phosphonium coupling agents. 
 
Swelling the resin causes the active sites to be more exposed. The first amino acid is added to the 
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Double coupling is a process by which the first amino acid is coupled twice but only on the 
second coupling the protecting group (Fmoc) is removed, using a mixture of two bases 
(Piperdine, DBU) in a solvent such as DMF (Step 2, Scheme 1-7). The next amino acid is then 
added and the process is repeated until the desired peptide is obtained (Step 3, Scheme 1-7).  In 
the final step the protecting group is removed from the last amino acid and the peptide is cleaved 
from the resin. 
 
 
1.1.5 Cyclic Peptides 
Cyclic peptides are cyclic rings that have restrictions on conformation, increased 
stability, and reduce the absorption of the molecule.
8
 Cyclic peptides are formed using linear 
peptides with a free carboxylic acid (C-terminus) and free amine (N-terminus) groups. The linear 
peptide is then cyclized using coupling agents under dilute conditions.  
 
 
Figure 1-11: Cyclic hexapeptide. 
 
Cyclic peptides have been synthesized in different sizes, such as cyclic tripeptides, cyclic 
tetrapeptides, cyclic pentapeptides, and cyclic hexapeptides.
8
 The structure of a generic cyclic 
















is needed for oral availability.
9
 Conformations of cyclic peptides are determined by the number 




1.1.6 Determining the Primary Structure of a Peptide 
Determining the primary structure of a peptide or protein can be performed using several 
methods, the most common are nuclear magnetic resonance (NMR), mass spectrometry (MS), 
and circular dichroism (CD). In 1953, Fredrick Sanger performed the first known protein 
sequencing of insulin.
10
 There are two common ways to determine the sequence of a peptide, 
using a chemical or an enzymatic methodology. A chemical methodology is normally used for 




























































One method is using 1-dimethylamino-naphthalene-5-sulfonyl chloride (dansyl chloride), which 
reacts with the primary amine producing dansylated polypeptides.
10
 This is followed by an acid 
hydrolysis work-up that produces a N-terminal residue as a dansylamino acid, which has intense 
yellow fluorescence (see Scheme 1-8). Both dansyl chloride and Edman degradation are used for 
determining the sequence of small peptides.
10
 To date, Edman degradation is one of the best 
techniques used to determine the sequence of a peptide starting from the N-terminus and ending 
with the C-terminus. 
10,11
 
Scheme 1-9 shows the reaction of Edman degradation, which proceeds in three steps: 
coupling, cleavage, and conversion.
10,12
 Coupling begins when phenylisothiocyanate (PITC, 
Edman’s reagent) reacts with the N-terminal group under mildly alkaline basic conditions to 
produce phenylthiocarbamyl (PTC). 
 
 



























































Cleavage occurs by using an anhydrous acid work-up with TFA that cleaves the N-terminal 
residue producing thiazolinone and the remaining peptide sequence. Conversion is the work-up 
of thiazolinone to its more stable product phenylthiohydantoin (PTH) using aqueous conditions.  
The C-terminus end group is often determined by using enzymatic degradation with 
different enzymes such as exopeptidases.
10,13
 There are different classes of exopeptidases, 
including carboxypeptidases, aminopeptidases, and dipeptidases. Each peptidase has its own 
function. Carboxypeptidases are used for cleaving amino acids from the C-terminus of a peptide. 
The use of carboxypeptidases for determining the amino acid sequence of a peptide is not 
accurate since it can cleave more than one amino acid at a time, causing sequence determination 
to be difficult. The aminopeptidases are used to determine the amino acid sequence by beginning 
with the N-terminus and cleaving each amino acid thereafter of a polypeptide. Dipeptidases are 
used to hydrolyze bound pairs of amino acids called dipeptides.  
Peptides that have more than 40 residues cannot be directly sequenced. Larger peptides 
and proteins must be first cleaved into smaller segments in order to determine its amino acid 
sequence. The specific peptide cleavage approach must be accurate and highly specific to ensure 































Trypsin is a serine protease that is found in the digestive system of invertebrates. This enzyme 
has the ability to cleave peptide bonds after positively charged residues.
10
 Trypsin will cleave the 
carboxylic functional group of amino acids such as lysine and arginine. If these amino acids are 
followed by proline then it will not cleave the peptide at that residue. Scheme 1-10 shows the 
enzyme trypsin cleaving the peptide at the lysine residue. Another way to specifically cleave 
polypeptides is by using cyanogen bromide.
10
 Cyanogen bromide is a pesudohalogen that cleaves 






Scheme 1-11: Mechanism of cyanogen bromide cleaving a peptide at a methionine residue. 
 
This reaction is performed in acidic conditions that will denature the protein allowing cleavage to 
occur at all methionine residues. Scheme 1-11 shows the mechanism of cyanogen bromide 























































acid sequence can be determined by further fragmentation to determine each residue using 
Edman degradation.  
Mass spectrometry (MS) is commonly used to determine the amino acid sequence of 
peptides. MS is a technique that allows for ionization of gas phase molecules to be analyzed. 
Matrix-assisted lasers desorption ionization (MALDI) and electrospray ionization (ESI) are two 
MS techniques that ionize large molecules with little to no fragmentation. In particular, MALDI-
MS-MS is a growing technique that provides high sensitivity and uses a target platform with a 
matrix to assist in the generation of ions by forming crystals with the molecule.
14
 Different 
modes, including laser-induced dissociation (LID), high-energy collision-induced dissociation 
(CID) or in-source decay in the reflector mode (reISD), are then used to fragment the peptides 
into multiple amino acids fragments generating a mass spectrum list of the ions generated.
14
 To 
determine the peptide sequence MALDI-MS-MS employs the use of the peptide mass fingerprint 
(PMF) to screen a protein sequence database, when the sequence is not known. The mass 
spectrum list is screened against the PMF and provides useful information for an amino acid 
sequence.
14
 When the peptide sequence is known, the data is compared to different software 
programs, such as Analyst QS, that predicts fragmentation of the known peptide. These 
approaches provide information that determines the sequence of the peptide with its molecular 
weight.
14
   
 
1.1.7 Secondary Structure of a Peptide 
All peptide bonds have a planar structure. The backbone of a peptide is defined as the 
amine, the ! carbon, and the carbonyl carbon; these atoms are highlighted in blue (in Figure 1-
12).  Figure 1-13 shows that the carbonyl carbon, the oxygen atom, the amide nitrogen, and the 
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hydrogen atom lie in the plane. The side chains of the peptides are trans to each other and the ! 





Figure 1-12: Planar peptide (backbone highlighted in blue). 
 
Peptides have a torsional angle (") that is equal to 0. The torsional angle of the peptide bond 
consists of two parts phi and psi (# and $).  
 
 
Figure 1-13: Peptide structure in a plane. 
 
When both the phi and psi are equal to zero the peptide is planar.
1
 Peptides can adopt different 
secondary structures including a well-defined conformation and those that do not have a well-
defined conformation. Peptides that do not have a well-define conformation are known as having 
a random coil conformation. Random coil conformations typically show in their CD spectra 























Peptides that have a well-defined secondary structure are classified into alpha helix (!-
helix), beta sheet ("-sheet), and turns and loops. In this dissertation turns and loops will not be 
discussed. For the !-helix structure, the peaks observed are at 197 nm and is a weak positive 
peak, 205 nm and 216 nm are both negative peaks.15-16 The !-helix has a spiral structure that is 
stabilized by intramolecular hydrogen bonding between the carbonyl oxygen and amide 
hydrogen roughly four residues apart. The amide hydrogen bonds are parallel to the axis of the 
helix allowing 3.6 residues in one turn with a pitch (distance between turns) of 5.4 Å, (Figure 1-
14).5  This allows the carbonyl oxygen and amide nitrogen to have a repeating distance of 1.5 Å. 
 
 
Figure 1-14: Model of !-helix. 
 
"-Sheet conformations have characteristic peaks at 195 nm (positive peak) and at 216 nm 
(negative peak), as seen in Figure 1-15.15-16,18 "-Sheets form by having more than one peptide 
chain connected through hydrogen bonding.5 The different chains can be parallel or anti-parallel. 































Figure 1-15: Model of a !-sheet.
 
 
1.1.8 Applications of Peptides 
Peptides are important molecules with diverse uses. Peptides can be found in animals, 
plants, and humans or synthesized (unnatural peptides). Each peptide in living systems has 
specific uses and different applications. When a specific peptide sequence is isolated and 
determined this provides a way to investigate its medicinal properties. The use of synthetic 
peptides is another way to exploit the current medicinal properties and change its properties 
through the use of un-natural amino acids, N-methylated amino acids, ","-disubstituted amino 
acids. Synthetic peptides have a growing popularity in the medical field, material science, 
proteomics, biological applications and generation of mimotopes, peptide libraries.  
Studies have shown that self-assembly oligomeric peptides are being used as a way to 
generate molecular nanofibers.
19

































































AEAEAKAKAEAEAKAK that has a !-sheet conformation in water.
20
 When salt is added, the 
peptide self-assembles to form interwoven nanofibers (10-20 nm in diameter).
19,20
 These 




 In the growing area of nanoscience and nanotechnology Arai et. al. in 2011 investigated 
chemical imaging in water by using AFM probes modified with the titanium-binding peptide 
(TBP) aptamers with the sequence RKLPDAPGMHTWC.
21
 Peptide aptamers are molecules that 
bind to target proteins with high specificity and strong affinity. Three different probes were 
designed Type I probe (the probe is bound directly to TBP), Type II probe (a PEG spacer is 
placed between the probe and TBP) and Type III probe (uses a methoxy-terminated PEG moiety 
that changes the density of the TBP).
21
 AFM probes are suitable for chemical imaging and to 
determine the character of the bond between the titanium oxide surface.
21
 The results of this 
work suggest the fixation of TBP and the contact time are critical factors for chemical imaging 
composition with a clear contrast. 
 Malakouikhah et. al. generated Trojan horses, peptide sequences with N-methylated 
amino acids, that can be used as carriers that pass through the blood brain barrier (BBB) by 
passive diffusion.
3
 Trojan horses use their lipophilic character as a result of the N-methylated 
amino acids as a way to permeate the BBB.  Current methods used to deliver drugs to the BBB 
include the use of drugs that temporarily opening the BBB, administration of high doses of 
drugs, and direct injection of a drug into the spinal cord.
3
 It is difficult to treat illnesses of the 
brain because most molecules generated can not cross the BBB. This application of peptides 
would provide a way to get more drugs across the BBB that can provide a better and more 
effective treatment of brain disease. 
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The application of peptides is an area that is constantly growing with new ways to use 
these molecules. Select peptides have been designed to act as ligands for different receptors and 
for different cell lines. This application is a beneficial technique because it provides a way to 
selectively target a specific receptor for specific diseases. This method can ensure that a drug or 
imaging agent reaches its desired site. Different fluorophores including porphyrins and 
phthalocyanines have been conjugated to peptides as imaging agents.
22
 Furthermore, peptides 
have been conjugated to porphyrins as treatment for photodynamic therapy. Photodynamic 
therapy (PDT) is a treatment for cancer that involves the oral or intravenous administration of a 
photosensitizer into the body, followed by its activation by light. The photosensitizer, a drug that 





Figure 1-16: Structure of Visudyne. 
 
PDT allows control over the targeted area without affecting the surrounding area. Without light 
the photosensitizer does not affect surrounding tissues or cells. The activation of the 





These ROS generate toxic effects causing apoptosis or necrosis depending 
on the site of localization of the photosensitizer. Two porphyrin derivatives Photofrin and 
Visudyne have been approved by the FDA for the PDT treatment of melanoma, early and 
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advance stages of cancer in the lung and digestive tract.
25,27-28
  Figure 1-16 shows the structure of 
Visudyne, also known as verteporfin. Visudyne is a mixture of two compounds as shown in 
Figure 1-16.
29
 Visudyne can cause several side effects and the patient must be protected form 





Figure 1-17: Structure of Photofrin.
 
 
Figure 1-17 shows the structure of Photofrin.
30-31 
Porfimer Sodium is another name for Photofrin, 
which is a complex mixture of polymers with a low absorption band at 630 nm. Photofrin also 
can cause several side effects, including photosensitivity of the patients for several weeks. 
Several peptide drugs have been approved by the US Food and Drug Administration 
(FDA) to treat different illness. Leuprolide is a peptide with a sequence of Pyr-His-Trp-Ser-Tyr-
D-Leu-Leu-Arg-Pro-NHEt. Leuprolide has been used to treat prostate cancer, breast cancer, 
endometriosis, central precocious puberty, and acquired immune deficiency syndrome 
(AIDs).
32,33,34
 Fuzeon is a 36 amino acid residue peptide with a sequence of Ac-Tyr-Thr-Ser-
Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-
Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2. Fuzeon is used in combination with 
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other drugs, that acts as a HIV fusion inhibitor to treat AIDs.
34
 One peptide drug is able to 
effectively treat more than one illness.  
While peptides have proven to be very useful molecules they have their drawbacks. One 
of the limitations to using peptides as therapeutic agents is their low chemical stability.
7a,13
 
Peptides are susceptible to enzymatic cleavage, breaking down into smaller fragments. N-
methylated peptides are shown to have improved pharmacological parameters such as 
lipophilicity, proteolytic stability, bioavailability, conformational rigidity, and new receptor 
subtype selectivity.
7a,13
 Another method used to improve stability of peptides is to form a cyclic 
ring.
35,36 
Even though peptides have drawbacks these molecules are encouraging for the use and 
design of new peptide drugs. A benefit of using peptides as drug is that they provide rapid 





Amino acids are the building blocks of peptides and proteins. There are twenty essential 
amino acids that are DNA encoded along with unusual amino acids such as L and D amino acids, 
! and " amino acids, N-methylated amino acids, and #,#-disubstituted amino acids. These amino 
acids are incorporated into various peptides and protein sequences. Amino acids have various 
properties such as zwitterionic and the isoelectric point. Peptides are mostly synthesized using 
standard Fmoc chemistry, other methods can be employed such as the acyl chloride method, acyl 
azide method, anhydrides, active esters, and coupling agents. The primary structure of a peptide 
is determined by chemical and enzymatic methodologies. Circular dichroism is used to 
determine the secondary structure of peptides and proteins. Peptides have proven to be useful 
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SYNTHESIS AND APPLICATION OF PEPTIDES THAT TARGET EGFR 
 
2.1. Introduction 
2.1.1 Colorectal Cancer (CRC) 
In a growing society, a demand for new imaging drugs and effective treatments for 
colorectal cancer (CRC) are needed. In 2009, there were 106,100 new diagnosis of CRC; of this 
amount 52,010 were in men and 54,090 were in women.
1
 Colorectal cancer is the second leading 
cause of cancer-related deaths in both men and women.
1
 Cancer is a disease with uncontrolled 
cell growth that can spread to other parts of the body. CRC starts as a growth of tissue on the 
inner lining of the colon. This growth is sometimes called adenomatous polyps (adenomas). 




2.1.2 Current Methods for Detection of CRC 
Currently, several screening processes are used to detect CRC including flexible 
sigmoidoscopy, standard colonoscopy, radiography, and CT colonoscopy. Flexible 
sigmoidoscopy is a process that uses a long, flexible, lighted tube called a sigmoidoscope. This 
tube is inserted into the anus and is slowly guided through the colon to view only the sigmoid 
colon.
2 
Conversely, standard colonoscopy is similar to sigmoidoscopy, but it provides a view of 
the entire colon. A long, flexible, lighted tube called a colonoscope is inserted into the rectum 
while the patient is lying on his/her side. This tube releases CO2 to inflate the colon and, with the 
use of a camera, provides images of the large intestine.
3
 CT colonoscopy is used to diagnoses 
CRC; if polyps are detected, conventional colonoscopy is used to remove the tumor.
4
 This 
process is carried out by having the patient lay flat on an examination table and slides into the 
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machine. During this time numerous X-ray beams and electronic x-ray detectors rotate around 
the body, thus measuring the amount of radiation absorbed. The examination table also moves 
allowing the X-ray beam to have a spiral path. The data collected is analyzed, displayed on a 
monitor, and this process is also known as helical or spiral CT.  A benefit to the procedure is the 
low risk of perforating the colon. There are several limitations of this procedure such as a slight 
chance of cancer due to the constant exposure of radiation and the potential effects have on a 
baby if the patient is pregnant. Another limitation of CT colonoscopy is that a large person may 
not be able to fit into the machine and the examination table may not be able to support the 
heavy weight. The current most effective screening method is standard colonoscopy. All of the 
above methods only target the large adenoma lesions and do not focus on the small adenomas 
nor flat lesions. Detecting small adenomas and flat lesions early on reduces and prevents the 
development of malignant tumors.
5
 Early detection will also decrease the overall health care 
cost.  
New methods have been developed to detect small adenomas and flat lesions, including 
chromoendoscopy and narrow band imaging. Chromoendoscopy is a technique that requires the 
use of an absorptive or contrast dye to stain the surface of the mucosa, enhancing tissue 
characterization, differentiation, and diagnosis.
6-7
 An absorptive dye is absorbed on the surface 
of the mucosa whereas a contrast dye is not absorbed but is retained in small pits and valleys on 
the surface giving structural information. This enhances the visual of subtle mucosal 
abnormalities that are not readily observed.
8
 During the process of administering an absorptive 
dye such as methylene blue, a long rod is inserted into the colon; from this rod the dye is sprayed 
in a clockwise and counter-clock wise direction to ensure coating of the colon. Water is used to 
remove the excess dye and imaging is performed using white light colonoscopy. The dye will 
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only stain normal cells leaving abnormal cells unstained. Narrow band imaging is another 
technique that has been used for differentiating between neoplastic and non-neoplastic cells.
5
 
This also consists of a scope that is inserted into the rectum until it reaches the colon. This probe 
uses a xenon arc lamp as a source but it uses a blue and green filter to narrow the white 
colonoscopic light, excites the mucosa, and uses a CCD detector.  
Confocal laser endomicroscopy is a technique that requires the illumination of tissue with 
a low-power laser and subsequent detection of fluorescence light, reflected from the tissue 
through a pinhole.
9
 A confocal laser endomicroscopy provides an alternative imaging route and 
uses fluorescence to label neoplastic mucosal tissues. The fluorescence dyes used are fluorescein 
(Ex. 494 nm, Em. 521 nm), acriflavine (Ex. 463 nm, Em. 490 nm) and cresyl violet (Ex. 601nm, 
Em. 632 nm). All of these dyes fluoresce in the visible region of the spectrum at wavelengths 
lower than 630 nm.
9
 Longer wavelengths reduce background auto-fluorescence from blood 
plasma and tissues, and photodecomposition of the dye molecule is also reduced.
10
 However, 
disadvantages of common molecules that emit at longer wavelengths have poor water-solubility, 
tendency to aggregate in polar solvents, and small Stokes shifts.
10
 Porphyrin molecules 
(photosensitizers) are used because they typically emit at long wavelengths greater than 650 nm 
and are water-soluble when coupled to pegylated peptides. Therefore, we propose the use of 
pegylated peptides conjugated to porphyrins as fluorescent dyes for the early detection of CRC. 
Porphyrin molecules have been used for many years as fluorescent, phosphorescent, and as 








2.2 Solid Phase Peptide Synthesis 
2.2.1 Synthesis of EGFR-L1 and EGFR-L2 Peptides 
EGFR-L1 with the sequence LARLLT (see Figure 2-1) was selected by Li and Song 






Figure 2-1: Structure of EGFR-L1 
 
The peptide library was screened against the X-ray crystal structure of EGFR in silico and tested 












































































EGFR-L2 with the sequence YHWYGYTPQNVI (see Figure 2-2) was selected by screening a 





Figure 2-3: Structure of EGFR-L1-GLY. 
 
EGFR-L1 and EGFR-L2 are both peptide ligands that target EGFR but vary in residue length 
and sequence. EGFR plays an important role in cell growth, differentiation, and migration.  
 
 
Figure 2-4: Structure of EGFR-L2-GLY 
 
Both peptides were synthesized using solid phase peptide synthesis with standard Fmoc 
chemistry.
13
 Fmoc-Pal-PEG-PS resin was used to produce an amide for the C-terminus. Selected 
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Scheme 2-2: The solid phase peptide synthesis of EGFR-L2-GLY. 
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DMF was used to swell the Fmoc-PAL-PEG-PS resin expanding the active sites, facilitating 
amino acid coupling to the resin. Scheme 2-1 and Scheme 2-2 shows how solid phase peptide 
synthesis of EGFR-L1 and EGFR-L2 proceeds, respectively.
 14,15,16
 The tyrosine group on the N-
terminus of EGFR-L2 can cause steric hindrance in any reaction. As a way to reduce sterics, a 
glycine group was introduced on the N-terminus to produce EGFR-L1-GlY and EGFR-L2-GLY 
(see Figure 2-3 and Figure 2-4, respectively). 
The Fmoc group on the Fmoc-PAL-PEG resin was removed using piperidine and DBU in 
DMF (5/2/95). The free amine was washed and coupled to the first amino acid using 
TBTU/HOBT in 1M DIEA. Peptide coupling reagents TBTU and HOBT were used to couple the 
first amino acid to the resin and to couple sequential amino acids. This process was repeated to 
achieve the desired peptide sequence. The peptide was cleaved from the resin using a cleaving 
cocktail consisting of TFA, H2O, Phenol, and Tris (88/5/5/2). The peptide (EGFR-L1 or 
EGFRL2) was precipitated using cold anhydrous ethyl ether.
14,15,16
 The filtrate was centrifuged, 
the supernatant decanted, and fresh ether added. This was repeated three times and the peptide 
was dissolved using a water and acetonitrile mixture (90/10). The dissolved mixture was freeze-
dried and lyophilized. The peptides were purified using RP-HPLC.
14,15, 16
 Table 2-1 shows the 
molecular weight, retention time from RP-HPLC, and yield of the peptides. (See Appendix for 
1
H-NMR, ESI-MS, RP-HPLC for both EGFR-L1 and EGFR-L2). 
 
Table 2-1: Molecular Weight, Retention Time from RP-HPLC*, and Percent Yield 
# Name Abbreviation Molecular Weight Retention Times % Yield 
1 EGFR-L1 2-1 684.871 g/mol 18.015 48% 
2 EGFR-L2 2-2 1539.69 g/mol 22.93 37% 
3 EGFR-L1-GLY 2-3 741.92 g/mol 38.05  
4 EGFR-L2-GLY 2-4 1596.74 g/mol 31.22 32% 
*




2.2.2 N-Methylation of EGFR-L1 and EGFR-L2 Peptides 





Scheme 2-3a: The solid phase peptide synthesis of EGFR-L1 with bench top N-methylation. 
DMF 5 x 30 s
O-NBS-Cl (4 equiv) 
& Collidine (10 equiv) 


































































DBU (3 equiv) in NMP 6 min
DMSO4 (10 equiv) in NMP 2 min
Wash with NMP 5 x 30s
Repeat step


































NMP 5 X 30s
!-mercaptoethanol (10 equiv) 
& DBU (5 equiv) in NMP 5 min





Scheme 2-3a and 3b shows the N-methylation of EGFR-L1 and Scheme 2-4a and 4b shows the 
N-methylation of EGFR-L2.
18
 To the free amine peptidyl resin (EGFR-L1 or EGFR-L2) a 
solution of o-NBS-Cl and collidine in NMP was added. Collidine was used as a base to remove a 
proton from the ! amino group on either ligand, thus allowing the lone pair on the ! amino group 
to attack the sulfur group of the protecting group o-NBS-Cl.  
 
 
Scheme 2-3b: The solid phase peptide synthesis of EGFR-L1 with bench top N-methylation. 
 
The resin was washed with NMP and methylated with a solution of DBU in NMP, DBU removes 
the proton from the protected amine. This was followed by the addition of DMSO4 in NMP, 































NMP 5 X 30s
Dry High Vaccum 24H
88% TFA, 5% H2O,
5% Liquified Phenol


























Scheme 2-4a: The solid phase peptide synthesis of EGFR-L2 with bench top N-methylation. 
 
This step was repeated and the resin was washed with NMP. The o-NBS protecting group was 
removed using a mixture of mercaptoethanol, used to reduce the disulfide bond formed with the 
DMF 5 x 30 s O-NBS-Cl (4 equiv) 
& Collidine (10 equiv) 








NMP 5 x 30 s
NMP 5 X 30s
DBU (3 equiv) in NMP 6 min
DMSO4 (10 equiv) in NMP 2 min
Wash with NMP 5 x 30s
Repeat step
NMP 5 X 30s
!-mercaptoethanol (10 equiv) 
& DBU (5 equiv) 
in NMP 5 min
Wash with NMP 
























































































































































protecting group, and DBU in NMP. The N-methylated peptides were purified using RP-HPLC. 
The retention times of EGFRL1-D1 and EGFR-L2-D1 and improved percent yields of n-
methylated peptide are listed in Table 2-2. The structures of EGFR-L1 and EGFR-L2 D1 were 
confirmed by ESI-MS and 
1
H-NMR. Due to the low yields of N-methylation on solid support a 
new method was adopted. This method requires synthesizing the peptide using the solid peptide 
synthesizer and adding a sarcosine residue to the N-terminus during the synthesis. Sarcosine is 
N-methylated glycine that is commercially available. It is coupled through standard coupling 
conditions using TBTU/HOBT with a 1M DIEA in DMF. 
 
 
Scheme 2-4b: The solid phase peptide synthesis of EGFR-L2 with bench top N-methylation. 
1. DMF 5 x 30 s
2. 88% TFA,
    5% H2O, 
    5% Liquified
    Phenol, and
    2% Tris 3-5h
    Dry Hgh Vacuum









































































































The last amino acid added to this sequence is sarcosine and is synthesized as shown in Scheme 
2-1 and Scheme 2-2. The N-methylated peptides were purified using RP-HPLC. Only EGFR-L2 





Table 2-2: Molecular Weight, Retention Time from RP-HPLC*, and Percent Yield 
# Name Abbreviation Molecular Weight Rt Time Percent Yield 
1  EGFR-L1-D1 2-5 699.88g/mol 19.933 min 35% 
2 EGFR-L2 D1 2-6 1544.76g/mol 26.87 min 17.5% 
3 EGFR-L2-SAR 2-7 1610.768 g/mol 28.66 min 35% 
*
C18 X-Bridge 4.6 x 250 mm column using water/acetonitrile gradient
 
 
2.2.3 Coupling of EGFR-L1 and EGFR-L2 to 3PEG 
The 3PEG (tri ethylene glycol) chain is coupled to the peptides to act as a spacer between 
the porphyrin and the peptide, to reduce intra-molecular and inter-molecular interactions, to 
improve water solubility, to decrease aggregation, and to favor an extended conformation of the 
conjugates.
18,19,13
 The 3PEG used, has a Fmoc protecting group on the amine functional group 
and with a free carboxylic acid functional group. Solution phase chemistry was used for the 
coupling of peptides (EGFR L1 or EGFR-L2) to a 3PEG. Two coupling reaction conditions were 
studied. An aqueous coupling agent EDC, a derivative of DCC was chosen to couple the peptides 
to the 3-PEG. This carbodiimide catalyzes the formation of an amide bond between the free 
carboxylic acid of the 3PEG and the amine group on the peptide. NHS was used as an additive to 
stabilize the intermediate generated.
20,21,22
 Scheme 2-5 shows the pegylation of EGFR-L1 and 
Scheme 2-6 shows the pegylation of EGFR-L2.
13
 3-PEG was added to purified EGFR-L1, along 
with water-soluble coupling agents EDC, NHS, and DIEA in water. This mixture was allowed to 
stir for 24 hours. The reaction mixture was allowed to react until the Kaiser test was negative. 
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The second reaction consisted of adding EGFR-L2 to 3-PEG, EDC, HOBT, DIEA, in THF.
23
 
The reaction mixture was allowed to react until the Kaiser test was negative. The Fmoc group 




Scheme 2-5: Solution phase coupling of EGFR-L1 to 3PEG. 
(1equiv)



































































































Scheme 2-6: Solution phase coupling of EGFR-L2 to 3PEG. 
 
 Table 2-3 shows that the best coupling conditions are EDC/NHS/DIEA in H2O. Both EGFR-L1-











































































































































































Based on the reversed phase retention time, the hydrophobic character of the peptide PEG 
conjugates follows the order EGFR-L2-3PEG (HOBT) > EGFR-L2-3PEG (H2O) > EGFR-L1-





Table 2-3: Molecular Weight, Conditions, Retention Time from RP-HPLC
*
, and Percent Yield 







































EDC/NHS/H2O 3.40 - 19 % 50 % 
*
C18 column using water/acetonitrile gradient
 
 
2.3 Characterization of Peptides 
2.3.1 Circular Dichroism  
The conformational character of a molecule is evaluated by different buffer systems.  For 
the purposes of this study, a membrane-mimicking environment is important because it provides 
information about how the peptide behave in a cell. Conformational studies of the peptides, N-
methylated peptides, and peptide-PEG conjugates were conducted in 10 % TFE/H2O at pH 7.00 
and in a 0.5mM PBS with 10% TFE at a pH of 7.4 using AVIV 620S circular dichroism 
spectrometer using 1 mm cell at 25°C. The wavelength was plotted verses molar ellipticity to 
compare the differences in concentrations adjusted to the desired pH using concentrated NaOH 
solution. The molar ellipticity (!) of each compound was calculated. All spectrums correspond to 
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an average of three scans and the baseline was corrected using peptide free solutions. Random 
coil structures typically show strong peaks at 200 nm (negative peak), at 218 nm (positive), and a 
peak at 220 nm (negative shoulder).
24
 All peptides show peaks in these regions.  
 
 
Figure 2-5: CD spectra for EGFR-L1 (A) and EGFR-L1-D1 (B) in 10% TFE/H20 at pH 7.00. 
 
EGFR-L1 has a sharp peak at ~ 198 nm confirming a random coil structure at all concentrations 
(see Figure 2-5A). EGFR L1-D1 has a peak at ~ 197 nm confirming a random coil structure at all 
concentrations (see Figure 2-5B). EGFR L2 at concentrations below 250 µM consists of a 
random coil structure with a peak at ~ 195 nm. There is a slight presence of the beginning of a !-
helix structure at the 250 µM concentration, showing peaks at 197 nm and 200 nm. A dominant 
secondary structure is observed at 500 µM  and higher. !-helix structures consist of three peaks, 
two negative peaks at 222 nm and 208 nm, with a positive peak at 190 nm.
24
 The peaks observed 
for the 500 µM concentration are at 193 nm (positive peak), 205 nm and 215 nm are both 
negative peaks. The 1000 µM have peaks at 200 nm (positive peak), 213 nm ("-"*) and 218 nm 
(n-"*) are both negative peaks (see Figure 2-6A). EGFR L2-D1 at concentrations below 125 µM 
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adopts a random coil structure with a peak at ~ 197 nm. There is a slight presence of the 
beginning of a !-helix structure at the 250 µM concentration, with peaks at 197 nm and 200 nm.  
 
 
Figure 2-6: CD spectra for EGFR-L1 (A) and EGFR-L1-D1 (B) in 10% TFE/H20 at pH 7.00. 
 
At concentrations above 500 µM consists of an !-helix structure the peaks observed are at 197 
nm and is not considerably a positive peak, 205 nm and 216 nm are both negative peaks. The 
1000 µM have peaks at 197, a positive peak, and an intense peak at 213 nm ("-"*). This 
concentration does not have three peaks that typically characterize a !-helix conformation (see 
Figure 2-6B).  
At 0.5 mM PBS with 10% TFE the various concentration both EGFR-L1 and EGFR-L1-
D1 has a random coil chain. EGFR-L1 and EGFR-L1-D1 has a sharp peak at ~ 198 nm. As the 
concentration of EGFR-L1 and EGFR-L1-D1 increases the depth of molar ellipticity increases. 








The molar ellipticity at every concentration was calculated for EGFR-L1 and EGFR-L1-D1. 
Only the molar ellipticity of the 50 µM concentration is shown for EGFR-L1 and EGFR-L1-D1 
in both buffer systems (see Table 2-4).  
 
Table 2-4: Molar Ellipticity of EGFR-L1 and EGFR-L1-D1 





 Name Concentration 10 % TFE/H2O  
at pH 7.00  
0.5mM PBS with  
10% TFE at pH 7.4 
1 EGFR-L1 75 µM
*
, 50 µM -5824 (199 nm) -59355 (197 nm) 
2 EGFR-L1-D1 75 µM
*
, 50 µM -4867 (196 nm) -1425 (197 nm) 
*
The 75 µM concentration corresponds for 10 % TFE/H2O at pH 7.00. 
 
These finding imply that the buffer system used does influence the confirmation for these 
peptides. 
At 0.5 mM PBS with 10% TFE the 250 µM and below of EGFR-L2 (see Figure 2-8A) 
have a random coil conformation. At concentrations higher than 250 µM a !-helix conformation 
is observed. At the 750 µM concentration and higher a "-sheet is observed. At 250 µM and 
below EGFR-L2 D1 (see Figure 2-8B) has a random coil chain. At 250 µM and higher a !-helix 
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conformation is observed. At 750 µM concentration the conformation is !-helix but it is 
transitioning to a beta sheet. At 1000 um the peptide does have a "-sheet conformation at 217 
nm. Between the peptide and the N-methylated peptide a difference is only observed at the 1000 
µM where a defined "-sheet is observed. 
 
 
Figure 2-8: CD spectra for EGFR-L2 (A) and EGFR-L2-D1 (B) in 0.5mM PBS with 10% TFE at 
pH 7.4. 
 
EGFR-L2-GLY has a random coil chain at concentration lower than 125 µM with a 
negative peak at 197 nm (see Figure 2-9). At 125 µM and higher a !-helix conformation is 
observed for 250 µM, 500 µM and 750 µM with negative peaks between 206 nm and 218 nm. At 
750 µM concentration the conformation is !-helix but it is transitioning to a "-sheet. At 1000 µM 
the peptide is transitioning to a "-sheet conformation with a negative peak at 213 nm. In 
comparison to EGFR-L2 and EGFR-L2-D1, EGFR-L2-GLY has a favored !-helix conformation. 





Figure 2-9: CD spectra for EGFR-L2-GLY (A) in 0.5mM PBS with 10% TFE at pH 7.4. 
 
A larger peptide contains an increased number of residues and will have more of a defined 
secondary structure. The molar ellipticity at every concentration was calculated (see appendix) 
but only the molar ellipticity of the 50 µM concentration are shown for EGFR-L2 peptides in 
both buffer systems (see Table 2-5). These findings imply that the buffer system used does 
influence the confirmation for these peptides. 
 
Table 2-5: Molar Ellipticity of EGFR-L2, EGFR-L2-D1, and EGFR-L2-GLY 





 Name Concentration 10 % TFE/H2O  
at pH 7.00  
0.5mM PBS with  
10% TFE at pH 7.4 
1 EGFR-L2 50 µM -12750 (199 nm) -22749 (198 nm) 
2 EGFR-L2-D1 50 µM -5556 (200 nm) -143083 (203 nm) 
3 EGFR-L2-GLY 50 µM - -24097 (198 nm)!
 
The highest concentration tested for the peptide-PEG conjugates was a 300 uM 
concentration. This was done to reduce the amount of the peptide-PEG conjugate used. EGFR-
L1-PEG has a 310-helix conformation that is carried out at all concentrations (see Figure 2-10A). 
It is unclear what is causing the formation of the 310-helix at these concentrations. One lucid 
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character of the peptide-PEG conjugates is that it is longer. However a tri ethylene glycol linker 
does not have chirality therefore it should not persuade any changes in conformation.  
 
 
Figure 2-10: CD spectra for EGFR-L1-3PEG (A) and EGFR-L2-3PEG (B) in 0.5mM PBS with 
10% TFE at pH 7.4. 
 
EGFR-L2-PEG was characterized using PBS/TFE (9/1) with a pH of 7.4. Using this condition, 
the same conformation was observed for EGFR-L2, EGFR-L2-D1, and EGFR-L2-GLY. EGFR-
L2-PEG has characteristics of a random coil at ~200 nm for concentrations 125 µM and 75 µM 
(see Figure 2-10B). At increased concentrations of 250 µM, 275 µM, and 300 µM all have 
characteristic conformations of a !-helix. The peaks observed for the 250 µM concentration are 
at 195 nm (positive peak), 206 nm and 215 nm are both negative peaks. The 275 µM 
concentration have peaks at 197 nm (positive peak), 203 nm and 216 nm are both negative peaks. 
The 300 µM concentration has a peak at 204 nm and 216 nm are both negative peaks. The molar 
ellipticity at every concentration beginning with 300 µM was calculated (see appendix) but only 
the molar ellipticity of the 50 µM concentration are shown for EGFR-L1-3PEG peptides in both 
 
!53 
buffer systems (see Table 2-6). These findings imply that the buffer system used does influence 
the confirmation of these peptides. 
 
Table 2-6: Molar Ellipticity of EGFR-L2, EGFR-L2-D1, and EGFR-L2-GLY 





 Name Concentration 10 % TFE/H2O  
at pH 7.00  
0.5mM PBS with  
10% TFE at pH 7.4 
1 EGFR-L1-PEG 50 µM - 37040 (208 nm) 
2 EGFR-L2-PEG 75 µM -1436 - 
 
2.3.2 MALDI-MS/MS 
MALDI-MS/MS provides an easy and robust way to determine the amino acid sequence 
of peptides. MS/MS is the use of two mass analyzers that separates the ions regarding the mass-
charge-ratio (m/z). This technique generates fragmented a, b, c, x, y, and z ions that are 
selectively used to determine the sequence.
25,26
 Fragmentation of peptides requires breaking C-C 
bonds, C-N bonds, and N-C bonds. Cleavage at the C-C bonds generates a and x ions, cleavage 
at the C-N bonds generates b and y ions, and cleavage at the N-C bonds generates the c and z 
ions that are not typically observed, see Figure 2-11.
25,26
 A and b ions are generated from the N-
terminus of the peptide when the charge is retained at the N-terminus. 
 
 


















































Peptides retaining the charge at the C-terminus generates the x and y ions from the C-terminus of 
the peptide. Fragmentation of peptides EGFR-L1 and EGFR-L2-GLY was analyzed using 
MALDI-MS/MS, see Figure 12 and Figure 13.  
 
Table 7: Ions generated for EGFR-L1 
 Name a ions b ions y ions 
1 LEU 86.09 114.89 - 
2 ALA 157.83 185.12 - 
3 ARG 313.23 341.22 - 
4 LEU 426.31 454.31 - 
5 LEU 539.40 567.39 - 
6 THR 640.45 668.45 - 
 
Table 7 and 8 list the a and b ions generated for EGFR-L1 and EGFR-L2-GLY. Both the a and b 













Table 8: Ions generated for EGFR-L2-GLY 
 Name a ions b ions y ions 
1 GLY - - - 
2 TYR 1147.95 221.09 - 
3 HIS 330.23 358.15 - 
4 TRP 516.23 544.23 - 
5 TYR 679.29 707.29 - 
6 GLY 736.32 764.31 - 
7 TYR 899.38 927.37 - 
8 THR 1001.43 1028.42 - 
9 PRO 1097.48 1125.47 - 
10 GLN - 1253.53 - 
11 ASN 1339.58 1367.58 - 
12 VAL 1438.65 1466.64 - 




Two peptides EGFR-L1 and EGFR-L2, which vary in sequence and charge, were 
synthesized and derivatized. EGFR-L1 (LARLLT) contains six residues peptide with a 
+
1 
positive charge and EGFR-L2 (YHWYGYTPQNVI) contains seven residues peptide without a 
charge. The derivatives of these peptides include EGFR-L2-GLY, EGFR-L1-D1, EGFR-L2-D1, 
and EGFR-L2-SAR that have the potential to act as ligands for EGFR. EGFR-L2 was coupled to 
a PEG using both aqueous and organic coupling conditions with the highest yield of 8% 
(aqueous conditions). The low yield of this reaction was due to the steric hindrance of the 
tyrosine amino acid on the N-terminus. The yield was improved by the addition of a glycine 
residue on the N-terminus of the peptide sequence, generating EGFR-L2-GLY, and resulting in 
higher yields of 19% and 50% respectively. EGFR-L1-D1 and EGFR-L2-D1 were N-methylated 
on the N-terminus using a standard bench top approach with yields of 35% and 17.5%, 
respectively. The yield of EGFR-L2-D1 was improved by using solid phase peptide synthesis for 
the addition of a N-methylated amino acid sarcosine to generated EGFR-L2-SAR.  
Each peptide generated was characterized using CD in membrane mimicking 
environments. All peptides have a random coil conformation at various concentrations lower that 
250 µM. In comparison of EGFR-L2, EGFR-L2-D1, and EGFR-L2-GLY as the size of the 
molecule changes differences in the CD spectra are observed.  The addition of the methyl group 
verses the glycine causes changes in the conformation of the peptide at the 500 µM and 750 µM 
that favors a !-helix conformation. The evaluation of the peptide PEG conjugates suggests that 
the addition of PEG does alter the conformation (310-helix) of the conjugates. This change may 
occur due to the extended length that the PEG provides even though it is not a chiral molecule.  
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All molecules generated have been characterized and confirmed using various techniques 
such as mass spectrometry including ESI-MS and MALDI-MS to determine the molecular 
weight of each peptide. MALDI-MS/MS and 
1
H-NMR were used to confirm the sequence of the 
peptides and to determine the structure of the peptide respectively. 
 
2.5 Experimental Procedures 
2.5.1 Solid Phase Peptide Synthesis Purification and 
1
H-NMR  
All peptide synthesis reagents were purchased from Fisher Scientific or Sigma Aldrich 
grade ACS or peptide synthesis grade solvents. Amino acids were purchased from AnaSpec or 
Applied Biosystems. Peptide sequences were prepared on an automated peptides synthesizer 
(Applied Biosystems Pioneer, Peptide Synthesis System) in a 0.2 mmole scale following 
standard Fmoc strategy. A 4-fold excess of the L-Fmoc protected amino acids were coupled 
using TBTU/HOBT as the activating agent and coupling additive. The peptide sequences 
prepared using this methodology were as follows: LARLLT and YHWYGYTPQNVI. Fmoc 
deprotection: "#$%&'(! %)! *+#! ,$%-! ./%01! )/%$! *+#! ('2*! '$34%! '-35!6'2! *+#! )34'(! 2*#1! )%/!
#'-+!274*+#232!'45!32!1#/)%/$#5!%4!*+#!274*+#238#/9!:,!*+#!,$%-!6'2!4%*!/#$%&#5!%4!*+#!
274*+#238#/!then resin-bound Fmoc peptide was treated with 93% DMF, 5% Piperidine and 2% 
DBU once for 3 minutes, once for 5 minutes, and once for 10 minutes9!;+32!6'2!)%((%6#5!<7!
6'2+34.!*+#!1#1*35#!2#&#/'(!*3$#2!63*+!=>,9  
Once the peptide is removed from synthesizer it is washed with DMF (5 x 30s) and then 
washed with DCM (3 x 30s) and dried in high vacuum overnight.  
A cleavage cocktail of TFA (88%), Water (5%), Liquified phenol (5%) and 
Triisopropylphenol (2%) is added to the resin for 3 – 5 hours. The cocktail was then released into 
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cold (-80°C) anhydrous ethyl ether, and centrifuged. The supernatant was decanted and washed 
several times with cold anhydrous ethyl ether. The solid was dissolved in a mixture of water and 
acetonitrile, freeze dried and lypohlized. HPLC separation was carried out using on a Waters 
system including a 2545 quaternary gradient module pump, 2489 UV/Visible detector, and a 
fraction collecter III. Analytical HPLC was carried out using a XBridge C18 300Å, 5µm, 4.6 x 
250 mm (Waters, USA) or an Atlantis C18 300 Å, 5 µm, 4.6 x 250 mm (Waters, USA) column 
using a stepwise gradient. Semipreparative HPLC was carried out on XBridge C18 300 Å, 5 µm, 
10 x 250 mm (Waters, USA) column using a stepwise gradient. The solvent system for the 
peptides consisted of millipure water and HPLC grade acetonitrile with 0.1% trifluoroacetic acid. 
Mass spectra were obtained using ESI-MS 6210 time of flight LC/MS Agilent Technologies, 
USA or Bruker UltrafleXtreme (MALDI-MS/MS) using CHCA matrix. 
 
• EGFR-L1 (LARLLT-NH2) The solid white compound has a yield of 48%; HPLC tR = 18.01 
min; MS (ESI) m/z 685.5 [M+1]; 1H NMR (DMSO, 400MHz): ! 8.64 (1H, d, J = 6.912 Hz), 
8.16 (1H, d, J = 7.25 Hz), 8.12 (1H, d, J = 8.639 Hz), 8.03 (2H, s), 7.93 (1H, d, J = 8.29 Hz), 
7.44 (2H, d, J = 8.984 Hz), 7.10 (2H, d, J = 10.366 Hz), 4.91 (2H, d, J = 4.837 Hz), 4.40 (1H, 
t, J = 6.911 Hz), 4.32 (1H, t, 4.837 Hz), 4.27 (2H, t, J = 7.256 Hz), 4.05 (1H, d, J = 8.98 Hz), 
4.00 (1H, s), 3.76 (1H, s), 3.08 (2H, q, J = 5.87 Hz), 1.64 (2H, m), 1.52 (5H, m), 1.22 (1H, d, 
J = 6.22 Hz), 0.98 (1H, d, J  = 5.87 Hz), 0.82 (3H, q, J = 3.80 Hz). 
 
• EGFR-L2 (YHWYGYTPQNVI-NH2) The solid white compound has a yield of 37%; 
HPLC tR = 22.93 min; MS (ESI) m/z 1540.7 [M+1]; 
1H NMR (DMSO, 400MHz): ! 9.35 (1H, 
s), 9.14 (1H, s), 8.76 (3H, m), 8.11 (4H, m), 7.95 (3H, m), 7.56 (1H, d, J = 8.70 Hz), 7.412 
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(1H, s), 7.27 (1H, d, J = 8.13 Hz), 7.06 (1H, d, J = 8.13 Hz), 6.97 (14H, m), 6.59 (6H, t, J = 
7.07 Hz), 4.64 (1H, d, J = 6.83 Hz), 4.59 (5H, m), 4.46 (2H, q, J = 8.542 Hz), 4.38 (3H, m), 
4.07 (1H, t, J = 8.51 Hz), 3.94 (1H, m), 3.59 (2H, m), 2.89 (10H, m), 2.71 (4H, m), 2.12 (3H, 
m), 2.04 (3H, m), 1.88 (4H, m), 1.09 (4H, d, J = 9.27 Hz), 0.82 (11H, m).  
 
• EGFR-L1-GLY (GLARLLT-NH2) The solid white compound has a yield of 32%; HPLC tR 
= 38.05 min; MS (MALDI) m/z 742.712 [M+1]; 
1
H NMR (DMSO, 400MHz): ! 8.44 (1H, d, 
J = 8.74 Hz), 8.31 (1H, d, J = 7.64 Hz), 8.14 (1H, d, J = 9.83 Hz), 7.92 (4H, m), 7.43 (2H, t, 
J = 9.83 Hz), 7.10 (2H, td J = 10.9 Hz), 4.45 (2H, q, J = 8.45 Hz), 4.29 (4H, m), 4.07 (1H, 
m), 3.99 (1H, s), 3.57 (2H, t, J = 6.57 Hz), 3.09 (2H, q, J = 4.70 Hz), 1.60 (5H, m), 1.46 
(10H, m), 71.19 (3H, d, J = 7.64 Hz), 0.96 (3H, d, J = 6.55 Hz), 0.86 (18H, m). 
!
• EGFR-L2-GLY (GYHWYGYTPQNVI-NH2) the solid white compound has a yield of 
32%; HPLC tR = 31.25 min; MS (MALDI) m/z 1596.7 with a sodium adduct 1619.7 [M+23]; 
1
H NMR (DMSO, 500MHz): ! 9.18 (3H, d, J = 18.13 Hz), 8.49 (2H, m), 8.26 (3H, m), 8.11 
(6H, m), 7.56 (1H, d, J = 8.18 Hz), 7.41 (1H, s), 7.29 (1H, d, J = 8.18 Hz), 7.08 (1H, s), 6.97 
(14H, m), 6.61 (6H, m), 4.69 (1H, s), 4.50 (2H, m), 4.57 (5H, m), 4.43 (2H, m), 4.37 (3H, 
m), 4.16 (2H, m), 4.06 (2H, t, J = 8.18 Hz), 3.86 (2H, m), 2.89 (9H, m), 2.67 (4H, m), 2.13 
(3H, t, J = 7.16), 2.02 (2H, m), 1.87 (4H,m), 1.23 (2H, s), 1.10 (6H, s), 0.821 (11H, m).  
 
2.5.2 N-Methylation of Peptides Purification and 
1
H-NMR 
A solution of o-NBS-Cl (4 equiv) and collidine (10 equiv) in NMP was added to the 
resin-bound free amine peptides and shaken for 30 minutes at room temperature, Followed by 
washing the resin with NMP (5 x 10 mL). A small amount of the resin was cleaved using TFA 
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cocktail for 3 to 5 hours (see cleaving peptide form resin procedure) and analyzed by RP-HPLC 
(MECN 10-100%) and ESI-MS.
8  
A solution of DBU (3 equiv) in NMP was added to the resin bound o-NBS-protected 
peptides and shaken for 6 minutes. A solution of dimethyl sulfate (10 equiv) in NMP was then 
added to the reaction mixture and shaken for 5 minutes. The resin was filtered off and washed 
several time with NMP. This step was repeated followed by washing with NMP (5 x 10mL A 
small amount of the resin was cleaved using TFA cocktail for 3 to 5 hours (see cleaving peptide 
form resin procedure) and analyzed by RP-HPLC (MECN 10-100%) and ESI-MS.
   
The resin was treated with a solution of mercaptoethanol (10 equiv) and DBU (5 equiv) 
in NMP for 10 minutes. The resin was washed with NMP (3 x 10mL) and this step was repeated 
once more.
 
See protocols mentioned above for cleaving of peptides, purifying peptides and 
characterization of peptides. 
• EGFR-L1-D1 ((CH3)LARLLT-NH2) The yellowish brown oil has a yield of 35%; HPLC tR 
= 19.93 min; MS (ESI) m/z 698.897 [M+1]; 
1
H NMR (DMSO, 400MHz): ! 8.84 (3H, m), 
8.178 (3H, d, J = 6.98), 7.92 (2H, d, J = 5.82), 7.11 (2H, d, J = 17.46), 4.46 (1H, p, J = 6.98), 
4.31 (3H, m), 4.07 (2H, d, 9.31), 3.77 (1H, q, J = 5.652), 3.61 (1H, t, J = 6.59), 2.93 (3H, d, J 
=18.84), 2.68 (2H, t, J = 7.53), 2.02 (2H, m), 1.61 (5H, m), 1.48 (8H, m), 1.25 (3H, d, J = 
6.77), 0.99 (3H, d, J = 6.77), 0.87 (18H, m).  
 
• EGFR-L2-D1 (YHWYGYTPQNVI-NH2) The solid white compound has a yield of 17.5%; 
HPLC tR = 26.87 min; MS (MALDI) m/z 1553.7 [M+1]; 
1
H NMR (DMSO, 400MHz): ! 9.30  
(1H, d, J = 10.95), 9.15 (3H, m), 8.25 (2H, m), 8.11 (3H, m), 7.89 (1H, m), 7.75 (4H, t, J = 
6.85), 7.56 (1H, d, J = 8.19), 7.41 (1H, s), 7.21 (1H, s), 6.97 (14H, m), 6.78 (3H, s), 6.61 
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(6H, d, J = 8.19), 6.52 (3H, s), 4.69 (1H, m), 4.58 (5H, t, J = 4.09), 4.35 (3H, m), 4.16 (3H, 
m), 4.07 (2H, t, J = 8.21), 3.86 (2H, m), 3.49 (3H, s), 2.87 (10H, m), 2.65 (2H, m), 2.11 (3H, 
m), 1.85 (4H, m), 1.10 (6H, d, J = 5.69), 0.80 (11H, m). 
 
• EGFR-L2-SAR (SAR-YHWYGYTPQNVI-NH2) The solid light yellow compound has a 
yield of 35%; HPLC tR = 28.66 min; MS (MALDI) m/z 1610.9 with a sodium adduct 1632.9 
[M+23]; 
1
H NMR (DMSO, 400MHz): ! 9.12 (2H, m), 8.90 (1H, m), 8.22 (2H, m), 8.06 (4H, 
m), 7.94 (2H, m), 7.66 (3H, m), 7.54 (1, d, J = 7.56), 7.40 (1H, s), 7.29 (2H, m), 6.96 (14H, 
m), 6.60 (9H, m), 4.56 (7H, m), 4.38 (2H, m), 4.15 (6H, m), 3.87 (1H, m), 3.63 (6H, m), 2.87 
(8H, s), 2.72 (2H, m), 2.11 (5H, m), 2.01 (1H, m), 1.85 (4H, m), 1.09 (6H, m), 0.81 (11H, 
m). 
  
2.5.3 Coupling of Peptides to 3-PEG Purification and
1
H-NMR 
To the EGFR L1, EGFR-L2, or EGFR-L2-3PEG peptide (1 equiv) was added N-Fmoc-
N’-succinyl-1, 12-diamino-4, 7, 10-trioxatriadecane (1 equiv), EDC (1.05 equiv), NHS (1.25 
equiv), DIEA (3 equiv) and water. To a second batch of peptides EGFR-L1 and EGFR-L2 (1 
equiv) was added N-Fmoc-N’-succinyl-1, 12-diamino-4, 7, 10-trioxatriadecane (1 equiv), EDC 
(1.05 equiv), HOBT (1.25 equiv), DIEA (equiv), and THF. The reaction mixture was allowed to 
react until the Kaiser test was negative. The peptide peg was then purified using RP-HPLC. The 
Fmoc group can be removed by using TFA (1 equiv) and ACN (1 equiv) followed by 
purification. 
• EGFR-L1-3PEG-Fmoc (3PEG-LARLLT-NH-Fmoc) The solid white compound has a 
yield of 29%; HPLC tR = 3.85 min; MS (ESI) m/z 1210.7 [M+1]; 
1
H NMR (DMSO, 
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400MHz): ! 10.54 (1H, s), 8.82 (1H, m), 8.16 (2H, m), 7.81 (8H, m), 7.40 (4H, m), 6.08 (1H, 
s), 6.00 (1H, s), 4.28 (4H, m), 4.03 (1H, m), 3.76 (1H, s), 3.59 (5H, m), 3.49 (8H, m), 3.12 
(4H, m), 3.04 (4H, m), 2.83 (2H, m), 2.42 (4H, t, J = 6.13), 2.29 (3H, t, J = 7.16), 1.74 (5H, 
m), 1.59 (6H, m), 1.46 (5H, m), 1.26 (18H, m).  
 
• EGFR-L2-3PEG (3PEG-YHWYGYTPQNVI-NH2) the solid white compound has a yield 
of 8%; HPLC tR = 4.18 min; MS (MALDI) m/z 1842.9 [M+1]; 
1
H NMR (DMSO, 400MHz): 
! 9.26 (1H, s), 9.20 (1H, s), 9.06 (1H, s), 7.22 (2H, d, J = 8.19), 7.09 (3H, d, J = 8.35), 7.03 
(4H, t, J = 8.18), 6.89 (3H, t, J = 6.36), 6.74 (5H, m), 6.69 (2H, s), 6.66 (4H, m), 6.49 (2H, 
m), 4.93 (3H, q, J = 6.36), 4.55 (4H, m), 4.46 (3H, d, J = 6.36), 4.34 (2H, d, J = 6.37), 3.49 
(18H, s), 2.87 (2H, s), 2.72 (2H, s), 2.68 (2H, m), 2.31 (1H, m), 2.18 (4H, t, J = 7.28), 2.06 
(2H, s), 1.22 (9H, m), 0.94 (11H, m). 
 
• EGFR-L2-GLY-3PEG (3PEG-GYHWYGYTPQNVI-NH2) the yellowish oil has a yield 
of 50%; HPLC tR = 5.00 min; MS (MALDI) m/z 1899.262; 
1
H NMR (DMSO, 400MHz):  
10.72 (1H, s), 9.13 (3H, m), 8.21 (2H, s), 8.05 (3H, m), 7.90 (1H, m), 7.67 (3H, m), 7.54 
(1H, d, J = 8.60), 7.40 (2H, m), 7.29 (1H, d, J = 7.33), 7.18 (4H, m), 6.93 (14H, m), 6.19 
(9H, m), 4.70 (1H, s), 4.58 (5H, m), 4.53 (4H, m), 4.15 (3H, m), 4.07 (2H, t, J = 7.37), 3.86 
(1H, m), 3.67 (4H, m), 3.49 (12H, s), 3.05 (2H, m), 2.87 (5H, m), 2.67 (2H, m), 2.31 (1H, 






2.5.4 Characterization of Peptides 
Circular dichroism measurements were carried out on a AVIV 620S circular dichroism 
spectrometer using 1mm path length quartz cell. Peptide solutions (various concentrations) were 
prepared in water/trifluroethanol (9/1), pH 7.00. A second peptide solution was used consists of 
phosphate buffered solution/trifluroethanol (9/1) with a pH of 7.4. All spectra correspond to an 
average of three runs and were corrected by the baseline obtained for peptide free solutions. 
Mass spectra were obtained using ESI-MS 6210 time of flight LC/MS Agilent Technologies, 
USA or Bruker UltrafleXtreme (MALDI-MS) and MALDI-MS/MS using CHCA matrix. 
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DESIGN AND SYNTHESIS OF PORPHYRIN PEPTIDE BIOCONJUGATES FOR 
DIAGNOSIS AND TREATMENT OF CRC 
 
3.1  Introduction 
3.1.1 Porphyrins  
Porphyrins are fluorescent aromatic molecules that are both naturally occurring and 
synthetic. Porphyrins can be found in plants where they are involved in photosynthesis, in blood 
to transport oxygen throughout the body, as well as in oxygen storage and drug metabolism.
1
 
Porphyrins contain two imino nitrogens and four pyrrole rings that are joined through methine 
bridges designated at the meso positions, as shown in Figure 3-1. Porphyrins are important 
molecules with intense rich colors that are present in most biological systems.  
 
 
Figure 3-1: The unsubstituted porphyrin macrocycle and nomenclature. 
 
The word porphyrin is derived from the Greek word “porphura” that means the color purple.
1
 
The color of the porphyrin is a result of its conjugated !-system and depends on the substituents 
on the porphyrin ring. Figure 3-1 shows an unsubstituted porphyrin. Different substituents can be 
placed onto the macrocycle at the meso and "-positions.
1
 Simple variations in the design of the 
porphyrin can lead to porphyrin-based compounds for a variety of applications, for example in 







































Porphyrins and metalloprophyrins can undergo different types of reactions such as electrophilic 
aromatic substitution, electrophilic addition, nucleophilic reactions, oxidations, reductions, and 









Depending on the substituents on the porphyrin macrocycle different methods are employed to 
synthesize porphyrins, including Alder and Longo’s method,
2





 The Alder and Longo’s method uses a mono-pyrrole with an aryl aldehyde 





































Scheme. The MacDonald’s approach uses dipyrrylmethanes to synthesize porphyrins of lower 
symmetry, see Scheme 3-2. The Lindsey method provides a gentle approach to synthesizing 
porphyrins in comparison to the Alder and Longo’s method.
4
 Benzaldehyde, pyrrole, and triethyl 
orthoacetae are reacted under inert condition in DCM, followed by the addition of an oxidizing 
agent p-chloranil.
4
 Another synthetic method for the synthesis of porphyrins is via open chain 
tetrapyrroles, such as bilane, a, c biladiene, bilin, a-bilene, and b-bilene.
5,6 
Porphyrins have special characteristics that are studied using various techniques such as 
UV-VIS, fluorescence spectroscopy, and NMR. UV-Vis determines where molecules absorb in 
the UV and visible spectrum at specific wavelengths. 
 
 
Figure 3-2: The visible spectrum. 
 
The absorption of the porphyrin in the visible spectrum accounts for the color of the molecule, as 
shown in Figure 3-2. A UV-Vis spectrum of 3,8-diethyl-2,7,12,18-tetramethylporphyrin-13,17-
dipropionic acid (Mesoporphyrin IX or MesoPOR), the porphyrin used these studies, is shown in 
Figure 3-3. Porphyrins typically have a strong absorption band between 390 - 425 nm that is 





Porphyrins can have different types of UV-Vis spectrums such as rhodo-type, oxo rhodo-type, 
and phyllo-type, the one shown in Figure 3-3 is an etio-type spectrum. From the UV-Vis 
spectrum shown in Figure 3-3, the molar absorptivity of MesoPOR can be determined.  
 
 






The molar absorptivity determines how strongly a molecule absorbs at a specific wavelength. 
Table 3-1 lists the !max and the molar absorptivity determined for the Soret and Q-bands of 
MesoPOR. Porphyrins have various applications and uses, including molecular wires, optical 




Table 3-1: The !Max and molar 
absorptivity of MesoPOR in DMF 





1 397 295276 
2 497 27067 
3 530 17224 
4 566 12303 




Porphyrins, including MesoPOR, have several characteristics that make them favorable 
photosensitizers, including their fluorescence at long wavelengths (> 600 nm) with high quantum 
yields, general low dark toxicity, and natural affinity for cancer cells.
9
 Emission at long 
wavelengths (!max > 600 nm) reduces interferences from background auto-fluorescence from 





Phtalocyanines (Pc) are synthetic molecules that are similar to porphyrins in aromaticity 
and absorb in the infrared region (IR) due to their extended "-system. Linstead et. al. determined 
the structure of Pc using several methods in the early 1930s at London’s Imperial College.
1
 
Phthalocyanines usually have high stabilites, strong absorption and emission in the near IR, 





Figure 3-4: General structure of a phthalocyanine macrocycle. 
 
Figure 3-4 shows the structure of a phthalocyanine macrocycle. Reactions can occur only at the # 


























dicyanobenzene (phthalonitrile) under basic conditions; often in the presence of metal salt, such 
as NiCl2 or Zn(OAc) shown in Scheme 3-3. A number of functional groups can be added to Pc 
framework via the benzene rings. Functional groups such as alkyl chains, ethers, amine, thiols 





Scheme 3-3: Synthesis of phthalocyanines. 
 
The substitutions can be made directly onto the Pc framework or on the phthalonitrile precursor 
before condensation to form the macrocyclic Pc ring. The use of substituted precursors usually 
leads to cleaner reactions but mixtures of regioisomers are obtained from unsymmetric 
precursors. Substitutions can be carried out directly at any of the 16 available positions on the Pc 
framework.
11 
Phthalonitriles are the standard and most useful precursors for synthesizing 
phthalocyanines and can readily be functionalized and tetracyclized. Unlike porphyrins that have 
a purplish color, phthalocyanines have bluish green color due to their absorption at longer ! as a 
result of their extended "-system; Pcs typically absorbs and emits in the near IR. In contrast to 
porphyrins, phthalocyanines have a weak near UV band and strong visible or near-IR bands, as 
shown in Figure 3-5.
1
 The difference in the UV-Vis spectrums of porphyrins and 




























Figure 3-5: UV-Vis spectrum of a Zn phthalocyanine in DMF. 
 
Table 3-2 lists the characteristic maximum wavelength and the molar absorptivity for ZnPc in 
Figure 3-5 in DMF. Pcs have various applications such as surface coatings, paper dyes, floor 
coverings, as paint colorants for blue and green cars, and as a sensitizer for photodynamic 
therapy.
1,11





Table 3-2: The "Max, molar absorptivity, and 





) Log #  
669 266969 5.43 
604 47112 4.67 




Due to the red-shift in the absorption and emission bands of these molecules, Pcs typically emit 





3.1.3 Selection of Porphyrin 
This project focuses on the design, synthesis, and characterization of peptides coupled to 
porphyrins and pegylated porphyrins to serve as a fluorescent labels and/or photosensitizers for 
CRC cells. The sensitizers discussed herein will be described as “bioconjugates.”  
 
 
 Figure 3-6: The structures of Mesoporphyrin IX (A) Protoporphyrin IX (B) and Heme (C). 
 
These molecules will provide a potential method for selective targeting, better imaging, and 
treatment of CRC cells, compared with the currently used fluorophores. The porphyrin selected 
for this study was MesoPOR because it is similar to 3, 8-vyinl-2,7,12,18-tetramethylporphyrin-
13,17-dipropionic acid (protoporphyrin IX) and to a heme (FeII complex of protoporphyrin IX) 
that is found in blood (see Figure 3-6). MesoPOR is a metal-free compound that varies from 
protoporphyrin IX in the vinyl substitution at the 3 and 8 positions. The crystal structure of 






















Figure 3-7: Crystal structure of Mesoporphyrin IX dimethyl ester. 
 
The vynil groups at the 3 and 8 position are reactive groups in comparison to the ethyl groups at 
the 3 and 8 position of MesoPOR. MesoPOR is an amphiphilic porphyrin due to the hydrophobic 
methyl and ethyl groups on one side of the macrocycle and the hydrophilic propionic acid groups 
on the other side.  
 
 


























To enhance the selectivity for targeting CRC tumor cells, two peptides were selected based on 
published studies, EGFR-L1 (6 amino acids, see Figure 3-8) and EGFR-L2 (12 amino acids, see 
Figure 3-9), to act as ligands for EGFR, which is over expressed in CRC cells.
15-16
 Li and Song 
et al have shown that EGFR-L1 and EGFR-L2 will bind to EGFR both in vitro and in vivo. A 
PEG linker between the porphyrin macrocycle and the peptide ligand will increase water-
solubility, reduce aggregation, and increase bioconjugate stability.
17
 Furthermore, porphyrins can 




Figure 3-9: Structure of EGFR-L2-GLY 
 
Therefore, the first series of bioconjugates synthesized in this work consist of three important 
elements: a) N-methylated or non-methylated peptides which will direct the bioconjugates to 
EGFR, b) a PEG linker, which will promote solubility of the bioconjugates, and c) a highly 
fluorescent porphyrin or phthalocyanine with an innate affinity for cancer cells. The second 
series of bioconjugates will be synthesized without a PEG linker (defined as “peptide-porphyrin 




















































cell targeted conjugate that directs the porphyrin to the desired tumor site is enhanced selectivity 
for CRC for both imaging/detection and potential treatment of CRC.  
 
3.2  Synthesis of Bioconjugates 
The synthesis of EGFR-L1 and EGFR-L2 and their couplings to 3PEG was presented in 
Chapter 2 of this Dissertation. In this Chapter, I will describe the coupling reactions to 
MesoPOR. 
 
3.2.1 Coupling of Peptide-3PEG to MesoPOR 
The coupling of EGFR-L1-3PEG to MesoPOR and was unsuccessful using 
EDC/NHS/DIEA in H2O. Therefore alternative coupling results were investigated. When EGFR-
L1-PEG, still containing unreacted PEG, was coupled to MesoPOR using TBTU/HOBT and 
DIEA in DMF. Several products were formed, as shown in Scheme 3-4 after purification of the 
reaction mixture, all products were isolated except for EGFR-L1-(di)3PEG-MesoPOR, which 
was formed in very low yield. MALDI MS/MS shows that this molecule was generated in the 
reaction but it was not isolated due to the very small amount. Table 3-6 summarizes the products 
that were isolated, their molecular weight, retention time from RP-HPLC, and yields (see 
Appendix for HPLC chromatograms and spectra). The structure of both MesoPOR-3PEG (3-1 
and 3-2) and bioconjugates (3-3 and 3-4) were confirmed by MALDI. The same reaction was 
performed using EGFR-L2-GLY-3PEG but no products were detected by MALDI-MS nor 
isolated. This result might be a consequence of the low solubility of EGFR-L2. Even after the 
solvent was changed several times still no product was formed. Coupling reagents was changed 
but the reaction was still not successful. Therefore, a different methodology was used to prepare 
!
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Table 3-3 lists the molecular weight, conditions for reactions, retention time, and percent yield 
for 3-1, 3-2, 3-3, and 3-4 
 
Table 3-3: Molecular Weight, Conditions for Reactions, Retention Time, and Percent Yield. 










1 MesoPOR-(m)3PEG 3-1 869.484 TBTU/HOBT/DMF/
DIEA 
14.60 14 % 
2 MesoPOR-(di)3PEG 3-2 1171.669 TBTU/HOBT/DMF/
DIEA 





- 0 %  
TBTU/HOBT/DMF/
DIEA 







Xbridge C18 or Atlantis C18 column using water/acetonitrile gradient 
 
 
3.2.2 Coupling of MesoPOR to 3PEG 
The second approach to generating the bioconjugates begins with coupling MesoPOR to 
the 3PEG containing a tertiary butyl protecting group on the carboxylic acid functionality. This 
reaction was performed several times to optimize conditions. The reaction was initially 
performed using TBTU, HOBT, and DIEA in DMF, which gave a 14 % yield for both the mono 
and di substituted molecules 3-7 and 3-8, as shown in Scheme 3-5 and Table 3-4. The 
experiment was repeated using TBTU, HOBT, and DIEA in THF, which gave percent yields of 
20% and 48% for 3-7 and 3-8 respectively. To determine the effect of heat, the reaction mixture 
was heated to 60 for 5 days but the yields obtained for 3-5 and 3-6 were low after purification by 
RP-HPLC. Free MesoPOR was present in every fraction collected and was not isolated from the 




Scheme 3-5: Solution phase coupling of MesoPOR-3PEGTbutyl. 
 
Purification by RP-HPLC was difficult using a mixed solvent system consisting of H2O/ACN 

































2. TBTU (2.10 equiv)
    HOBT (2.50 equiv)
    stir for 30 min at 60°C
3. PEG Linker (2 equiv)
    stir at 60°C
1. DIEA (12 equiv)
    DMF
    stir for 2 h at 60°C
100% TFA



























diluting the crude in ethyl acetate and extracting with H2O. Column chromatography with a 
solvent system of MeOH/DCM (2:8) was used to separate the remaining free MesoPOR from 3-5 
and 3-6. 3-6 was isolated in 88% percent yield, see Scheme 3-5 and Table 3-4. The tertiary butyl 
group was removed with TFA at room temperature for four hours (see Scheme 3-5). Table 3-4 
lists the molecular weight, conditions for reactions, retention time, percent yield, and purification 
technique for 3-5, 3-6, 3-7, and 3-8. All molecules synthesized were characterized by MALDI-
MS, MALDI-MS/MS, 
1
H-NMR, UV-Vis and Fluorescence Spectroscopy (see experimental 
procedures).  
 
Table 3-4: Molecular Weight, Conditions for Reactions, Retention Time, and Percent Yield. 




























34.18 48 % 












Xbridge C18 or Atlantis C18 column using water/acetonitrile gradient. 
+
solid phase 
extraction, extraction, centrifugation, and/or column chromatography was used to purify 
bioconjugates. 
 
3.2.3 First Series of Bioconjugates MesoPOR-3PEG to Peptides 
The first series of bioconjugates couple 3-8 to free peptides EGFR-L1, EGFR-L2-GLY, 
and EGFR-L2-SAR, described in Chapter 2.  Each bioconjugate was prepared with different 
conditions. To synthesize 3-10, aminium coupling agents were used with an electron-poor 
!
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additive HOBT that increases reactivity. TBTU and HOBT was added to 3-8 at 60°C and 














































































































1. DIEA (12 equiv)
    DMF
    stir for 2 h at 60°C
2. TBTU (2.10 equiv)
    HOBT (2.50 equiv)
    stir for 30 min at 60°C
3. EGFR-L1 (2 equiv)






EGFR-L1 does not undergo many side reactions through the side chains in comparison to EGFR-
L2-GLY. EGFR-L1 has lower possibility of racemization with one tyrosine group.
18
 TBTU with 
the coupling additive HOBT are good coupling agents to synthesize EGFR-L1. Purification by 
RP-HPLC did not produce the isolated products. Using water and acetonitrile as the solvent 
system did not effectively separate the 3-8 from products 3-9 and 3-10. TLC was used to 
determine the best solvent system (MeOH/DCM 1:9) to separate 3-8 from 3-9 and 3-10. The 
mono bioconjugate 3-9 is a mixture of 2 regioisomers. The peptide can couple to the propionic 
acid on position 13 or 17 of the porphyrin macrocycle. C18 solid phase extraction was used to 
isolate the di product of MesoPOR-diPEG-EGFR-L1 (3-10). Once isolated, any remaining 3-8 
was removed by sonicating and centrifuging with acetone. 3-10 was isolated in 16 % yield (see 
Table 3-5). It is difficult to synthesize and purify bioconjugates containing EGFR-L2-GLY due 
to its poor solubility. Initial couplings to EGFR-L2-GLY were attempted using TBTU and 
HOBT, which produced the expected products as determined by MALDI-MS. After purification 
the MesoPOR-diPEG-EGFR-L2-GLY (3-11) was not isolated. To evaluate the effects of 
different coupling agents for EGFR-L2-GLY bioconjugates, DEPBT and PyBroP were used. 
DEPBT, an organophosphorus coupling agent, is known to reduce racemization of amino acids 
such as tyrosine, serine, threonine, and the imidazole group of histidine.
19,18
 3-8 was activated 
using DIEA in DMF at 60°C for two hours. EGFR-L2-GLY containing three tyrosine residues, 
one threonine, and histidine making DEPBT a good coupling agent for this reaction.
18
 3-11 was 
synthesized using the same procedure for 3-9 and 3-10 except DEPBT was used as the coupling 
agent instead of TBTU (see Scheme 3-7). 3-11 was purified by sonicating the sample in acetone 
(since the free MesoPOR-3PEG is soluble in it) and centrifuging, causing the product to form a 
separate layer. Under the various conditions tested the di product 3-12 was not produced. This 
!
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might be due to racemization or/and steric hindrance from the second peptide trying to couple to 
the free carboxylic acid of 3-12.  
 
 














1. DIEA (12 equiv)
    DMF
    stir for 2 at 60°C
2. DEPBT (2.10 equiv)
    HOBT (2.50 equiv)
    stir for 2 h at 60°C
3. EGFR-L2-GLY (2 equiv)

















































































































































































MesoPOR-diPEG-EGFR-L2-SAR (3-13) was synthesized by activating 3-8 for 2 hours in DIEA 
and DMF. TBTU and HOBT were added to the reaction and allowed to stir for 30 minutes. 
 
 














1. DIEA (12 equiv)
    DMF
    stir for 2 hours at 60°C
 2. DEPBT (2.10 equiv)
     HOBT (2.50 equiv)
     stir for 2 hours at 60°C
3. EGFR-L2-SAR (2 equiv)













































































































































































EGFR-L2-SAR was then added and reacted for four days (see Scheme 3-8). MALDI-MS 
confirmed that this reaction worked but the product was not isolated after RP-HPLC. EGFR-L2-
SAR has a secondary amine on the N-terminus due to sarcosine being an N-methylated glycine 
residue. The N-methylated glycine is more sterically hindered and is preventing the reaction 
from working. All molecules synthesized were characterized by MALDI-MS, MALDI-MS/MS, 
1
H-NMR, UV-Vis and Fluorescence spectroscopy (see experimental procedures). Table 3-5 lists 
the different bioconjugates synthesized with molecular weight, conditions for reactions, and 
percent yield. 
 
Table 3-5: Molecular Weight, Conditions for reactions, and Percent Yield. 

























































Xbridge C18 or Atlantis C18 column using water/acetonitrile gradient. 
+
Solid phase 
extraction, extraction, centrifugation, and/or column chromatography was used to purify 
bioconjugates. 
 
3.2.4 Second Series of Bioconjugates MesoPOR to Peptides 
The second series of bioconjugates was synthesized without the PEG moiety. These 
bioconjugates were synthesized using the same procedure used for the first series of 
!
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bioconjugates.  MesoPOR was coupled directly to the free peptide by activating the porphyrin in 
DIEA/DMF for 2 hours. To the activated solution TBTU and DIEA were added and allowed to 
stir for 30 minutes. The free peptide EGFR-L1 was then added to this solution and allowed to stir 
for 4 days, as shown in Scheme 3-9. These reaction products were purified using two separate 
conditions using RP-HPLC and SPE. RP-HPLC isolated the MesoPOR-(m)EGFR-L1 (3-15) and 
MesoPOR-(di)EGFR-L1 (3-16) with a yield 67 % and 28 %, respectively. TLC was used to 
determine the best solvent system containing MeOH, acetone, and ACN (1/2/7) to separate the 
free MesoPOR from products 3-15 and 3-16. Using two equivalents of coupling agents and two 
equivalents of peptide under heat produced the di product 3-16, isolated in 88% yield. The mono 
bioconjugate 3-15 was isolated as a mixture of regioisomers from couplings at the 13 and 17 
positions. MesoPOR was coupled to the N-methylated EGFR-L1 using TBTU and HOBT. Due 
to the low racemization of EGFR-L1-D1 this bioconjugate was synthesized and purified in 
30.4% yield. Scheme 3-9 shows the procedure for synthesizing MesoPOR-EGFR-L1-D1 (3-17 
and 3-18) as shown in Scheme 3-10. EGFR-L2-GLY was coupled using various conditions 
including PyAOP and HOAT as a coupling agent and isolated with a percent yield of 20%, (see 
Scheme 3-11). The protocol for this reaction is similar to the previous protocol but this reaction 
was not heated. PyAOP is a phosphonium salt that produces cleaner reactions and is used for 
coupling difficult reactions.
20,21
 This reaction was repeated using DEPBT and PYBroP. Both 
reactions worked but MesoPOR-EGFR-L2-GLY (3-19 and 3-20) was not a pure fraction isolated 
from SPE. DCM/MeOH (0.25 /9.75) was the best solvent system as determined by TLC to purify 
MesoPOR-EGFR-L2-GLY (3-19). A fraction from each reaction was isolated and tested by 
1
H-
NMR. The protons from the meso position of the porphyrin were not observed at ~10 ppm. 






Scheme 3-9: Solution phase coupling of MesoPOR-EGFR-L1 (3-15 and 3-16). 
 
The optimized conditions for synthesizing 3-19 is to activated the MesoPOR for 2 hours in 
DMF/DIEA at 60°C and add coupling agents DEPBT and HOBT at 60°C. The free peptide 
EGFR-L2-GLY was added at 60°C and the reaction mixture was allowed to stir for 4 days, see 
Scheme 3-11. This reaction mixture was purified by dissolving the compound in MeOH/DCM 
(1/9) sonicated and centrifuged. The precipitate was then purified using SPE with MeOH/DCM 








2. TBTU (2.10 equiv)
    HOBT (2.50 equiv)
    stir for 30 min at 60°C
3. EGFR-L1 (2 equiv)
    stir at 60°C
1. DIEA (12 equiv)
    DMF   














































































Scheme 3-10: Solution phase coupling of MesoPOR-EGFR-L1-D1 (3-17 and 3-18). 
 
MesoPOR-EGFR-L2-SAR was prepared using to different coupling agents, PyAOP/HOAT and 
DEPBT/HOBT. The reaction with PyAOP gave the expected products, as determined by 
MALDI-MS but purification by RP-HPLC did not yield the bioconjugate. The second reaction of 
DEPBT and HOBT under heat gave a 40 % yield of after purification. To purify MesoPOR-







2. TBTU (2.10 equiv)
    HOBT (2.50 equiv)
    stir for 30 min at 60°C
3. EGFR-L1 (2 equiv)
    stir at 60°C
1. DIEA (12 equiv)
    DMF   













































































































































2. DEPBT (2.10 equiv)
  HOBT (2.50 equiv)
       stir for 30 min at 60°C
3. EGFR-L2-GLY (2 equiv)
    stir under at 60°C
1. DIEA (12 equiv)
    DMF








































































































































































2. DEPBT (2.10 equiv)
  HOBT (2.50 equiv)
       stir for 30 min at 60°C
3. EGFR-L2-SAR (2 equiv)
    stir under at 60°C
1. DIEA (12 equiv)
    DMF









































































































The precipitate was then purified using SPE with MeOH/DCM (1:9). All molecules synthesized 
were characterized by MALDI-MS, MALDI-MS/MS, 
1
H-NMR, UV-Vis and Fluorescence 
spectroscopy (see experimental procedures). Table 3-6 lists the different bioconjugates 
synthesized with molecular weight, conditions for reactions, percent yield, and purification 
technique. 
 
Table 3-6: Molecular Weight, Conditions for reaction, Retention Time from RP-HPLC, and 
Percent Yield 

















































































Xbridge C18 or Atlantis C18 column using water/acetonitrile gradient. 
+
Solid phase 






3.3 Characterization of Bioconjugates 
3.3.1 Circular Dichroism 
Circular dichroism was used to evaluate the conformation of the free peptide alone in 0.5 
mM PBS with 10% TFE at pH 7.37. TFE was added to mimic membrane environment which 
usually increase the propensity of forming a !-helix by increasing the intramolecular hydrogen 
bonding. The free peptides were evaluated at 1000 µM, 750 µM, 500 µM, 250 µM, 125 µM, 75 
µM, and 50 µM in Chapter 2. EGFR-L1 and EGFR-L2-GLY at concentrations lower than 250 
µM have random coil conformations. At concentrations above 250 µM EGFR-L2-GLY 
transitions from random coil to a !-helix. At 500 µM the conformation is shifting from a !-helix 
to a "-sheet. The initial approach to synthesizing these conjugates was to couple the peptide to 
the PEG and then to the porphyrin. The pegylated peptides were characterized by CD to observe 
that EGFR-L1-PEG produced a 310-helix and EGFR-L2-GLY-PEG produced a !-helix 
conformation. Studies have shown that peptide conjugates tend to retain the original 
conformation (random coil, !-helix, or "-sheet) before conjugation.
22
 To evaluate the influence 
of the porphyrin and the PEG linker on the peptide configuration select bioconjugates were 
tested using 0.5 mM PBS with 10% TFE as a membrane mimicking environment. Porphyrins are 
aromatic molecules that absorb strongly in the visible to near IR region of the spectrum. The 
absorption of the porphyrin macrocycle might suppress the signal of the peptide bond due to the 
strong absorption in the 250 nm to 280 nm aromatic region. A strong CD signal can be observed 
if the peptide contains a long chain of peptide bonds. It has been shown that the conformation of 
peptide bioconjugates can be observed by CD where the length of the peptide contains 6 or more 
residues.
22,23,24,25
 The concentrations of the bioconjugates tested were 37.5 µM and 15 µM, at 
these low concentrations the peptides are expected to have a random coil conformation, as 
!
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described in Chapter 2. Concentrations of bioconjugates up to 300 µM were investigated but due 
to saturation of the high voltage the best dilutions were 37.5 µM and 15 µM. In comparison to 
the literature the bioconjugates were tested at a 20 µM concentration.
22,23,24,25
 Figure 3-10 shows 
the CD spectra of 3-10. Common conformations of CD are random coil, !-helix, and " sheet; 
other conformations such as 310-helix. The 310-helix varies from the !-helix with hydrogen bond 
between the carbonyl (C=O) of residue n to the amide (N-H) of residue n + 3 (as opposed to the 





Figure 3-10: CD spectrum of MesoPOR-di3PEG-diEGFR-L1 at 37.5 µM and 15 µM. 
 
The 310-helix favors an alpha helix but has a circular peak at 205 nm. 3-10 at 37.5 µM 
concentration shows a 310-helix conformation with a positive peak at 195 nm and two negative 
peaks at 205 nm and 228 nm in its CD spectrum (see Figure 3-10). The 15 µM concentration has 
an ! helix conformation with peaks at 193 nm and two negative peaks at 205 nm and 227. Figure 
3-11 shows the CD spectrum of MesoPOR-diEGFR-L1. This bioconjugate shows a mixture of a 
!-helix and "-sheet conformation at the 37.5 µM and 15 µM concentrations. For 3-16 at the 37.5 
!
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µM one negative peak is observed at 217 nm, associated with a positive peak at 200 nm. For the 
15 µM concentration two negative peaks are observed at 213 nm and 224 nm, associated with a 
positive peak at ~ 200 nm. 3-16 has two peptides and depending upon the conformation the 
peptide, may lie parallel to the other. This would increase the possibility of hydrogen bonding 
between the two peptides to form a week !-sheet due to the size of the peptides.  
 
 
 Figure 3-11: CD spectrum of MesoPOR-diEGFR-L1 at 37.5 µM and 15 µM. 
 
The peptides herein are small peptides consisting of six and thirteen residues but they could 
adopt secondary structures. Studies have also shown that bioconjugates containing eight amino 
acids tend to have a random coil conformation.
23
 Other bioconjugates were tested but 
informative CD spectra were not obtained. The molar ellipticity values for each bioconjugate 
was calculated, as shown Table 3-7. Sibrian-Vazquez reported that the hydrophobic character of 
the peptides may be responsible for the changes in conformation such as the "-helix in 
membrane mimicking environments.
22
 Therefore, the percent composition of the peptides in 
bioconjugates 3-10 and 3-16 were evaluated as shown in Table 3-8. 
!
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Table 3-7: Molar Ellipticity of EGFR-L1 and EGFR-L1-D1 





 Name Concentration 0.5mM PBS with  
10% TFE at pH 7.4 
1 MesoPOR-(di)3PEG-(di)EGFR-L1 
37.5 µM 
-13129 (205 nm) 
-4860 (227 nm) 
15 µM  
-3821 (205 nm) 
- 2854 (227 nm) 
2 MesoPOR-(di)EGFR-L1 37.5 µM -5519 (217 nm) 
15 µM 
-4921 (213 nm) 
-4223 (224 nm) 
 
The free peptides (see Chapter 2) were 100 % peptide while a different percent of peptide is 
present in the bioconjugate. The percent composition of a pegylated porphyrin to peptide ranged 





Table 3-8: Percent Composition of peptides in bioconjugates 
# Name Abbreviation Percent Composition 
of Peptide 
1 MesoPOR-(di)3PEG-(m)EGFR-L1 3-9 41.7 % 
2 MesoPOR-(di)3PEG-(di)EGFR-L1 3-10 57.9 % 
3 MesoPOR-(di)3PEG-(m)EGFR-L2 3-11 62.5 % 
4 MesoPOR-(m)EGFR-L1 3-15 55.5 % 
5 MesoPOR-(di)EGFR-L1 3-16 66.3 % 
6 MesoPOR-(m)EGFR-L1-D1 3-17 56 % 
7 MesoPOR-(m)EGFR-L2 3-19 74.4 % 
8 MesoPOR-EGFR-L2-SAR 3-21 74.5 % 
 
Web-based programs were used to assess the percentage of secondary structures present 
in the conformation of each bioconjugates.
27
 These programs are not very accurate but K2D2 
was used to evaluate the secondary structures.
28
 Table 3-9 lists the percentage of !-helix and "-
sheet conformation determined for each bioconjugate. To further confirm that the conformations 
consist of a mixture it is reported that for a 100% "-sheet protein with a CD signal range of 215 – 
!
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 The calculated molar ellipticity value of MesoPOR-
(di)EGFR-L1 (3-16) at 217 nm is -5519. This suggests that the conformation contains 25% of a 
!-sheet conformation and is in agreeance with the K2D2 calculations.  
 
Table 3-9: Percentage of "-helix and !-sheet Conformation of each Bioconjugate 
  Concentration K2d2 
190 nm to 240 nm 
# Name  "-helix !-sheet 
1 EGFR-L1-PEG 50 µM 10.45 %  29.09 % 
2 MesoPOR-(di)3PEG-(di)EGFR-L1 37.5 µM 14.13 %  27.49 % 
15 µM 3.44 % 47.08 % 
3 MesoPOR-(di)EGFR-L1 37.5 µM  25.35 % 24.96 % 
15 µM 1.82 % 47.7 % 
 
Calculations for the two bioconjugates were performed to observe the potential structure 
and to determine if this could assist with explaining the CD results. Chem3D was used to 
calculate the minimization energy using molecular dynamics and molecular mechanics (MM2) in 
vacuum. These calculations were performed without considering any solvent, the true 
conformation of the bioconjugate may be different when calculations are performed explicit or 
implicit. The atoms in Figure 3-12 and Figure 3-14 are represented as follows nitrogen (blue), 
carbon (grey), and oxygen (red). Figure 3-12 shows the lowest conformation was determined for 
the following molecules EGFR-L1 (A), MesoPOR-(di)PEG (3-8) (B), MesoPOR-(di)PEG-
(m)EGFR-L1 (3-9) (C) and  MesoPOR-(di)PEG-(di)EGFR-L1 (3-10) (D). EGFR-L1 adopts non-
linear conformation and MesoPOR-(di)PEG adopts a planer conformation with the PEG groups 
in opposite directions. MesoPOR-(di)PEG-(m)EGFR-L1 (3-9) and MesoPOR-(di)PEG-
(di)EGFR-L1 (3-10) have an extended conformation but the peptide-PEG repulses each other 
and extends in the opposite direction. Both 3-9 and 3-10 appear to form circular loops that may 




Figure 3-12: Chem3D spectrum of MesoPOR-(di)PEG-(di)EGFR-L1 (3-10). 
 
Figure 3-13 shows the lowest conformation of EGFR-L1 (A), MesoPOR (B), MesoPOR-
(m)EGFR-L1 (3-15) (C), and MesoPOR-(di)EGFR-L1 (3-16) (D). Figure 3-13C EGFR-L1 
coupled to the porphyrin folds onto the porphyrin macrocycle. For MesoPOR-(di)EGFR-L1, 
shown in Figure 3-13D, the peptides interact more instead of extending away from each other, as 
observed for MesoPOR-(di)PEG-(di)EGFR-L1. To form a !-sheet the peptide must lie parallel or 
antiparallel to each other. It is hard to see the amides lying in range to bind to the carbonyl. It can 
also be observed that a small circular formation is seen (Figure 3-13D) and this may also account 




Figure 3-13: Chem3D spectrum of MesoPOR-(di)EGFR-L1 (3-16). 
 
Figure 3-14 shows the molecular conformations for EGFR-L2-GLY (A), MeosPOR-EGFR-L2-
GLY (B), MesoPOR-EGFR-L2-SAR (C), and MesoPOR-(di)PEG-EGFR-L2-GLY (D). EGFR-
L2-GLY forms a non-linear conformation so that the aromatic amino acids (histidine and 
tyrosine residues) extended away form the peptide backbone. This conformation is maintained 
for MesoPOR-EGFR-L2-SAR and MesoPOR-EGFR-L2-GLY. EGFR-L2-GLY appears to adopt 




Figure 3-14: Chem3D spectrum of MesoPOR-(di)EGFR-L1 (3-16). 
 
3.3.2 Photophysical Studies 
UV-Vis and Fluorescence spectroscopy were used to investigate the absorption and 
emission properties of the first and second series of bioconjugates. The first series of 
bioconjugates red shifts from 398 nm for the MesoPOR-(di)PEG to 408 nm in the absorption of 
MesoPOR-(di)PEG-(di)EGFR-L1 (3-10) and MesoPOR-(di)PEG-(di)EGFR-L2-GLY (3-11), 
were observed in Figure 3-15.  The shift in absorption of these bioconjugates might be due to 
aggregation.
29
 Roeder et. al. investigated the photophysical properties of mesoporphyrin, 




Figure 3-15: Structures of Hematoporphyrin (A) and Chlorin e6 (B). 
 
They reported that mesoporphyrin and hematoporphyrin aggregated in neutral phosphate buffer 
solution containing 1% ethanol.
29
 Chlorin e6 did not aggregate in the aqueous environment. It 
was suggested that the short fluorescence decay of chlorin e6 was due to the relaxation of the 
porphyrin.
29
 While equilibrium aggregates formed in the aqueous environments shifts the 




















Figure 3-15 shows the structures of hematoporphyrin and chlorin e6. The bioconjugates 
synthesized and investigated in this chapter were evaluated in a polar aprotic solvent, such as 




Figure 3-17: UV-Vis spectrum of Porphyrin Peptide bioconjugates. 
 
The absorbance of the second series of bioconjugates is shown in Figure 3-17. The second series 
of bioconjugates may not aggregate as much as the first series of bioconjugates. The PEG 
moiety, might enhance the effects of aggregation in the first series of bioconjugates. The peaks 
for these conjugates are broad with a slight shift in absorbance as observed for MesoPOR-EGFR-
L1 (3-15) and MesoPOR-(di)EGFR-L1 (3-16). The average maximum excitation of the 
bioconjugates is 400 nm. The molar absorptivity of the Soret band and the Q-bands for first and 




Figure 3-18: Fluorescence spectrum of Porphyrin PEG Peptide bioconjugates. 
 
Fluorescence spectroscopy was used to determine the maximum emission of the bioconjugates. 




Figure 3-19: Fluorescence Spectrum of Porphyrin PEG Peptide bioconjugates. 
!
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A shift in emission is observed for MesoPOR-(di)PEG-(di)EGFR-L1 (3-10) and MesoPOR-
(di)PEG-EGFR-L2-GLY (3-11) in comparison to MesoPOR-(di)PEG (3-8) alone that might be 
due to aggregation, see Figure 3-18. The emission of the second series of bioconjugates is shown 
in Figure 3-19 as observed by the red-shift for MesoPOR-EGFR-L2-GLY (3-11). Table 3-10 
lists the molar absorptivity (!) and the fluorescent quantum yield of ("F) of the first and second 
series of bioconjugates. The "F of mesoporphyrin in DMF is reported to be 0.102.
30
 The "F of 
MesoPOR here is 0.57, which is very high, and will be reevaluated. 
 
Table 3-10: Molar Absorptivity and Quantum Yield of Bioconjugates 
First Series of Bioconjugates in DMF 
# Compound 
#max ! #Em "F 
Stokes 
Shift 
1 MesoPOR-(di)3PEG 398, 497 225000, 15000 618, 651 0.086 220 
530, 566 15000, 10000 665, 684   
616 5000    
2 MesoPOR-(di)PEG-
(di)EGFR-L1 
408, 497 156000, 12000 620, 655 0.124 212 
530, 573 10000, 8000 670, 686   
618 4000    
3 MesoPOR-(di)PEG-
(m)EGFR-L2-GLY 
408, 497 174000, 14000 621, 655 0.132 213 
531, 574 12000, 10000 670, 686   
618 4000    
Second Series of Bioconjugates in DMF 
4 MesoPOR 397, 497 295276, 27067 617, 645 * 220 
530, 566 17224, 12303 665, 684   
615 9843    
5 MesoPOR-(m)EGFR-
L1 
398, 497 132500, 11250 619, 643 0.110 222 
530, 566 8750, 6250 665, 684   
617 3750    
6 MesoPOR-(di)EGFR-
L1 
407, 497 154286, 11429 618, 645 0.089 220 
530, 577 10000, 8571 665, 684   
615 4286    
7 MesoPOR-(m)EGFR-
L2-GLY 
397, 497 118750, 11250 620, 646 0.124 223 
530, 566 7500, 6250 670, 690   
618 3750    




The !F of the first and second series are close in proximity to the reported !F of MesoPOR of 
0.102. The Stokes shift, difference in the "max emission and maximum "max absorbance of the 
conjugates are shown in Table 3-10. 
 
3.4 Conclusions 
Two series of bioconjugates were synthesized using solution phase coupling reactions. 
Various coupling agents were used, including TBTU, DEPBT, PyBroP, PyAOP, and additives 
HOBT and HOAT. The bioconjugates were synthesized with an average yield ranging from 15 
% to 83%. These bioconjugates were characterized using Circular Dichroism and by 
computational studies to investigate their conformations, as well as by UV-Vis spectroscopy, and 
fluorescence spectroscopy. MesoPOR-(di)PEG-(di)EGFR-L1 (3-10) was evaluated using CD 
where a 310 helix was potentially observed. The computational studies, while not conclusive, 
suggest that MesoPOR-(di)PEG-(di)EGFR-L1 (3-10) folds in #-helix or a 310 helix manner. 
MesoPOR-(di)EGFR-L1 (3-16) at higher concentrations might adopt (37.5 µM) $-sheet 
conformation and at lower concentrations (15 µM) a mixture of #-helix and $-sheet were 
observed. The behavior of these bioconjugates might be due to hydrophobicity. The percentage 
of secondary structures was calculated using K2D2 program with a #-helix range 2% - 25% and 
a $-sheet range from 25% - 48%. UV-Vis and fluorescence spectroscopy of the first series and 
second series of bioconjugates gave an average excitation at 400 nm and an average emission at 
620 nm, respectively. The broad peaks and red-shifts observed for MesoPOR-(di)PEG-
(di)EGFR-L1 (3-10), MesoPOR-(di)PEG-EGFR-L2-GLY (3-11), MesoPOR-(di)EGFR-L1 (3-




3.5 Experimental Procedures 
3.5.1 Solid and Solution Phase Synthesis  
All reactions were carried out under nitrogen atmosphere. All peptide synthesis reagents were 
purchased from Fisher Scientific or Sigma Aldrich grade ACS or Peptide synthesis Grade 
solvents. Amino acids were purchased from AnaSpec or Applied Biosystems. Silica gel 60Å 
(230 x 400 mesh, Merck) was used for column chromatography. Analytical thin layer 
chromatography (TLC) was performed using silica G TLC Plates w/UV254 (precoated sheets, 
0.2 mm thick). HPLC separation was carried out using on a Waters system including a 2545 
quaternary gradient module pump, 2489 UV/Visible detector, and a fraction collecter III. 
Analytical HPLC was carried out using a XBridge C18 300Å, 5µm, 4.6 x 250 mm (Waters, USA) 
column using a stepwise gradient. Semipreparative HPLC was carried out a XBridge C18 300Å, 5 
µm, 10 x 250 mm (Waters, USA) column using a stepwise gradient. The solvent system for the 
peptides consisted of millipure water and HPLC grade acetonitrile with 0.1% TFA. 1H-NMR 
spectra were obtained using a Bruker AV 400 MHz spectrometer; chemical shifts are expressed 
in ppm relative to TMS (0 ppm). Photophysical studies were performed on a Perkin Elmer 
Lambda 35 UV-VIS and Jobn-yvon Spec-3 Fluorescence spectrophotomer. High-resolution mass 
spectra (HRMS) were obtained using Bruker Ultraflex Extreme MALDI Tandem TOF Mass 
Spectrometer. !-cyano-4-hydroxycinnamic acid (CHCA) was used for the matrix. Purified 
peptides were used for solution phase coupling with select coupling agents and coupling 
additives TBTU, DEPBT, or PYBROP, PYAOP, and HOBT.   
• First Attempt to Synthesize First Series of Bioconjugates Into a round bottom flask 
FMOC-PEG was activated using DMF and DIEA. EGFR-L1 coupling agents TBTU, HOBT, 
DIEA, and DMF was added to the flask and allowed to stir for five days. The contents of the 
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flask was concentrated using nitrogen. A mixture of diethylamine and acetonitrile (50:50) 
was used to remove the FMOC group from PEG-EGFR_L1. This mixture was then dried 
down. The contents in the round bottom flask was resuspended in DMF. In a separate flask 
MesoPOR was activated using DMF and DIEA for one hour. Into the same flask containing 
MesoPOR, TBTU (2.10 equiv), HOBT (2.50 equiv), DMF, and DIEA was added. This was 
placed under inert conditions and allowed to react for 2 hours. The last step was to added the 
porphyrin and coupling agent mixture to the original round bottom flask mixture and allowed 
to stir for three days. The reaction mixture was allowed to react until the Kaiser test was 
negative. The bioconjugates was then purified using RP-HPLC. These conjugates were not 
full characterized due to amount of bioconjugate recovered after RP-HPLC.  
 
• Second Approach to Synthesize Bioconjugates MesoPOR-(di)3PEG-Tbutyl (MesoPOR-
3PEG-Tbutyl) To a round bottom flask MesoPOR was activated for two hours in DMF and 
DIEA (12 equiv) under inert conditions at 60°C. TBTU, HOBT, DMF, and DIEA was added 
to the flask and allowed to stir for thirty minutes under inert conditions at 60°C. 3PEG was 
dissolved in DMF and DIEA and added into the round bottom flask at 60°C. The reaction 
was allowed to stir for 5 days. Ethylacetae was then added to the flask. Water and 
ethylacetate was added to a separatory funnel and gently swirled. The crude product was 
further purified by column chromatograph by loading the sample with MEOH/DCM (2/98) 
and running the column with MEOH/DCM (5/95). The solid red compound has a yield of 88 
%; HPLC tR = 34.18 min; MS (MALDI) m/z 1084.37 [M+1]; 
1
H NMR (DMF, 400MHz): ! 
10.4 (1H, s), 10.29 (3H, s), 8.10 (2H, p, J = 6.26 Hz), 4.46 (4H, m), 4.19 (4H, p, J = 6.81 
Hz), 3.70 (14H, m), 3.59 (2H, d, J = 3.23 Hz), 3.46 (4H, t, J = 6.14 Hz), 3.20 (12H, m), 3.03 
!
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(2H, t, J = 5.50 Hz), 2.90 (2H, m), 2.67 (8H, m), 2.32 (4H, m), 1.88 (6H, m), 1.36 (18H, m), 
-3.80 (2H, s). 
!
• MesoPOR-(di)PEG One hundred percent TFA was added to MesoPOR-(di)PEGTbutyl to 
remove the tertbutyl protecting group. The solid dark red compound has a yield of 96%; 
HPLC tR = 19.43 min; MS (MALDI) m/z 974.00 [M+1]; 
1
H NMR (DMF, 500MHz): ! 10.29 
(2H, s), 10.23 (2H, m), 8.08 (2H, m), 4.40 (4H, m), 4.22 (4H, m), 3.69 (12H, m), 3.55 (4H, 
m), 3.29 (4H, s), 3.20 (12H, m), 3.04 (4H, m), 2.91 (8H, m), 2.44 (4H, m), 1.86 (6H, m). 
 
• MesoPOR-(di)3PEG-(di)EGFR-L1 To a round bottom flask MesoPOR-diPEG was 
activated for two hours in DMF and DIEA (12 equiv) under inert conditions at 60°C. TBTU, 
HOBT, DMF, and DIEA was added to the flask and allowed to stir for thirty minutes under 
inert conditions at 60°C. EGFR-L1 was dissolved in DMF and DIEA and added into the 
round bottom flask. The reaction was allowed to stir for 5 days. The reaction was then dried 
under nitrogen and the solvent system was determined using TLC. The crude was dissolved 
in acetone, sonicated, and centrifuged. The supernatant was removed and the precipitate was 
dissolved in MeOH/Acetone/ACN (5/60/35) for purification C18 solid phase extraction 
(SPE). The SPE was conditioned with methanol (5 times), water (5 times) and 
MeOH/Acetone/ACN (3 times). The crude was loaded onto the SPE cartridge and washed 
until the solvent was clear. TFA was then added to the solvent system to elute the compound 
that was stuck to the column. The solid dark red compound has a yield of 15.8 %, HPLC tR  = 
19.86 min; MS (MALDI) m/z 2306.48; 
1
H NMR (DMF, 400MHz): ! 10.46 (1H, s), 10.33 
(3H, m), 8.42 (6H, m), 7.90 (6H, d, J = 5.83 Hz), 7.81 (3H, d, J = 6.72 Hz), 7.46 (4H, d, J = 
8.52 Hz), 7.14 (2H, s), 7.09 (2H, s),  4.46 (8H, m), 4.36 (4H, m), 4.22 (24H, m), 3.71 (20H, 
!
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m), 3.58 (12H, m), 2.47 (4H, m), 1.90 (16H, t, J = 7.27 Hz), 1.74 (14H, m), 1.32 (6H, m), 
1.15 (6H, m), 0.894 (37H, m). 
 
• MesoPOR-(di)3PEG-EGFR-L2-GLY Into a round bottom flask MesoPOR-diPEG was 
activated for 2 hours using DMF and DIEA under inert conditions at 60°C. Into the same 
flask DEPBT, HOBT, DMF, and DIEA was added and allowed to stir for thirty minutes 
under inert conditions at 60°C. EGFR-L2-GLY was dissolved in DMF and base into the 
round bottom flask at 60°C. This was allowed to stir for 5 days. The sample was dissolved in 
acetone, sonicated, and centrifuged several times. The solid red compound has a yield of 38.7 
%; HPLC tR = 25.862 min; MS (MALDI) m/z 2551.27; 
1
H NMR (DMF, 400MHz): ! 10.30 
(1H, s), 10.23 (3H, s), 9.14 (2H), 8.23 (4H, m), 7.94 (4H, m), 7.68 (3H, d, J = 12.11 Hz), 
7.42 (2H, m), 7.20 (6H, m), 6.96 (14H, m), 6.61 (9H, d, J = 6.05 Hz), 4.69 (1H, s), 4.57 (3H, 
t, J = 4.03 Hz), 4.33 (10H, m), 4.10 (12H, m), 3.86 (1H, m), 3.63 (26H, m), 3.32 (16H, m), 
3.03 (14H, m), 2.72 (3H, m), 2.11 (5H, m), 1.80 (14H, m), 1.10 (6H, m), 0.82 (11H, m). 
 
• MesoPOR-(di)PEG-EGFR-L2-SAR Into a round bottom flask MesoPOR-diPEG was 
activated for 2 hours using DMF and DIEA under inert conditions at 37°C. Into the same 
flask TBTU, HOBT, DMF, and DIEA was added and allowed to stir for thirty minutes under 
inert conditions at 37°C. EGFR-L2-SAR was dissolved in DMF and base into the round 
bottom flask at 37°C. This was allowed to stir for 5 days. The sample was dissolved in 




• Mesoporphyrin IX dihydrocholoride (MesoPOR) The solid red compound was 
commercially purchased. MS (MALDI) m/z 567.318; 
1
H NMR (CDCl3 w/TFA, 400MHz): ! 
10.94 (1H, s), 10.67 (3H, s), 8.10 (2H, t, J = 5.97 Hz), 4.46 (4H, m), 4.18 (4H, q, J = 6.63 
Hz), 3.69 (12H, s), 3.35 (4H, q, J = 5.30 Hz), 1.88 (6H, q, J = 6.63 Hz) -3.65 (2H, s), -3.85 
(2H, s). 
 
• Mesoporphyrin IX dihydrochloride EGFR-L1 (MesoPOR-(m)EGFR-L1) To a round 
bottom flask MesoPOR was activated for two hours in DMF and DIEA (12 equiv) under 
inert conditions at 60°C. TBTU, HOBT, DMF, and DIEA was added to the flask and allowed 
to stir for thirty minutes under inert conditions at 60°C. EGFR-L1 was dissolved in DMF and 
DIEA and added into the round bottom flask. The reaction was allowed to stir for 5 days. RP-
HPLC was used to purify this conjugate. The solid red compound has a yield of 67 %; HPLC 
tR = 41.62 min; MS (MALDI) m/z 1233.91; 
1
H NMR (DMF, 400MHz): ! 10.41 (1H, s), 
10.30 (3H, s), 8.44 (1H, d, J = 5.39), 8.35 (1H, s), 8.26 (1H, m), 7.91 (2H, d, J = 7.19), 7.76 
(4H, m), 7.56 (2H, m), 7.21 (3H, m), 4.48 (10H, m), 4.28 (6H, m), 3.70 (16H, m), 2.02 (4H, 
m), 1.88 (12H, m), 1.77 (6H, m), 1.17 (6H, m), 0.91 (18H, m). 
!
• MesoPOR-(di)EGFR-L1 To a round bottom flask MesoPOR was activated for two hours in 
DMF and DIEA (12 equiv) under inert conditions at 60°C. TBTU, HOBT, DMF, and DIEA 
was added to the flask and allowed to stir for thirty minutes under inert conditions at 60°C. 
EGFR-L1 was dissolved in DMF and DIEA and added into the round bottom flask. The 
reaction was allowed to stir for 5 days. The reaction was then dried under nitrogen and the 
solvent system was determined using TLC. A ratio of MeOH/Acetone/ACN (5/60/35) was 
used for C18 solid phase extraction (SPE). The SPE was conditioned with methanol (5 
!
 111 
times), water (5 times) and MeOH/Acetone/ACN (3 times). The crude was dissolved and 
sonicated in MeOH/Acetone/ACN (0.5/6/3.5) and loaded onto the SPE cartridge. The 
cartridge was the eluted until the solvent was clear. TFA was then added to the solvent 
system to elute the compound that was stuck to the column. The solid red compound has a 
yield of 83 %; HPLC tR = 35.01 min; MS (MALDI) m/z 1900.39; 
1
H NMR (DMF, 500MHz): 
! 10.43 (1H, s), 10.33 (3H, s), 8.51 (2H,s), 8.41 (2H, s), 7.98 (2H, m), 7.91 (2H, m), 7.78 
(1H, m), 7.68 (1H, m), 7.52 (6H, m), 7.17 (4H, d, J = 8.42 Hz), 4.49 (5H, m), 4.32 (9H, m), 
4.20 (12H, m), 3.81 (2H, m), 3.7 (14H, m), 1.89 (9H, m), 1.70 (19H, m), 1.40 (17H, m), 1.13 
(12H, m), 0.83 (37H, m). 
 
• MesoPOR-EGFR-L2-GLY Into a round bottom flask MesoPOR was activated for 2 hours 
using DMF and DIEA under inert conditions at 60°C. Into the same flask DEPBT, HOBT, 
DMF, and DIEA was added and allowed to stir for thirty minutes under inert conditions at 
60°C. EGFR-L2-GLY was dissolved in DMF and base into the round bottom flask at 60°C. 
This was allowed to stir for 5 days. To purify this reaction TLC was used to determine the 
best solvent system of MeOH/DCM (1/9) on normal phase silica. The compound was 
dissolved in MeOH/DCM sonicated and centrifuged several times. Mostly the porphyrin was 
soluble and this allowed the compound to clump on the SPE. The solid red compound has a 
yield of 50.6; HPLC tR = 36.20 min; MS (MALDI) m/z 2145.23; 
1
H NMR (DMF, 400MHz): 
! 10.80 (1H, s), 10.34 (3H, s), 9.07 (1H, p, J = 11.70 Hz), 8.36 (4H, m), 7.77 (1H, m), 7.65 
(3H, m), 7.46 (1H, m), 7.34 (1H, m), 7.25 (3H, m), 7.04 (14H, m), 6.71 (8H, m), 4.71 (5H, 
m), 4.47 (5H, m), 4.21 (9H, m), 3.71 (22H, m), 3.29 (5H, m), 3.09 (2H, m), 2.33 (3H, m), 




• MesoPOR-EGFR-L2-SAR Into a round bottom flask MesoPOR was activated for 2 hours 
using DMF and DIEA under inert conditions at 60°C. Into the same flask PyBroP, HOBT, 
DMF, and DIEA was added and allowed to stir for thirty minutes under inert conditions at 
60°C. EGFR-L2-SAR was dissolved in DMF and base into the round bottom flask at 60°C. 
This was allowed to stir for 5 days. To purify this reaction TLC was used to determine the 
best solvent system of MeOH/DCM (1/9) on normal phase silica. The compound was 
dissolved in MeOH/DCM sonicated and centrifuged several times. The solid red compound 
has a yield of 40 %; HPLC tR = 2.73 min; MS (MALDI) m/z 2159.35. 
 
3.5.2 Characterization of Bioconjugates 
Circular dichroism measurements were carried out on a AVIV 620S circular dichroism 
spectrometer using 1mm path length quartz cell. Peptide solutions (various concentrations) were 
prepared in Phosphate Buffered Solution/Trifluroethanol (9/1) with a pH of 7.4. All spectra 
correspond to an average of three runs and were corrected by the baseline obtained for peptide 
free solutions. Photophysical studies were performed on a Perkin Elmer Lambda 35 UV-VIS and 
Jobn-yvon Spec-3 Fluorescence spectrophotomer in peptide sequencing grade DMF. Mass 
spectra were obtained using Bruker UltrafleXtreme for (MALDI-MS) and MALDI-MS/MS 
using CHCA matrix.  
1
H-NMR spectra were obtained using a Bruker 250 MHz or 400 MHz and 
a Varian 500 MHz in CDCl3 with a drop of TFA, DMSO-d6, or DMF-d7. 
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BIOLOGICAL EVALUATION OF PEPTIDE-BASED PORPHYRIN AND 
PHTHALOCYANINE BIOCONJUGATES FOR THE DETECTION OF CRC 
 
 
4.1  Introduction 
4.1.1 Fluorescent Dyes 
Selective targeting has been an improved technique and is considered the gold standard 
for targeting different diseases such as cancer.
1
 Often the flat or depressed neoplasms or polyps 
are difficult to detect.
1
 Detection at the initial stage of CRC provides the best odds of fighting 
CRC before it develops into adenoma carcinoma. There are different types of dyes that can be 
divided into three different classes such as contrast, adsorptive, and reactive stains.
2
  The use of 
near infrared (NIR) fluorescing molecules reduces the background auto-fluorescence from blood 
plasma and tissues. Therefore, the design of NIR fluorescent molecules provides a form of 
selectivity by reducing the auto-fluorescence from surrounding tissues. Furthermore, using 
specific molecules as a homing sequence to CRC cells provides another form of selectivity. 
Additional characteristics of dyes used for selective receptor targeting are: low cytotoxicity to 
cancerous or noncancerous cells. Toxicity is often determined using colorimetric assays such as 
the MTT and the cell titer blue assay. The MTT assay is an absorbance-based assay that converts 
MTT to formazan upon excitation at 540 nm. Cell titer blue, a fluorescence-based assay, 
converts a redox dye resazurin to a fluorescent product resorufin at the excitation of 570 nm and 
emission at 590 nm.
3
 These assays differ in the excitation and emission of such as MTT Assay 
that is absorbance based and. Fluorescence microscopy is used to determine where 
molecules/dyes localize within cells. Different fluorophores are used to image different 
organelles. Figure 4-1 diagram of a cell with a receptor (A) and labeled organelles cellular 
""""""""""""""""""""""""!
*Reprinted by permission of Journal of Medicinal Chemistry. 
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membrane (B), lysosomes (C), endoplasmic reticulum (D), vesicle (E), nucleus (F), Golgi 
apparatus (G), and the mitochondria (H). 
 
 
Figure 4-1: A diagram of a cell with the internal organelles. 
 
Toxic molecules that localize in cellular organelles, specifically the mitochondria (power house 
of the cell) are excellent candidates for PDT. Hsiung et. al. reported the use of a seven residue 
peptide (VRPMPLQ) coupled to fluorescein for targeting of HT-29 human adenocarcinoma 
cells; a 20-fold greater binding than to HS738.st/int nonmalignant human intestinal cells was 
observed.
4
 However, the molecular target for this peptide is unknown i.e. receptor, but this 
peptide has a partial homology to Caspr-1 (the laminin-G domain of contactin-associated protein 
1).
4
 This conjugate had a 81% sensitivity to dysplastic colonocytes than to normal cells with an 
82% selectivity.
1,4
 In the present work two peptides EGFR-L1 and EGFR-L2 were used as the 
ligand conjugated to a fluorescent porphyrin (MesoPOR) or phthalocyanine for better detection 










4.1.2 Surface Plasmon Resonance 
Surface Plasmon Resonance (SPR) is an optical technique used to evaluate the interaction 
between an immobilized ligand and a analyte.
5
 Binding of the analyte to the surface is based on 
the detection of changes in the refractive index caused by mass changes at the sensor surface.
6
 
The interaction between the analyte and the immobilized ligand causes a shift in the SPR angle, 
which is the intensity of reflected light at a specific angle, that produces a signal measured in 
SPR units (RU).
5
 SPR has been used for studies of protein-protein interactions, protein-peptide 




4.1.3 Selection of Cell Lines 
Four cells lines human larynx squamous cell carcinoma (HEp-2 cells),
8
 human 
epidermoid carcinoma (A431 cells), cercopithecus aethiops kidney (Vero cells), and human 
colorectal adenocarcinoma (HT-29 cells) were used to investigate whether the conjugates herein 
target the EGFR found on the membrane of colon cancer cells. In this study HEp-2 cells, were 
used a model cell line, Vero was used as the negative control (lowest number of EGF receptors), 
A431 was used as a positive control (~ 1-3 million EGFR per cell, highest expression of EGFR), 




4.1.4 Bioconjugates Used For Biological Evaluation 
Different dyes were designed to target EGFR including phthalocyanine (Pc) peptide 
conjugates and porphyrin peptide conjugates. The peptides EGFR-L1 and EGFR-L2 vary in the 
net charge of the peptide of 1 and 0 respectively. EGFR-L1 has a positive charge due to the 




Figure 4-2: Pc bioconjugates evaluated in these studies. 
 
In this chapter we investigate the biological effects of the phthalocyanine bioconjugate series and 








































































































































































































































































































































































































































































































































The structures of the Pcs evaluated in these studies are given in Figure 4-2. The Pc bioconjugates 
are located at the ! or " position of the Pc. Pc-PEG (4-1) was used as the control for the Pc 
bioconjugates. Figure 4-2B shows Pc-PEG-EGFR-L1 (4-2) coupled at the ! position of the Pc. 
Figure 4-2C contains Pc-PEG-EGFR-L1 (4-3) coupled at the " position of the Pc. Figure 4-2D 
shows Pc-PEG-EGFR-L2 coupled at the ! position of the Pc and Figure 4-2E shows Pc-EGFR-
L2 at the " position of the Pc (4-5). The second series of bioconjugates tested were the 
MesoPOR bioconjugates. Figure 4-3 shows the MesoPOR bioconjugates MesoPOR-(di)PEG-
(di)EGFR-L1 (3-10) A, MeosPOR-(di)PEG-EGFR-L2 (3-11) B, MesoPOR-(di)EGFR-L1 (3-16) 
C, MesoPOR-EGFR-L2 (3-19) D, and MesoPOR-EGFR-L2-SAR (3-21) E. 
 
4.2 Toxicity Using the Cell Titer Blue Assay 
Cell Titer Blue Assay was used to evaluate the toxicity of the Phthalocyanine 
bioconjugates and the MesoPOR bioconjugates. Cell Titer Blue (CTB) is a fluorescence-based 
assay used to measure the toxicity of different substrates.
3
 CTB is used to measure the living 
cells that converts resazurin into a fluorescent product resorufin.
3
 Each bioconjugate was 
represented by a color for the four different cell lines and were tested at the various 
concentrations of 6.25, 12.5, 25, 50, and 100 µM for phototoxicity. The color of each 
bioconjugate was repeated for dark toxicity and for time dependent cellular uptake. The 
concentrations used for dark toxicity was 25, 50, 100, and 125 µM.  
 
4.2.1 Phototoxicity 
The phototoxic effect of the Pc bioconjugates on four different cell lines was determined. 
Low dose light (1 J/cm
2
) was used to excite the bioconjugates to determine their phototoxicity. 
!
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The Pc bioconjugates and the MesoPOR bioconjugates are used for detection and should not be 
toxic. Figure 4-4 shows the results obtained in four different cell lines A431 cells (A), Vero cells 
(B), HEp2 cells (C), and HT-29 cells (D) of the Pc bioconjugates. As tested on the A431 cells, 
Pc-PEG (4-1), Pc-PEG-EGFR-L1 at the ! position (4-3), Pc-PEG-EGFR-L2 (4-4), Pc-PEG-
EGFR-L2 (4-5) does not show any toxicity at the various concentrations.  
 
 
Figure 4-4: Phototoxicity of A431 cells (A), Vero cells (B), HEp2 cells (C), HT-29 cells (D). Pc 




Pc-PEG-EGFR-L1 at the " position is cytotoxic at 12.5 µM and higher. Figure 4-4B shows the 
phototoxicity toward Vero cells and 4-3, 4-4, and 4-5 are not toxic at the concentrations tested. 
The Pc-bioconjugates 4-1 and 4-2 are toxic at concentrations higher than 12.5 µM. " substituted 
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Pc have shown to be more phototoxic than ! substituted Pc.
12,13 
Even though 4-2 has a high 
toxicity and low IC50 it is not toxic in the HT-29 cells and may still be used as a imaging agent.
12
 
The phototoxicity of 4-1 and 4-2 may be observed due to the high accumulation of EGFR-L1, 
which is a cationic peptide due the 
+
1 charge of the arginine residue, in the cell in comparison to 
the accumulation of EGFR-L2 in the cell.
12
 Figure 4-4C correlates to the toxicity in HEp2 cells 
and neither 4-1 or 4-5 are cytotoxic. None of the Pc bioconjugates were toxic at the different 
concentrations tested, as shown in Figure 4-4D. There was no observed phototoxic effect 
between the first and second series of Pc bioconjugates.
12
 Table 4-1 summarizes the IC50 values 
of the four cell lines tested. 
 













4-1 >100 >100 >100 >100 
4-2 >15.8 >17 >47 >100 
4-3 >100 >100 >100 >100 
4-4 >100 >100 >100 >100 
4-5 >100 >100 >100 >100 
 
4.2.2 Dark Toxicity 
The dark toxicity was determined by leaving the cells in the dark with no exposure to 
light and measuring cell viability using CTB. The dark toxicity of the Pc bioconjugates was 
tested on A431 cells, Vero cells, HEp2 cells, and HT-29 cells. The Pc bioconjugates were not 
toxic at the concentrations tested. Figure 4-5 shows the results obtained for the dark toxicity of 





Figure 4-5: Dark Toxicity of A431 cells (A), Vero cells (B), HEp2 cells (C), HT-29 cells (D). Pc 




4-5 shows a slight toxicity to HEp2 cells at concentrations higher than 25 !M. Table 4-2 list the 
IC50 values determined for the Pc bioconjugates tested on the various cell lines, which was 
always above >125 !M.  
 
Table 4-2: Summary of IC50 for Dark Toxicity.
12
 








4-1 >125 >125 >125 >125 
4-2 >125 >125 >125 >125 
4-3 >125 >125 >125 >125 
4-4 >125 >125 >125 >125 




4.3 Time Dependent Cellular Uptake 
Cellular uptake of the Pc bioconjugates was investigated in human A431, Vero, HEp2, 
and HT-29 cells. The time dependent uptake of conjugates 4-1, 4-2, 4-3, 4-4, and 4-5 at a 
concentration of 10 µM was investigated.  
 
4.3.1 Peptide-Phthalocyanine Bioconjugates 
At 10 µM, none of the Pc bioconjugates were toxic to the cells as determined by CTB. 
Figure 4-6 shows the results obtained for the time-dependent cell uptake of the Pc bioconjugates 
on the four cell lines. Differences were observed for the bioconjugates containing EGFR-L1 and 
EGFR-L2. EGFR-L1 varies from EGFR-L2 in charge, solubility, and its tendency to aggregate. 
EGFR-L1 is a cationic peptide and EGFR-L2 is a hydrophobic peptide with no charge. Peptides 
having a cationic charge could behave as a cell penetrating peptide and can readily go into the 
cell. The cationic charge for EGFR-L1 (Pc conjugates 4-2 and 4-3) allows the peptide to have a 
higher cellular uptake as shown in Figure 4-8. A higher uptake in A431 cells (~3 to 4 times) 
compared with Vero cells and a ~3 to 2 fold increase in HT-29 cells and HEp2 cells is observed, 
respectively.
12
 The increase in uptake confirms that these bioconjugates can selectively target 
cells overexpressing EGFR.
12
 Furthermore, this confirms that the Pc has a higher selectivity for 
the cancer HEp2 cells compared to Vero, with the lowest expression of EGF receptors.
12
 4-2 and 
4-3 differ in the substitution on the Pc macrocycle (! or " position) but the kinetic uptake for 
A431 and HT-29 cells is the same, 4-2 has a faster uptake than 4-3. EGFR-L2 (Pc bioconjugates 
4-4 and 4-5) might have a higher affinity for the EGF receptor due to the binding on the inside of 
the EGFR Domain I and due to its strong hydrophobic character that may cause retention at the 
surface of the cell, thus having the lowest cellular uptake in Vero compared with HEp2 cells. Pc 
!
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Figure 4-6: Cellular Uptake of A431 cells (A), Vero cells (B), HEp2 cells (C), HT-29 cells (D). 




The uptake between 4-4 and 4-5 is the same in both A431 and HT-29. These bioconjugates differ 
in the functionalization of the Pc at the ! or " position and does not have a PEG moiety, 
respectively. 4-4 and 4-5 has a different response in Vero and HEp2 cells that have a lower 
expression of EGFR. 4-4 containing the PEG moiety has a higher uptake than 4-5, that does not 
contain a PEG moiety and is at the " position of the Pc. Bioconjugates containing the PEG 
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moiety may potentially have a higher cellular uptake than those without the PEG moiety and 
bioconjugates at the ! position of the Pc may have lower uptake in cells.  
 
4.4 Fluorescence Microscopy 
4.4.1 Peptide-Phthalocyanine Bioconjugates 
Fluorescence microscopy was used to determine the intracellular localization of the 
bioconjugates within the cells. Different organelle specific probes such as ER Tracker 
Blue/White fluorescence, MitoTracker green fluorescence, Bodipy Ceramide, and LysoSensor 
green fluorescence were used to determine where the bioconjugates localized.
12
 The ER tracker 
is used to image the endoplasmic reticulum (ER), MitoTracker is used to image the 
mitochondria, Bodipy Ceramide stains the Golgi apparatus, and Lysosensor stains the lysosomes. 
Intracellular localization was performed on two cells lines containing the highest expression of 
EGFR, A431 and HT-29. The microscopy of the different bioconjugates (first and second series) 
was separated in two parts. The subcellular fluorescence for Figure 4-7, Figure 4-8, and Figure 4-
9 are as follows Phase contrast (a), overlay of bioconjugate fluorescence and phase contrast (b), 
ER Tracker Blue/White fluorescence (c), MitoTracker green fluorescence (e), Bodipy Ceramide 
(g), LysoSensor green fluorescence, and (d, f, h, j) overlays of organelle tracers with 
bioconjugate. Figure 4-7 and Figure 4-8 shows the intracellular localization of A431 and HT-29 
cells with 4-1 (A), 4-2 (B), 4-3 (C), and 4-4 (D), respectively. All bioconjugates localized in 
multiple sites within the cells. 4-2 and 4-3 were found in the lysosomes, mitochondria, and Golgi 





















Bioconjugates 4-4 and 4-5 were localized in the lysosomes, mitochondria, and Golgi apparatus 
of both A431 and HT-29 cells, as shown in Figures 4-7, Figure 4-8, and Figure 4-9. The absence 
of the PEG moiety in 4-5 did not affect intracellular localization. 
 
 





4.5 Surface Plasmon Resonance 
Surface plasmon resonance (SPR) is used to characterize interactions between 
macromolecules.
5
 EGFR was immobilized on the CM5 sensor chip and each Pc bioconjugate 
ligand or MesoPOR-bioconjugate ligand was passed through the chip to determine the protein-
peptide interactions. The free peptides EGFR-L1 and EGFR-L2, select Pc bioconjugates, and the 
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EGF protein were tested by SPR.  
 
4.5.1 Peptide-Phthalocyanine Bioconjugates 
SPR of select Pc bioconjugates (first series of Pc bioconjugates) was tested and the 
results obtained are shown in Figure 4-10. The peptides, bioconjugates, and protein were 
represented as follows EGFR-L1 (green), EGFR-L2 (purple), EGF (orange), 4-1 (navy blue), 4-3 
(turquoise), and 4-4 (red) with EGFR.  
 
 
Figure 4-10: SPR sensorgram of EGFR-L1 (green), EGFR-L2 (purple), EGF (orange), 4-1 (navy 




Figure 4-10 shows the SPR sensorgram of the free peptides, bioconjugates, and EGF protein. 
The association and dissociation rates are measured in arbitrary units as a function of time.
16
 The 
association and dissociation rates of the compounds with EGFR are the same and will be further 
evaluated. The square association and dissociation of the bioconjugates is due to the 0.29% of 
DMSO as shown in previous studies by Karlsson et. al.
17
 4-1 has a lower binding affinity in 
!
! 132 
comparison to the free peptides and the bioconjugates. The epidermal growth factor (EGF) has 
the strongest affinity for binding to EGFR, as it is the natural ligand for that receptor. EGFR-L1 
has a lower biding affinity when compared to EGFR-L2. The bioconjugates 4-3 and 4-4 have a 
stronger binding affinity compared with the free peptides alone and 4-4 binds stronger than 4-3. 
The association and dissociation rates of the compounds with EGFR are the same and will be 
further evaluated. The binding resonance units of each compound are shown in Table 4-3. 
 
Table 4-3: Binding of Conjugates to EGFR 
# Name RU after 1 s RU after 2 s 
1 EGFR 12,296.4 RU 
2 EGFR-L1 149.5 RU 35RU 
3 EGFR-L2 209.3 RU 56.3U 
4 EGF - - 
5 3b 159.2 RU 52.6 RU 
6 5b 172.3 RU 92.2 RU 
7 6a 215.3 RU 64 RU 
 
4.5.2 Peptide-Porphyrin Bioconjugates 
Select peptides from the first and second series of bioconjugates were evaluated in the 
presence of immobilized EGFR on a gold surface. Figure 4-11 shows the results using the first 
and second series of bioconjugates binding to SPR. EGFR-L1 (green) and EGFR-L2 (purple) 
binds to EGFR with EGFR-L2 having a higher binding affinity of the two peptides. The rate of 
the two peptides associates and dissociate from the receptor are at the same rate. This behavior 
could be due weaker binding affinity in general. MesoPOR-EGFR-L2 (3-19) and MesoPOR-
EGFR-L2-SAR (3-21) bound to EGFR and had a slower dissociation. MesoPOR-EGFR-L2-SAR 
has a higher binding affinity and is more hydrophobic due to the N-methylation on the N-
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terminus than MesoPOR-EGFR-L2. MesoPOR-(di)PEG (3-8) and MesoPOR were used as 
control for the first and second series of bioconjugates, respectively.  
 
 
Figure 4-11: SPR sensorgram of EGFR-L1 (green), EGFR-L2 (purple), MesoPOR-(di)PEG-
(di)EGFR-L1 (turquoise), MesoPOR-(di)PEG (pink), MesoPOR (red), MesoPOR-EGFR-L2 
(navy blue), MesoPOR-EGFR-L2-SAR (yellow). 
 
It is not clear why the controls without a peptide would have a better binding affinity than free 
peptides alone. Porphyrin macrocycles have a natural affinity for cancer cells, however its 
binding affinity was expected to be lower. MesoPOR-(di)PEG-(di)EGFR-L1 (3-10) contains two 
peptides and has a stronger binding affinity and a lower dissociation rate from EGFR. This 
allows for a greater interaction at the target site. MesoPOR-(di)EGFR-L1 has a greater affinity 
than MesoPOR-(di)PEG-(di)EGFR-L1, which was an unexpected result, see Figure 4-12. 
MesoPOR-(di)EGFR-L1 (3-16) was graphed independently due to its strong intensity, as shown 
in Figure 4-12. MesoPOR-(di)EGFR-L1, while not definitive, had a slight !-sheet conformation 





Figure 4-12: SPR sensorgram of EGFR-L1 (green), EGFR-L2 (purple), MesoPOR-(di)PEG-
(di)EGFR-L1 (turquoise), MesoPOR-(di)PEG (pink), MesoPOR (red), MesoPOR-EGFR-L2 
(navy blue), MesoPOR-EGFR-L2-SAR (yellow).  
 
EGFR-L1, as observed from the computational studies folds back onto the porphyrin 
macrocycle, this may also account for improved binding.  
 
Table 4-4: Binding of Porphyrin Bioconjugates to EGFR!
# Name RU after 1 s RU after 2 s 
1 MesoPOR 373.4 RU 231 RU 
2 MesoPOR-(di)PEG 467.4 RU 265.9 RU 
3 EGFR-L1 149.5 RU 35RU 
4 MesoPOR-(di)PEG-(di)EGFR-L1 969.1 RU 944.4 RU 
5 MesoPOR-(di)EGFR-L1 11514.6 RU 11296.4 RU 
6 EGFR-L2 209.3 RU 56.3 RU 
7 MesoPOR-EGFR-L2 381.9 RU 335.8 RU 
8 MesoPOR-EGFR-L2-SAR 419.3 RU 373.5 RU 
 
The peptide porphyrin bioconjugates have an improved binding affinity for EGFR and a lower 
dissociation rate from EGFR when compared with the peptide Pc bioconjugates. Table 4-4 lists 




The goal of this research was to target the EGF receptors found on the surface of the 
cells. Our studies have shown that the Pc bioconjugates are not phototoxic and are not toxic in 
the dark. Only 4-2 is slightly toxic in the A431, Vero, and HEp2 cells but it is not phototoxic in 
HT-29 cells. This compound may still be used for cellular imaging of CRC. 4-2 and 4-3 had the 
highest cellular uptake in all cell lines while 4-4 and 4-5 had the lowest uptake. It was initially 
thought that EGFR-L2 did not have an association or strong affinity for EGF but SPR confirms 
that EGFR-L2 when compared with EGFR-L1 has the highest affinity. Through our 
investigation, we have observed that cells with a higher expression of EGFR have a higher 
uptake of the bioconjugates. There is a 3.5 fold uptake from the negative control (Vero cells) to 
the positive control (A431 cells). HT-29 colorectal cancer cells also showed a 3-fold increase. 
This proves that, these conjugates can target cancer cells over-expressing EGFR. In HEp-2 cells 
a 2-fold increase in uptake of the conjugates was observed. Not only are we able to target HT-29 
cells with a high expression of EGFR but we are also able to target cells with a moderate 
expression of EGFR. These conjugates have the potential of targeting/detecting a wide range of 
cancers with expression of EGFR. EGFR-L1 and EGFR-L2-GLY are the two peptides used in 
this study. Both EGFR-L1 and EGFR-L2-GLY are hydrophobic but EGFR-L1 is less 
hydrophobic due to its net charge of 
+
1 due to the arginine residue. This alone may account for 
its higher penetration and uptake of EGFR-L1 penetrates and has the highest uptake. Molecules 
with a net positive charge may have efficient binding at the surface however increasing the 
positive charge can also increase the cytotoxicity.
18
 Studies have shown that peptides with one 
arginine residue or more penetrate the cellular membrane.
19
  EGFR-L2-GlY has a net charge of 
0, is more hydrophobic, and may cause the peptide to be better retained at the surface. All 
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EGFR-L1 bioconjugates penetrated the cellular membrane as shown by fluorescence microscopy 
and targeted the lysosomes, the mitochondria, and the Golgi apparatus while EGFR-L2 poorly 
targeted the same organells. 4-2 also targeted the ER and this may account for its observed 
phototoxic effect. 
The Pc bioconjugate herein present a promising class of near-IR fluorescent imaging 
agent that can detect colorectal cancer cells. Due to hydrophobic nature of the Pc these 
conjugates require the use of a PEG moiety and a polar or charged peptide for adequate aqueous 
solubility.
12
 Substitution of the Pc at the ! position has a lower phototoxic effect and is more 





4.7 Experimental Procedures 
4.7.1 Cell Culture 
All tissue culture medium and reagents were purchased from Invitrogen. Human 
carcinoma HEp2 cells, human epidermoid carcinoma A431, cercopithecus aethiops kidney Vero 
cells, and human colorectal adenocarcinoma HT-29 cells were purchased from ATCC. HT-29 
cells were cultured and maintained in McCoy’s 5a Medium Modified supplemented with 10% 
FBS and 1% PS. Both A431 and VERO cells were cultured and maintained in ATCC formulated 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS and 1% PS. HEp2 
cells were cultured and maintained in 50:50 ATCC formulated Dulbecco’s Modified Eagle’s 
Medium /Advanced MEM containing 10% FBS and 1% PS. The cells were split twice weekly to 
maintain a sub-confluent stock. All conjugate solutions were filter sterilized using a 0.22 µm 
syringe filter. A 32 mM stock was prepared for each conjugate. Compounds were dissolved in 
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100 % DMSO (cell culture grade) and sonicated. If the conjugate does not dissolve 5 % 
Cremophor was added and the compound was sonicated again. Note: the dissolved conjugate can 
be stored in -80°C freezer. From the 32 mM stock, a 400 µM stock is prepared in desired media 
and filter sterilized using a 0.22 µm syringe filter.  All serial dilutions were made from this stock. 
All organelle tracers were purchased from Invitrogen. Pure recombinant protein EGFR was 
obtained from Leinco Technologies, St. Louis, MO. EGF ligand was obtained from Abcam, Inc., 
(Cambridge, MA). Remaining items were purchased from GE Health Science, Sigma Aldrich, 
and Fisher Scientific. 
 
4.7.2 Phototoxicity 
HEp2 cells and A431 cells were plated at 7,500 per well in a Costar 96 well plate and 
allowed to grow for 48 hours. Vero cells were plated at 7,500 per well in a Costar 96 well plate 
and allowed to grow for 24 hours. Phthalocyanine stock solutions (32mM) were made in DMSO 
and Cremophore and diluted to the desired concentration in medium. Different concentrations of 
6.25 µM, 12.5 µM, 25 µM, 50 µM, and 100 µM were made and added to cells for 24hours. 
Loading medium was removed and fresh medium was added. The conjugates were exposed to 
light using a 100 W halogen lamp at 1 J/cm
2
 for 20 minutes. The plates were chilled at 5 °C 
using a cooling block. Water was used as a filter for IR radiation. The plates were then incubated 
for another 24 hours followed by removing medium and adding medium containing Cell Titer 






4.7.3 Dark Toxicity 
HEp2 cells and A431 cells were plated at 7,500 per well in a Costar 96 well plate and 
allowed to grow for 48 hours. Vero cells were plated at 7,500 per well in a Costar 96 well plate 
and allowed to grow for 24 hours. HT-29 cells were plated at 7,500 per well in a Costar 96 well 
plate and allowed to grow for 96 hours. Phthalocyanine stock solutions (32mM) were made in 
DMSO and Cremophore and diluted to the desired concentration in medium. Different 
concentrations of 25µM, 50 µM, 100 µM, and 125 µM were made and added to cells for 24 
hours. Loading medium was removed and medium containing Cell Titer Blue was added to 
determine the toxicity of the compounds.  
 
4.7.4 Time-Dependent Cellular Uptake 
HEp2 cells and A431 cells were plated at 7,500 per well in a Costar 96 well plate and 
allowed to grow for 48 hours. Vero cells were plated at 7,500 per well in a Costar 96 well plate 
and allowed to grow for 24 hours. Phthalocyanine stock solutions (32mM) were made in DMSO 
and Cremaphore and diluted to the desired concentration in medium. A 10 µM concentration was 
made and added to the cells at different time periods of 0, 1, 2, 4, 8, and 24 hours. Uptake of the 
compounds was stopped by removing loading medium and washing once with PBS. Cells were 
solubilized by adding 0.25% Triton X-100 in PBS. The conjugate concentration was determined 
by reading its fluorescence emission at 650/700 nm (excitation/emission) using a BMG 






4.7.5 Fluorescence Microscopy 
All cell lines were grown on a glass bottom 6-well plate (MatTek) and allowed to grow 
for 48 h. The cells were exposed to 10 µM for each Pc bioconjugate for 6 h. Organelle tracers 
were used at the following concentrations: LysoSensor Green 50 nM, MitoTrackr Green 250 nM, 
ER Tracker Blue/white 100 nM, and BODIPY FL C5 ceramide 1 µM. Images were acquired 
using a Lecia DMRXA microscope with 40 x NA 0.8dip objective lens and DAPI, GFP, and 
Texas Red filter cubes (Chroma Technologies).  
 
4.7.6 Surface Plasmon Resonance 
Surface Plasmon Resonance was performed using Biacore X100 (GE Health Sciences) at 
25 °C. EGFR was immobilized on a CM5 chip using a standard amine coupling protocol. The 
carboxyl groups on the sensor chip was activated using a 0.2M N-ethyla-N-
(dimethylaminopropyl) carbodiimide (EDC) and 0.05 M N-hydroxysuccinimide (NHS) solution 
in water (flow rate 5 µL/min). Running buffer consisted of 0.01M HEPES, 0.15 M NaCl, 3 mM 
EDTA, 0.005% Tween at pH 7.5 (adjusted using a 4M NaOH solution in water). Regeneration 
buffer for the ligand were 50% acid cocktail (0.15 M malonic acid, 0.15 M oxalic acid, 0.15 
phosphoric acid, 0.15 formic acid, adjust to pH 5 with 4 M NaOH solution in water). 
Regeneration buffer for Peptide-Pc Bioconjugates was 100 mM glycine at pH 2.5 and 100 mM 
glycine at pH 1.5 for Peptide-Porphyrin Bioconjugates. For immobilization EGFR was dissolved 
in NaoAC at pH 4.5 (adjusted using 10% HCl) and injected onto the chips surface at 10 µL/min 
until 12000 response units (RU) was obtained. The remaining unreacted activated groups were 
blocked with 1 M ethanolamine at pH 8.5 (adjusted with 10% HCl). All peptides were dissolved 
in DMSO and diluted in running buffer to obtain the desired concentration. All conjugates were 
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dissolved in DMSO and Cremophor EL and diluted in the running buffer to obtain the desired 
concentration. All buffers/solutions made were filtered using 0.45 µm filter. 
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 CHAPTER 5 
SYNTHESIS AND INCORPORATION OF !, !-DISUBSTITUTED AMINO ACIDS INTO 




5.1.1 Alzheimer’s Disease  
Alzheimer’s disease (AD), named after Alios Alzheimer, is a neurodegenerative disease 
that is characterized by amyloid deposits on the brain and causes lapses in memory, thinking, and 
‘behavior.
1
 This disease was discovered in 1906, over 100 years ago and in the last 20 years a 
wealth of information has been discovered. Recent studies have given insight into Alois 
Alzheimer theory, that postmortem brains contained amyloid plaques, as a result of 
neurodegeneration.
1-2
 AD affects one out of every ten people over the of age 65 and more than 
35% over the age of 85.
3
 Every seventy-two seconds someone develops AD.  
 
 
Figure 5-1: Affected parts of the brain due to AD.  
 
The cause of this disease is unknown but studies have shown that people with AD have higher 
levels of amyloid plaques and tangles in the brain verses individual who don’t have AD. Two 
hallmarks of AD are plaques and tangles. AD is a terminal disease but individuals can live for 
""""""""""""""""""""""""!
*Reprinted by permission of ACS Chemical Neuroscience. 
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ten years or more with the disease. The three stages of AD are classified as mild to early, 
moderate to mid, severe to late.
4
 At each stage of AD, more plaques develop and the individual 
becomes more impaired. Figure 5-1 shows how the brain is affected at different stages of AD, 
mild to early-stage (A) moderate to mid-stage (B), severe to late-stage (C). In Figure 5-1A a 
small amount of plaques are visible but with time AD progresses and affects more areas of the 





Figure 5-2: Affected parts of the brain due to AD. 
 
The outer layer (wrinkled layer) of the cerebrum is known as the cortex. Different parts of the 
cortex controls different functions. Figure 5-2 displays the different parts of the cortex that are 
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affected (in orange) by AD.
5
 In the early stages of AD memory (Figure 5-2A), smells (Figure 5-
2B), and sounds (Figure 5-2C) are affected. The mid stage of AD affects sight (Figure 5-2D), the 
ability to generate thoughts, solve problems, and make plans (Figure 5-2E).
5
 In the last stages of 
AD sensation (Figure 5-2F) and control of voluntary movement (Figure 5-2G) is affected.
5
  
On a cellular level AD affects nerve cells. There are roughly 100 billion nerve cells in an 
adult brain and from these nerve cells branches (dendrites) are formed at more than 100 trillion 
points, this is known as a Neuron Forest.
5
 Nerve cells generate and transmit biological electrical 
impulses from one part of the body to the other parts of the body.
5
 Dendrites formed by nerve 
cells are connected to other dendrites by axons.
5
 Nerve cells are used to communicate between 
the central nervous system and other parts of the body.
5
 Plaques are proteins that consist of 
composites of A! clumped together and are insoluble polymers.
6
 As AD progresses with time 
more plaques are generated. Plaques form between nerve cells and prevent communication 
among axons and dendrites. Nerve cells contain tangles, which may cause the cells to die. 
Tangles are twisted strands of a different protein called tau. Tau is composed of 
hyperphosphorylated forms of the microtubule-associated protein.
7
 Studies have suggested that 




In the late stages of AD, the brain is completely deformed due to nerve cell death, tissue 
loss, and shrinkage. Figure 5-3 compares a normal brain to an AD brain in the last stage. The two 
brains defer by size, color, and appears to be dehydrated.
5
 In the last stages of AD, the individual 
would lose their ability to communicate and recognize family and friends. The finial stages of 
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Figure 5-3: Normal Brain and AD brain in the last stage. 
 
5.1.2 Different Stages of A! Aggregation 
AD generates amyloid plaques, which are deposits of amyloid beta (A!). A! is known to 
aggregate at physiological conditions via a nucleation dependent mechanism through formation 
of monomers, dimers, trimers, oligomers, protofibrils, fibrils, and plaques. Oligomers have a 
circular morphology and are small structures with a length scale of 10 nm.
8
 Amyloid Derived 
Diffusible Ligands (ADDLs) are globular oligomers that have been proven to be vital to AD. 
Within the past 10 years numerous investigations of ADDLs have been performed and suggest 
that ADDLs are a neurotoxic species as opposed to other oligomers.
6,9
 It is believed that the 
amyloid cascade hypothesis does not completely address the idea of AD as originally expected. 
The amyloid cascade hypothesis proposes that dementia occurs as a result of neuron death that is 
caused by amyloid fibrils; these fibrils are found in senile plaques.
6
 Klein et al. proposed the 
ADDL hypothesis, which potentially addresses the flaws of the amyloid cascade hypothesis.
10,11
  
The ADDL hypothesis states “ a major factor in Alzheimer’s dementia is the neurological impact 
of globular oligomers of A!1-42 (ADDLs).”
6
 This hypothesis contains three key features: (1) 
small oligomer neurotoxins provides the missing links for the correlation between dementia and 
 
!
! ! 147 
large insoluble fibrils of amyloid plaques, (2) low concentrations of ADDLs play a role in the 
early stages of AD and would proceed plaque formation, (3) early stage memory impairment 
does not stem from neuron death but from a different mechanism of malfunctions in memory-
specific signal transduction.
6
 According to the ADDLs hypothesis A! aggregates via a 
nucleation dependent mechanism through formation of monomers, dimers, trimers, oligomers, 
ADDLs, protofibrils, fibrils, plaques, and Tau, as shown in Figure 5-4.  
 
 
Figure 5-4: A! aggregation pathway. 
 
Protofibrils are a flexible rod like structure with a size of  <8 x <200 nm and are soluble.
12
 Fibrils 
(amyloid fibrils) are stable, structurally organized, highly insoluble, filamentous protein 
aggregates composed of repeating units of ! sheets.
12
 Plaques represent the final stage of A! 
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are surrounded by dystrophic dendrites and axons.
12
 There are many factors and conditions that 
affect how A! aggregates such as pH, aggregation concentration, ionic strength, temperature, 
and mixing protocol.
13
 In the aggregating phase, A! has the ability to self assemble into different 
toxic species including protofibrils, fibrils, and oligomers and.
14,15,16,17
 As A! aggregates it 
spreads and targets different parts of the cortex.  
 
5.1.3 Reducing Amyloid Aggregation and Current Treatment 
There are several approaches to reduce the constant production of amyloid 
aggregation.
1,18
 Twenty-years ago the amyloid precursor protein (APP) was identified as the 
protein that undergoes proteolytic degradation to produce A!1-40 and A!1-42. One of the 
approaches to prevent amyloid beta was to inhibit the proteases (!-secretase and "-secretase), 
which causes the cleavage of A! from APP.
19
 Inhibiting the proteases causes a reduction in the 
total load of A! and reduces the ratio of A!1-40 and A!1-42.
19,20
 Another approach to reducing the 
production of amyloid beta is Antibody therapy.  
 
 
Figure 5-5: Different cholinesterase inhibitors used for AD treatment. 
 
Antibody therapy has shown to be an effective treatment in vivo. Bard et al. has shown that 
antibodies in PDAPP transgenic mice (transgenic mice for an A! precursor protein (APP) mini-
gene driven by a platelet-derived (PD) growth factor promoter) model can travel across the 
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central nervous system (CNS), prevent aggregation, and removes pre-existing amyloid 
deposits.
21,22
 Currently there are different drugs used for the treatment of AD. Palliative drugs 
that includes cholinesterase inhibitors such as Aricept, Exelon, razadyne, and Cognex (also 
known as Tacrine) are used to treat AD, see Figure 5-5.
23
  The NMDA antagonist Namenda was 





Figure 5-6: Structure of NMDA antagonist Namenda. 
 
Cholinesterase inhibitors and NMDA antagonist have various side effects. However, these 
treatments haven’t been proven to be effective at reversing memory deficits or in slowing the 




5.1.4 Peptides as Current Drugs  
Several peptide-derived drugs have been approved by the FDA to treat different illnesses. 
Leuprolide is a peptide with a sequence of Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt. 
Leuprolide has been used to treat prostate cancer, breast cancer, endometriosis, central 
precocious puberty, and acquired immune deficiency syndrome (AIDs).
24,25,26
 Figure 5-7 shows 
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Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2. Fuzeon is used in 
combination with other drugs, that acts as a HIV fusion inhibitor to treat AIDs.
26
 One peptide 
drug is able to effectively treat more than one illness. These findings are encouraging for the use 
and design of new peptide drugs. A benefit of using peptides as drug is that it provides rapid 





Figure 5-7: Structure of Leuprolide. 
 
5.1.5 Designing Peptides to Treat AD: The Hydrophobic Core of A! 
The Hydrophobic core “KLVFF” (residues 16-20) is found at the core of A!1-40 and A!1-
42. KLVFF has previously been shown to be critical for A! self assembly into amyloid fibril 
formation, A! self interaction, and acts as a recognition element.
28,29,30
 Incorporating KLVFF 
into a peptide inhibitor sequence as a core recognition element of A! can alter A! aggregation 





Figure 5-8: Amyloid Beta (A!1-40) sequence. 
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Figure 5-8 and Figure 5-9 shows the sequence of A!1-40 and A!1-42, respectively. The 
“recognition” element or binding core is composed of one positively charged amino acid lysine 
(K) and four nonpolar amino acids leucine (L), valine (V), and phenylalanine (F). Non-polar side 
chains of amino acids Leucine (L), Valine (V), and Phenylalanine (F) promote the hydrophobic 
character for the binding core.  
 
 
Figure 5-9: Amyloid Beta (A!1-42) sequence. 
 
Lowe et al. has shown that peptides (KLVFFKKKK and KLVFFEEEE) containing the 
recognition KLVFF sequence with disrupting elements such as three or more lysine residues can 
reduce toxicity to PC12 cells and inhibit oligomer formation.  
 
 
Figure 5-10: Peptide binding to A! at the KLVFF sequence. 
 
One of Lowe’s peptide sequences contains positively charged lysine residues (KLVFFKKKK) 
and the other contains negatively charged glutamic acid residues (KLVFFEEEE).  He further 
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discovers that peptides containing serines (KLVFFSSSS) has no affect on A! due to its neutral 
charge. These findings suggest that the incorporation of KLVFF along with other amino acids 
with positive or negative charge are important for disrupting A! fibrillization. Furthermore, other 
studies have suggested the use of "," disubstituted amino acids have the capability of binding to 
A! and preventing its assembly into amyloid fibrils.
30
 Studies by Tjernberg et al have shown that 
the peptide sequence KLVFF has the ability to bind to A!, preventing the formation of amyloid 
fibrils.
28
 Figure 5-10 shows a peptide, designed in this study, which binds to A! through the 
KLVFF sequence by hydrogen bonding. Amyloid aggregation mitigating peptides (AAMPs ) 
containing KLVFF, positively charged amino acids, negatively charged amino acids, and ","-
disubstituted amino acids will be used to disrupt or inhibit A!. These peptides may serve as a 
new class of AD drugs.  
 
5.1.6 Amyloid Aggregating Mitigating Peptides (AAMPs) 
We hypothesize that AAMPs, which contain an ","-disubstituted amino acid (""AAs), 
uniquely alter the A! assembly process, and alters the A! aggregate morphology and toxicity. 
AAMPs are derivatized from the hydrophobic core of A! by incorporation of a variety of amino 
acids to the N and C terminus of the hydrophobic sequence.
33,34 
Peptides containing ","-
disubstituted amino acids inhibits the toxicity of A! when evaluated in aggregation studies and 
in SH-SY5Y neuroblastoma cells. All derivatives are incorporated into AAMP library.  
 
5.1.7 The Use of !, ! Disubstituted Amino Acids (!!AA) 
Due to the interest in controlling the structures of secondary peptides there is a demand 
for the synthesis and use of symmetrical "," disubstituted amino acids (""AA). Several synthetic 
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methods for !!AAs have been in practice for many years such as the Bucherer-Bergs, Strecker 
Synthesis, and the Ni-Schiff base. The Bucherer-Bergs method has been used in the preparation 
of hydantoins, which can be generated by reacting ketone with ammonium carbonate and 
potassium cyanide.
35
 This method produces low yields due to the high resistance of the 
formation and hydrolysis of the hydantoin. The Strecker Synthesis is another method used to 
prepare !!AA, it also produces low yields of forty to fifty percent.
35
 An improved method has 
been developed known as the Ni-Schiff base complex. The Ni-Schiff use alkylation of !-
nitroacetate that allows for the preparation of an array of !!AA in good yield.
35
 This method 
doesn’t allow highly hindered !!AA with branched side chains such as !,!-diisobutlglycine 
(Dibg) to be readily synthesized. A new approach has been taken in order to improve highly 
hindered !!AA with branched side chains by utilizing Pd-mediated diallylation of !-nitroacetate. 
This allows for the anchoring of !!AA onto Argoresin MP-TMT
36 
resin with mixed anhydrides. 
This method does not prove to be easy but highly hindered !!AA can be generated in yields 




5.1.8 Synthesis of AAMPs using Microwave Chemistry 
Solid phase peptide synthesizers are typically used for synthesizing peptides containing 
natural amino acids. When a sterically hindered amino acid such as !,!-disubstituted amino acids 
(both ! hydrogens are replaced) are incorporated into a peptide, peptide coupling can be difficult. 
Therefore, Applied Biosystem Automated Solid Phase Peptide Synthesizer (SPPS) and MARS 
Microwave chemistry was used to couple !!AA to the peptide on solid support. Depending on 
the location of the !!AA in the peptide sequence, the initial sequence was synthesized on an 
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automated biosynthesizer and the remaining sequence was coupled using Microwave Chemistry, 




Figure 5-11: Image of MARS Microwave. 
 
Microwave Chemistry uses single mode irradiation to produce energy to carry out chemical 
synthesis such as Heck Couplings, Stille Coupling, Diels-Alder Reactions, Peptide Synthesis, 
etc.
17,18 
The advantages of this system are faster cycle times, higher purity of synthesis, better 
yields, and greener chemistry.
19
 Microwave heating  provides a more efficient way to produce 
peptides than the standard bench top synthesis that would produce poorer yields, lower purity, 
and takes longer.  
 
5.2 Peptide Design for AAMPs 
5.2.1 Synthesis of AAMPs 
AMY-1 (KDibgVDbgFDpgK6) and AMY-2 (K6KDibgVDbgFDpg), previous peptide 
synthesized in the Hammer group, are mitigator peptides that disrupted fibril formation and 
formed spherical aggregates of different heights.
39,33
 AMY-1 and AMY-2 varies with the 
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but was toxic at high doses.
39
 The toxicity of AMY-1 may be due to the overall charge from the 
6 lysine or due to the size of the mitigator.
39
 Each AAMP was synthesized with specific 
characteristics that include reducing the charge and molecular weight, and incorporating different 





Scheme 5-1: Solid phase peptide synthesis of AAMP11. 
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Here we investigate the effects of adding different amino acids (positively and negatively 
charged) and neutral MiniPEGs on the N-terminus and C-terminus of the AAMPs. Solid phase 
peptide synthesis (SPPS), developed by R. B. Merrifield, was used to synthesize all peptides 
using standard Fmoc chemistry. All peptides were synthesized on Rink-Amide resin. Standard 
coupling reagents were used for AAMP11, AAMP12, AAMP13, AAMP14, AAMP15, 
AAMP16, AAMP17, AAMP18, and AAMP19 consisting of HBTU/HOBT in 1M DIEA and 
DMF solution. Scheme 5-1 shows the solid phase peptide synthesis of AAMP11. The net charge 
at pH 7 and the percentage of hydrophilic residues was determined for each AAMP using 
Innovagen peptide property calculator. The net charge of each AAMP may have an impact on A! 
fibrillization. The sequence of AAMP11, AAMP12, AAMP13, and AAMP14 compares the 
effect of arginine, lysine, glutamic acid, or a MiniPEG added to the N-terminus and C-terminus 
of the peptide. Glycine was incorporated as a spacer for all AAMPs synthesized. Austen et al. 
first reported the sequence of AAMP11 (RGKLVFFGR) that has a net charge of 3.
39
 Arginine 
has an amine functionality on the "-carbon that is basic because the positive charge is stabilized 
by resonance. AAMP11 was disrupted A!1-40 fibril formation and prevented neurotoxicity of 
SHSY5Y cells.
39
 SHSY5Y cells are a neuroblastoma cell line that is suited for in vivo studies of 
AD. AAMP 12 has the sequence of KGKLVFFGK and a net charge of 4.  
 
 
Figure 5-12: Structure of MiniPEG. 
 
This sequence is similar to AAMP11 except the two arginine residues are replaced with a basic 
amino acid lysine, that behaves as a disrupting element. AAMP13 contains two glutamic acids 
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that have a negative charge, and has a net charge of 0. One glutamic acid and one glycine residue 
is added to both the N-terminus and the C-terminus. AAMP14 has a MiniPEG and a glycine 
spacer located on the N-terminus and the C-terminus of KLVFF.  
 
 
Scheme 5-2: Solid phase peptide synthesis of AAMP14. 
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Poly ethylene glycol linkers (PEGs) are molecules that vary in the number of ethylene oxide 
units. PEGs are readily used since it can reduce aggregation, improve solubility, provide an 
extended conformation, and act as bifunctional spacer.
40
 Studies have suggested that the 
incorporation of PEGs into peptide sequences target A! and diminishes binding to A!.
41
 The 
MiniPEG, as shown in Figure 5-12, was incorporated into AAMP14 and AAMP17. Scheme 5-2 
shows the solid phase peptide synthesis of AAMP14, the same approach was used for AAMP17.  
 
 
Figure 5-13: Structure of AAMP17. 
 
AAMP15 has six basic arginine residues; three are added to both the N-terminus and C-terminus 
of the peptide with a net charge of 8.  
 
Table 5-1: AAMPS and AAMPs containing MiniPEGs 











1 AAMP11 RGKLVFFGR 1078.31 40 3 25 % 
2 AAMP12 KGKLVFFGK 1022.29 43 4 33 % 
3 AAMP13 EGKLVFFGE 1024.17 28 0 33 % 
4 AAMP14 MinipegGKLVFFGMiniPEG 1057.25 48 2 14 % 
5 AAMP15 RRRGKLVFFGRRR 1709.10 58 8 54 % 
6 AAMP16 KLVFFGR 864.53 18 3 29 % 
7 AAMP17 KLVFFGMiniPEG 854.05 44 2 17 % 
8 AAMP18 KLVFFGK 839.08 27 2 14 % 
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AAMP16, AAMP17, and AAMP18 are modified on the C-terminus of the peptide with glycine 
and arginine, glycine and MiniPEG, or glycine and lysine. These peptides have a net charge of 3, 
2, and 2, respectively. The structure of AAMP17 is shown in Figure 5-13. AAMP19 has a net 
charge of 3 and is modified on the N-terminus with arginine and glycine (a sequence of 
RGKLVFF). Table 5-1 list the sequences of each AAMP, molecular weight, percent yield, net 
charge and ratio of hydrophilic residues to total residues. Each peptide was purified using 
Reverse Phase High Performance Liquid Chromatography (RP-HPLC) and analyzed by LC-MS 
and MALDI-MS.  
 
5.2.2 Synthesis of !,!-Disubstituted Amino Acids (!!AA) 
In the last several years there has been a growing interest in !,!-disubstituted amino acids 
(!!AAs) due to its stability toward racemization in vivo and restricted conformational 
flexibility.
42
 Conformational flexibility is important for secondary structures, which could to lead 
to resistance against chemical and enzymatic degradation.
42,43
 !!AAs are present in many 
biologically active compounds and some antibiotics, such as altemicidin.
42
 !!AAs have been 
added into AAMP library as a way to disrupt A" and to reduce the conformational freedom that 
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Three !!AAs were synthesized using different protocols and included !,!-dibenzylglycine 
(Dbzg), !,!-diisobutylglycine (Dibg), and !,!-dipropylglycine (Dpg). Each !!AAs is sterically 
hindered due to branched side chains and it loses its chirality. Figure 5-14 shows the structure of 
each !!AAs. Dbzg is similar to phenylalanine except it contains an additional benzyl 
functionality at the !-carbon. Dibg is similar to leucine except it has an additional isopropyl 
group at the !-carbon of the amino acid. The structure of Dpg is different from the other !!AAs. 
Its structure is comparable to leucine but it contains two propyl groups. All !!AAs, Dbzg, Dpg, 
and Dibg were previously synthesized in our laboratory.  
 
5.2.3 Synthesis of AAMPS with !,!-Disubstituted Amino Acids  
Coupling of !!AAs to peptides is difficult due to the steric hindrance of the side chain. 
To improve coupling yields, several changes were employed: 1) MARs Microwave heating was 
used to couple the !!AAs and the remaining amino acid residues in the peptide sequence 2) 
double coupling (coupling the same amino acid residue twice before the Fmoc group is removed) 
was used to ensure successful coupling of the !!AAs to the resin 3) different coupling agents 
were used including HATU and PyAOP. Peptides containing !!AAs were synthesized in 2 
separate steps. All peptides AAMP20, AAMP21, AAMP22, and AAMP23 were synthesized 
using Rink-Amide. In Step 1, standard coupling reagents were used for SPPS including HBTU, 
HOBT in 1M DIEA and DMF. In Step 2, coupling agents HATU/HOBT or PyAOP/HOBT in 
1M DIEA in DMF solution was used. For example, AAMP20 has a one-letter code of 
KLVFFDpgGK and the initial sequence of AAMP20 (GK) was synthesized using SPPS and 
washed with DMF, as shown in Scheme 5-3. Once removed from the peptide synthesizer the 
resin was washed with DMF and swelled in DMF for one hour followed by the removal of the 
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Fmoc group. A deblock solution of DBU, piperdine, and DMF (ratio of 2/5/93) was used to 
remove the Fmoc group from the resin. 
  
 
Scheme 5-3: Step 1 solid phase peptide synthesis of AAMP20. 
 
Step 2 begins with double coupling of the first !!AA (Dpg) to the resin containing GK using 
MARs Microwave heating. Into a MARs Microwave vessel containing the swelled resin with 
GK a 1M solution of DIEA in DMF with Dpg, PyAOP, and HOBT was added and reacted for 10 
minutes at 95°C, see Scheme 5-4. The time period for coupling is determined by the amino acid 
being coupled (see experimental protocol). 
 
1. DMF 5 x 30 s
2. 5% Piperdine, 
    2% DBU, &
    95% DMF
2. LYS, HBTU,        
    HOBT in 1M        
    DIEA for 1.5h
2. GLY, HBTU,       
    HOBT in 1M        






























1. DMF 5 x 30 s
1. DMF 5 x 30 s
2. 5% Piperdine, 
    2% DBU, &
    95% DMF
1. DMF 5 x 30 s
 
!
! ! 162 
 
Scheme 5-4: Step 2 Microwave Chemistry used to complete synthesis of AAMP20 
 
Since Dpg was the first amino acid coupled using microwave heating and due to steric hindrance, 
this amino acid was doubled coupled. The resin is then removed from the vessel, washed with 
DMF, and the Fmoc protecting group is removed. A deblock solution of DBU, piperdine, and 
DMF (ratio of 2/5/93) was used to remove the Fmoc group from the resin. The free amine was 
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then washed with DMF and the fourth amino acid phenylalanine was coupled using a 1M 
solution of DIEA in DMF with HBTU and HOBT for 5 min at 75°C, as shown in Scheme 5-4. 
Coupling after !!AAs can be difficult due to the steric hindrance from the side chain, to ensure 
efficient coupling, phenylalanine was doubled coupled (see step with parenthesis in Scheme 5-4). 
The resin was then removed form the vessel and washed with DMF. Standard coupling 
conditions were used to couple the remaining sequence. The net charge of AAMP20 was 3 at pH 
7, see Scheme 5-4 for the complete structure. This peptide is similar to AAMP12 and AAMP17 
but includes a sterically hindered amino acid Dpg. 
 
 
Figure 5-15: Structure of AAMP21. 
 
AAMP21 has a sequence of KGK(Dibg)VFFGK and is similar to AAMP12. This peptide has a 
disrupted KLVFF sequence. Leucine is replaced with Dibg, two basic and two nonpolar residues 
were placed on both the N-terminus and C-terminus of the peptide. The structure of AAMP21 is 
shown in Figure 5-15 and has a net charge of 4 at pH 7. AAMP22 has a one-letter code of 
K(Dibg)VFF(Dpg)GKKK and has two !!AAs. Leucine and alanine are removed from the 
hydrophobic core and substituted with Dibg and Dpg respectively along with a spacer glycine 
and three basic amino acids incorporated on the C-terminus of the peptide. See Figure 5-16 for 
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Figure 5-16: Structure of AAMP22. 
 
AAMP23 has a sequence of KKKGKLVFF(Dpg)GKKK. This peptide has three basic lysine 
groups and added to both the N-terminus and C-terminus. AAMP23 also contains a Dpg 
immediately after the hydrophobic core. It has a net charge of 8 at pH 7. Figure 5-17 shows the 
structure of AAMP23. 
 
 
Figure 5-17: Structure of AAMP23. 
 
AAMP24 has a one-letter code of K(Dibg)VFFGKKK. Leucine is substituted with Dibg 
breaking the KLVFF sequence three basic lysine groups added to the C-terminus of the peptide. 
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Figure 5-18: Structure of AAMP24. 
 
AAMP25 has a sequence of KLVFFF(Dpg)GKKK. This peptide is modified on the C-terminus 
with two nonpolar phenylalanine residues, glycine and one !!AA Dpg. In addition, three basic 
lysine residues are added to counteract the hydrophobic character of the sequence. The structure 
of AAMP25 is shown in Figure 5-19 and has a net charge of 5 at pH 7. 
 
 
Figure 5-19: Structure of AAMP25. 
 
Each peptide was purified using chromatographic techniques (High Performance Liquid 
Chromatography) and analyzed by Mass Spectrometry (MALDI-MS).
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sequences of each AAMP, molecular weight, percent yield, net charge and ratio of hydrophilic 
residues to total residues. 
 
Table 5-2: Amyloid Aggregating Mitigating Peptides with !!AAs 











1 AAMP20 KLVFF(Dpg)GK 980.29 22 3 25 % 
2 AAMP21 KGK(Dibg)VFFGK 1081.42  4 38 % 
3 AAMP22 K(Dibg)VFF(Dpg)GKKK 1294.75  5 33 % 
4 AAMP23 KKKGKLVFF(Dpg)GKKK 1626.19  8 54 % 
5 AAMP24 K(Dibg)VFFGKKK 1153.54  5 50 % 
6 AAMP25 KLVFFF(Dpg)GKKK 1385.82  5 40 % 
 
5.3 Characterization of AAMPs using Circular Dichroism 
Conformational studies of the AAMP library was conducted in 50 mM PBS containing 
150 mM NaCl salt with 0.02% azide at pH of 7.4 using AVIV 620S Circular Dichroism 
Spectrometer using 1 mm cell at 25 degree’s Celsius. All CD Spectra shows the amide region 
190 nm to 240 nm. For the purposes of this study a membrane-mimicking system (50 mM PBS 
containing 150 mM NaCl salt with 0.02% azide at pH of 7.4) was used because it mimics the in 
vitro environment. The wavelength was plotted verses molar ellipticity to compare the 
differences in concentrations. The molar ellipticity (") of each compound was calculated. All 
spectrums correspond to an average of three scans and the baseline was corrected using peptide 
free solutions. Random coil structures typically show strong peaks at 200 nm (negative peak), at 
218 nm (positive peak), and a peak at 220 nm (negative peak).
42
 !-helix structures consist of 
three peaks, two peaks at 222 nm and 208 nm (negative peaks), and a peak at 190 nm (positive 
peak).
47
 #-sheet conformations have characteristic peaks at 195 nm (positive peak) and at 216 nm 
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(negative peak).
47-48,49
 When monomeric proteins aggregate there is an increase in !-sheet 
character. 
 
5.3.1 Circular Dichroism of AAMPs at Various Concentrations 
Each AAMP was tested at various concentrations of 50 µM, 100 µM, 200 µM, 300 µM, 
400 µM, and 500 µM in a membrane-mimicking environment. This investigation was performed 
to determine the changes in conformation at each concentration selected for AAMP.  
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AAMP11, AAMP12, and AAMP14 adopted a random coil conformation at the different 
concentrations, as shown in Figure 5-20. AAMP11 and AAMP12 contained a positively charged 
residue (arginine and lysine) on the N-terminus and C-terminus. AAMP14 has the MiniPEG on 
both the N-terminus and C-terminus that does not affect the predicted random coil conformation 
of peptides. AAMP13, as shown in Figure 5-20C has a mixture of random coil and !-helix 
confirmation at all concentrations. The change in conformation might be due to the negatively 
charged glutamic acid on the N-terminus and C-terminus. AAMP15 displays a random coil 
conformation, the positive charges from the 6 arginine residues does not influence the 
conformation at the concentrations tested. 
 
 
Figure 5-21: CD Spectra of AAMP15. 
 
Figure 5-21 shows the CD spectra of AAMP15. The conformation of AAMP16 is slightly 
ambiguous but it favors the characteristics of random coil and !-helix at all concentrations, as 
shown in Figure 5-22A. AAMP17 has the MiniPEG on the C-terminus of the peptide and 
displays a mixture of random coil and !-helix conformation at the concentrations tested, as 
shown in Figure 5-22B. AAMP18 displays a mixture of random coil and !-helix conformation at 
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the various concentrations tested. AAMP18 (KLVFFGK) has a sequence that is similar to 
AAMP16 (KLVFFGR). The addition of the positively charged lysine and arginine on the N-
terminus may increase the !-helix nature that is observed in Figure 5-22A and Figure 48C.  
 
 
Figure 5-22: CD Spectra of AAMP16 (A), AAMP17 (B), AAMP18 (C). 
 
AAMP19 has a mixture of random coil and !-helix conformation, see Figure 5-23. AAMP19 
(RFKLVFF) is similar to AAMP16 (KLVFFGR) except it has the arginine residue on the N-
terminus of the peptide. The position of the additional amino acids to the hydrophobic core does 
influence the conformational studies of AAMP.  
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Figure 5-23: CD Spectra of AAMP19. 
 
Web-based programs were used to assess the percentage of secondary structures present in the 




Table 5-3: Molar Ellipticity of AAMPs Percentage of !-helix and "-sheet 
 K2d2 
200 nm to 240 nm 
# Name Concentration (µM) !-helix "-sheet 
1 AAMP11 50 µM 11.53 % 28.35 % 
 500 µM 67.45 % 3.24 % 
2 AAMP12 50 µM 11.53 % 28.35 % 
 500 µM 67.45 % 3.24 % 
3 AAMP13 50 µM 60.44 % 4.67 % 
 500 µM 84.27 % 1.24 % 
4 AAMP14 50 µM 60.44 % 4.67 % 
 500 µM 84.27% 1.24 % 
5 AAMP15 50 µM 28.84 % 13.66 % 
 500 µM 60.4 % 4.67 % 
6 AAMP16 50 µM 84.44 % 1.23 % 
 500 µM 67.45 % 3.24 % 
7 AAMP17 50 µM 28.84 % 13.66 % 
 500 µM 61.33 % 4.06 % 
8 AAMP18 50 µM 25.42 % 18.35 % 
 500 µM 67.45 % 3.24 % 
9 AAMP19 50 µM 33.07 % 19.46 % 
 500 µM 67.45 % 3.24 % 
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These programs are not very accurate but K2d2 was used to evaluate the secondary structures.
50
 
Table 5-3 lists the percentage of !-helix and "-sheet conformation determined for each 
AAMP11, AAMP12, AAMP13, AAMP14, AAMP15, AAMP16, AAMP17, AAMP18, and 
AAMP19. µM 
Select AAMPs incorporating !!AA was tested at various concentrations of 50 µM, 100 
µM, 200 µM, 300 µM, and 400 µM in a membrane-mimicking environment. Each !!AA has a 




Figure 5-24: CD Spectra of AAMP20. 
 
Figure 5-24 shows the spectra of AAMP20, at all concentrations tested this AAMP produces a !-
helix conformation. In Figure 5-24 two negative peaks are observed at 215 nm and 197 nm and a 
positive peak at 193 nm. !-helix structures consist of three peaks, two peaks at 222 nm and 208 
nm (negative peaks), and a peak at 190 nm (positive peak). The shift in the peaks observed might 
be influenced by the presence of Dpg in AAMP20 sequence of KLVFF(Dpg)GK. The CD 
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spectra of AAMP23 is shown in Figure 5-25 and has a one-letter code of 
KKKGKLVFF(Dpg)GKKK. AAMP23 has an alpha helix conformation at 200 µM and higher. 




Figure 5-25: CD Spectra of AAMP23. 
 
Most conformations contain a mixture of random coil, !-helix, "-sheet, K2D2 program was used 
to estimate the secondary structure of AAMP20 and AAMP23 from its CD spectra.
50
  Table 5-4 
lists the percentage of !-helix and "-sheet conformation for AAMP20 and AAMP23 at 50 µM 
and 500 µM. 
 
Table 5-4: Molar Ellipticity of AAMPs with !,!-Disubstituted Amino Acids 
 K2d2 
200 nm to 240 nm 
# Name Concentration !-helix "-sheet 
1 AAMP20 50 µM 36.77 % 12.31 % 
400 µM 84.27 % 1.24 % 
2 AAMP23 50 µM 23.76 % 23.78 % 
500 µM 61.33 % 4.06 % 
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5.3.2 Circular Dichroism of AAMPs with A! 
 CD was used to determine the effect of A!1-40 alone and A!1-40 with select AAMPs at 40 
µM on Days 1, 3, and 7. CD was used to determine the behavior of AAMP in the presence of A!. 
Select AAMPs (AAMP11, AAMP13, AAMP14, AAMP17, and AAMP18) was tested at 
equimolar concentrations in the presence of A! and aged for one week. The Binding of AAMPs 
with A! would induce a different conformational effect and not form a !-sheet. These 
conformations were assed after 1, 3, and 7 days. Each Figure corresponds to A! (Red line) alone 
and the AAMP was mixed with A! at equimolar concentrations. Figure 5-26 shows the CD 
spectra in the amide region of AAMP11, AAMP13, and AAMP14 on Days 1, 3, and 7. The 
conformation of A!1-40 on Days 1, 3 and 7 is a !-sheet that can be observed in Figures 26, Figure 
5-27, and Figure 5-28. AAMP11, AAMP13, and AAMP14 have a mixture of random coil and "-
helix conformation on Day 1 and Day 3, as shown in Figure 5-26. On Day 7, AAMP11 and 
AAMP14 maintains a mixture of random coil and "-helix conformation. AAMP13 on Day 7 
have a mixture of "-helix and !-sheet conformation, see Figure 5-26. Of these three AAMPs, 
AAMP11 and AAMP14 disrupt or reduce the progression of A! fibrils.  AAMP11 contains 
positively charged residues on the N-terminus and C-terminus and AAMP14 contains a neutral 
charged MiniPEG on the N-terminus and C-terminus; this may result in the disruption of A!1-40 
fibrils.
39
 AAMP13 contains negatively charge glutamic acids that may favor or promote A!1-40 
fibril formation. Figure 5-27 shows the behavior of A!1-40 alone with AAMP17 and AAMP18, 
both are modified on the C-terminus. AAMP17 has a MiniPEG moiety and AAMP18 has a 
positively charged arginine residue. AAMP17 (blue) and AAMP18 (purple) adopted an unusual 
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On Day 1 and Day 3 the conformation that AAMP18 adopts is not clear. AAMP18 may contain a 
mixture of random coil and alpha helix conformation on Day7. AAMP17 and AAMP18 have a 
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 To determine effect of the AAMPs containing the !!AA on A"1-40 fibril formation each 
AAMP (AAMP20, AAMP22, AAMP24, and AAMP25) was tested at equimolar concentrations 
in the presence of A"1-40  and aged for one week. Figure 5-28 shows A"1-40  (red line) alone, and 
A"1-40  with AAMP20, AAMP22, AAMP24, and AAMP25 at equimolar on days 1, 3, and 7. 
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AAMP20, AAMP22, AAMP23, and AAMP24 in the presence of A!1-40 have a mixture of 
random coil and "-helix conformation on Days 1, 3, and 7. The ""AA AAMPs may disrupt A!1-











! ! 177 
AAMP20, AAMP24, and AAMP25 contain one !!AA and AAMP22 contains two !!AAs. This 
shows that the presence of !!AA in a peptide that is placed near or in the KLVFF sequence may 
disrupt or reduce the progression of fibril formation. 
 
5.4 Thioflavin-T Assay (ThT) 
ThioflavinT assay (ThT) is a cationic benzothiazole dye that is used to detect amyloid 
fibrils.
51
 ThT exhibits a strong fluorescence when it binds to amyloid fibrils causing the dye to 
have a 120 nm red shift emission spectrum upon excitation at 442 nm.
51
 The emission band at 
482 nm occurs if fibrils are present. ThT assay was used to evaluate AAMPs with or without A!, 
MiniPEG, and !!AA. AAMP11, AAMP12, AAMP13, AAMP14, AAMP15, AAMP16, 
AAMP17, AAMP18, and AAMP19 were evaluated with A! for one week, as shown in Figure 5-
29. AAMP11, AAMP12, AAMP13, AAMP14, and AAMP15 were modified on the N-terminus 
and the C-terminus with polar positively charge amino acids, negatively charged amino acids, or 
neutral MiniPEGs.
39
 These peptides exhibited a reduction in ThT fluorescence of ~ 15% to 70%. 




AAMP16, AAMP17, and AAMP18 were modified on the C-terminus with positively 
charged residues and/or a neutral MiniPEG. AAMP17 and AAMP18 were evaluated on Day 3 
and Day 7 only. AAMP16, AAMP17, and AAMP18 had a reduction in ThT fluorescence of ~ 
55% to 80 %, see Figure 5-29.  AAMP16 showed the greatest reduction (80%) in A!1-40 in the 
presence of Th-T. AAMP17 and AAMP18 showed a higher reduction on Day 7. Modification on 
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Adding a polar arginine to the N-terminus for AAMP19 reduced ThT fluorescence on Day 7 ~ 
85%, see Figure 5-29.  
ThT fluorescence AAMP20 and AAMP23 are shown in Figure 5-30. AAMP20 reduced 
A!1-40 fibril formation by ~ 40% on Day3 and ~ 85 % on Day7. AAMP23 has the greatest 
inhibition compared to AAMP20 with a reduction of 80% on Day3 and 95% on Day7. AAMP20 
contains modification on the N-terminus with Dpg and a polar lysine group. AAMP23 contains 
modification on the N-terminus and C-terminus with polar lysine and Dpg. In conclusion of the 
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Figure 5-30: Time dependent ThT fluorescence AAMPs containing !!AA. 
 
5.5 Conclusions  
An approach to establish a new treatment for AD is to use amyloid aggregating 
mitigating peptides (AAMPs) that are able to bind to A" and inhibit fibril formation. These 
peptides contain the KLVFF (or KLVFFA) motif, which is apart of the hydrophobic core of A". 
There are three different components to the AAMP library containing AAMPs that are modified 
on the N-terminus and/or C-terminus with polar amino acids that are negatively or positively 
charged amino acids, MiniPEGs, or the novel !!AA. These AAMPs were designed and 
synthesized with the aim of reducing the overall charge or sizes of these mitigating peptides.
39
 
The AAMP library was synthesized using SPPS and/or Microwave Chemistry with percent 
yields greater than 18%. Each AAMP was purified using RP-HPLC, confirmed using MALDI-
MS, and characterized using CD.  
A concentration study using CD was performed with select AAMPs (AAMP11, 
AAMP12, AAMP13, AAMP14, AAMP15, AAMP16, AAMP17, AAMP18, AAMP19, 



























! ! 180 
environment. The previously mentioned peptides formed a mixture of random coil and !-helix. 
K2D2, a program used to determine the secondary structure of peptides, estimated !-helix 
conformation was present in most of the CD spectra ranging from 12% to 84% of the select 
AAMPs studied by CD. The AAMP library was evaluated with A"1-40 on Days 1, 3, and 7 using 
CD. The AAMPs tested with A"1-40 were AAMP11, AAMP13, AAMP14, AAMP17, AAMP18, 
AAMP20, AAMP22, AAMP24 and AAMP25. A"1-40 has a "-sheet conformation on Days 1, 3, 
and 7. A"1-40 in the presence of select AAMPs (AAMP1, AAMP14, and AAMP20 -25) have a 
mixture of random coil and !-helix conformation on Days 1, 3, and 7. AAMP17 and AAMP18 
produced an unusual CD spectra that might be a "-sheet conformation for AAMP17 and random 
coil for AAMP18. However, this suggestion is conclusive. Select AAMPs containing !!AA 
(AAMP20, AAMP22, AAMP24, and AAMP25) maintained a mixture of random coil and an !-
helix conformation on Days 1, 3, and 7 in the presence of A"1-40. AAMP20, AAMP22, and 
AAMP24 did not have any significant difference in conformation.  
A"1-40 fibrilic formation was observed using ThT fluorescence assay. ThT in the presence 
of A" fibrils will produce a red shifted emission at 484 nm. Thioflavin-T Assay was used to 
confirm the growth of A" fibrils and if any reduction in A" fibril formation is observed with the 
AAMP library. The AAMPs were evaluated on Days 3 and 7 with A". In conclusion of the ThT 
results AAMP11, AAMP16, and AAMP23 produced the greatest reduction in ThT fluorescence. 
AAMP11 was modified on the N-terminus and C-terminus with polar amino acids and produced 
a 70% reduction in A"1-40 fibrils as observed by ThT. AAMP16 was modified on the C-terminus 
with polar amino acids and produced a 80% reduction in A"1-40 fibrils. AAMP23 was modified 
on the N-terminus and C-terminus with polar amino acids and contains Dpg with an 80% 
reduction of A"1-40 fibrils. 
 
!
! ! 181 
Modification of the N-terminus and C-terminus of the KLVFF sequence with polar amino 
acids that contain a positive charge and !!AA can disrupt or reduce A"1-40 fibrils. AAMP11, 
AAMP16, and AAMP23 may provide a new avenue to treating AD.  
 
5.6 Experimental Procedures 
5.6.1 Solid Phase Peptide Synthesis  
Peptide sequences were prepared on an automated peptides synthesizer (Applied 
Biosystems Pioneer, Peptide Synthesis System) in a 0.2mmole scale following standard Fmoc 
strategy.  A 4-fold excess of the Fmoc protected amino acids were coupled to Fmoc-Pal-PEG 
resin. Sequence was design according to the desired peptide.
3
 Fmoc Deprotection: The resin-
bound Fmoc peptide was treated with 93% DMF, 5% Piperidine and 2% DBU once for 3 
minutes, once for 5 minutes, and once for 10 minutes. The resin is then washed with DMF. 
HBTU/HOBT Coupling: A solution of amino acid (dependent on peptide being prepared) (4 eq), 
HBTU (4 eq), HOBT (4 eq), 1M DIEA in DMF (~6 eq) was added to the resin bound free amine 
and followed by washing with DMF. PYAOP/HOAT Coupling: A solution of amino acid 
(dependent on peptide being prepared) (4 eq), PyAOP (4 eq), HOAT (4 eq), 1M DIEA in DMF 
(~6 eq) was added to the resin bound free amine and followed by washing with DMF. Drying 
Resin: Once peptide is removed from synthesizer it is washed with DMF (5 x 30s) and then 
washed with DCM (3 x 30s) and dried in high vacuum overnight.  Cleaving Peptide From Resin: 
A cleavage cocktail of TFA (88%), Water (5%), Liquified phenol (5%) and Triisopropylphenol 
(2%) is added to the resin for 3 – 5 hours. The cocktail was then released into cold (-80°C) 
anhydrous ethyl ether, and centrifuged. The supernatant was decanted and washed several times 
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more with cold anhydrous ethyl ether. The solid was dissolved using water and acetonitrile, 
freeze dried, and lypohlized. 
 
5.6.2 Generation of !,!-Disubstituted Amino Acids 
All !,!-disubstituted amino acids including !,!-dibenzylglycine (Dbzg), !,!-
diisobutylglycine (Dibg), and !,!-dipropylglycine (Dpg) was previously synthesized in house. 
 
5.6.3 MARs Microwave Peptide Synthesis 
Initial peptide sequences were prepared on an automated peptides synthesizer. MARs 
Microwave Chemistry was used to couple !!AA to the desired peptide sequence and remaining 
residues, see Table 5-5 for protocol. PYAOP/HOAT Coupling: A solution of amino acid 
(dependent on peptide being prepared) (4 eq), PyAOP (4 eq), HOAT (4 eq), 1M DIEA in DMF 
(~6 eq) was added to the resin bound free amine and followed by washing with DMF. Drying 
Resin: Once peptide is removed from synthesizer it is washed with DMF (5 x 30s) and then 
washed with DCM (3 x 30s) and dried in high vacuum overnight.  
 
Table 5-5: Microwave Conditions 
# Name Ramp To 
Temperature 
Power (watts) Coupling 
Time 
Degrees 
1 Natural Amino Acid 1.0 minute 400 5.0 min < 75°C 
2 !!AAs  1.0 minute 400 10 min < 95°C 
3 Symmetrical Anhydride Val 1.0 minute 400 20 min < 75°C 
 
Cleaving Peptide From Resin: A cleavage cocktail of TFA (88%), Water (5%), Liquified phenol 
(5%) and Triisopropylphenol (2%) is added to the resin for 3 – 5 hours. The cocktail was then 
released into cold (-80°C) anhydrous ethyl ether, and centrifuged. The supernatant was decanted 
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and washed several times more with cold anhydrous ethyl ether. The solid was dissolved in a 
mixture of water and acetonitrile, freeze dried and lyopohlized. 
 
5.6.4 Purification of Peptides 
RP-HPLC purification was performed on a Waters system including a 486 Absorbance 
UV detector (MeCN 10-100%) and confirmed using LC-MS. The solvents used to purify 
peptides were Water and Acetonitrile with 0.1% TFA. 
 
5.6.5 Characterization of Peptides 
Various concentrations of the peptides were prepared in 0.5 mM PBS with 10% TFE was 
measured using AVIV 620S Circular Dichroism Spectrometer using 1mm cell at 25 degree’s 
Celsius. The wavelength was plotted verses Molar Ellipicity to compare the differences in 
concentrations adjusted to pH 7 using concentrated NaOH solution. The molar ellipticity (!) of 
each compound was calculated. All spectrums correspond to an average of three scans and the 




5.6.6 Thioflavin-T Assay 
A 100 µM ThT stock solution was prepared in autoclaved water. An 80 µM stock of A" 
1-40 was prepared in PBS buffer (150 mM PBS and 150 NaCl, pH 7.4) and was allowed to shake 
at 37°C. A" 1-40 was mixed with various AAMPs under the same conditions and allowed to 
shake at 37°C. At different stages of aggregation (Days 1, 3, and 7), 10uL of sample (A" 1-40 
with and without AAMP), 10uL of Thioflavin T Assay, & 180uL of PBS (150 mM PBS and 150 
NaCl, pH 7.4) was combined in a clear 96-well plate (Corning or Falcon). Fluorescence of ThT 
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was measured using BMG, LAB TECH spectrophotometer (excitation 440 nm and emission 480 
nm). Preparation of A! Purchased lyophilized A! was dissolved in neat TFA at 1mg/mL and 
sonicated for 10-15 minutes. Evaporation of TFA using centri-vacuum yielded dark yellow oil, 
which was re-dissolved in 1ml of HFIP (1mg/mL) and incubated at 37ºC for 1 hour and 30 
minutes. A! was then split into two eppendorf tubes evenly (splitting the A! makes it easier to 
solubilize). Removal of HFIP via centri-vacuum yielded a white powder. The HFIP cycle was 
repeated and the resulting powder lyophilized overnight. An 80 uM A! stock solution was then 
prepared. The white powder was then re-dissolved in 2mM KOH and 2 x PBS (100mM, 300mM 
NaCl, Ph 7.4) at 1:1 and centrifuged for 20 minutes at 13,000g. Prepare an80uM stock solution 
for each AAMP. Mix A! 1:1 with AAMP. From this stock the A! with AAMP mixture is spotted 
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APPENDIX A CHAPTER 2 
This data is associated with the results of chapter 2 that includes circular dichroism, HPLC, ESI-





Table 1: Calculation of EGFR-L1 and EGFR-L1-D1 for Theata 





 Name Concentration 10 % TFE/H2O  
at pH 7.00  
0.5mM PBS with  
10% TFE at pH 7.4 
1 EGFR-L1 1000 µM -1241275 (198 nm) -1416667 (197) 
750 µM - -1066666 (197) 
500 µM -661545 (197 nm) -700000 (197) 
250 µM -2621499 (198 nm) -3133324 (197) 
125 µM -174225 (196 nm) -186666 (197) 
75 µM -5824 (199 nm) -106667 (197) 
2 EGFR-L1-D1 1000 µM -417382 (197 nm) -440898 (197) 
750 µM - - 
500 µM -134559 (197 nm) -202969 (197) 
250 µM -45967 (196 nm) -56799 (197) 
125 µM -8048 (198 nm) -13956 (197) 
75 µM -4867 (196 nm) -4958 (197) 
 
 
Table 2: Calculation of EGFR-L2, EGFR-L2-D1, and EGFR-L1-GLY for Theata 





 Name Concentration 10 % TFE/H2O  
at pH 7.00  
0.5mM PBS with  
10% TFE at pH 7.4 
1 EGFR-L2 1000 µM -119607 (213 nm) -125742 (215 nm) 
750 µM - -157777 (213 nm) 
500 µM 
-161303 (205 nm) 
-100414 (216 nm) 
-156379 (205 nm) 
-141407 (212 nm) 
250 µM 
-90488 (198 nm) 
-38492 (216 nm) 
-111197 (204 nm) 
-64174 (218 nm) 
125 µM -56123 (197 nm) -71012 (198 nm) 
75 µM -12750  (199 nm) -3946 (205 nm) 
2 EGFR-L2-D1 1000 µM -170890 (212 nm) -232581 (216 nm) 
750 µM - -197452 (200 nm) 
500 µM 
-141506 (203 nm) 
-68842 (217 nm) 
-191680 (205 nm) 
-133152 (216 nm) 
250 µM 
-29550 (198 nm) 
50303 (216 nm) 
-124204 (200 nm) 
-64883 (217 nm) 
!
! 191 
125 µM -7559 (200 nm) -68005 (200 nm) 
75 µM -5556 (200 nm) -23237 (200 nm) 
3 EGFR-L2-GLY 1000 µM - -115219 (211 nm) 
750 µM 
- -105713 (210 nm) 
-136641 (216 nm) 
500 µM 
- -143873 (208 nm) 
-150289 (213 nm) 
250 µM 
- -98552 (203 nm) 
-74310 (213 nm) 
125 µM - -60480 (197 nm) 
75 µM - -29236 (198 nm) 
 
 
Table 3: Calculation of EGFR-L1-3PEG and EGFR-L2-3PEG for Theata 





 Name Concentration 10 % TFE/H2O  
at pH 7.00  
0.5mM PBS with  
10% TFE at pH 7.4 
1 EGFR-L1-3PEG 
300 µM 
- -43154 (204 nm) 
-35767 (224 nm) 
275 µM 
- -30873 (207 nm) 
-28718 (222 nm) 
250 µM - -21289 (207 nm) 
125 µM - -18049 (203 nm) 
50 µM - -37040 (208 nm) 
2 EGFR-L2-3PEG 
300 µM 
-70655 (203 nm) 
577431 (216 nm) - 
275 µM 
-71608 (204 nm) 
-49761 (216 nm) - 
250 µM 
-67843 (204 nm) 
-47407 (216 nm) - 
125 µM -40000 (198 nm) - 














Figure 1: HPLC chromatogram of EGFR-L1. 
 
Figure 1 shows the chromatogram of EGFR-L1 using RP-HPLC with a C18 column. Gradient 
used is shown in Table 4.  
 
Table 4: Gradient for EGFR-L1 
# Time Flow % of H2O  % of ACN 
1  1.00 90 10 
2 1.00 1.00 90 10 
3 35.00 1.00 30 70 











Figure 2: HPLC chromatogram of EGFR-L2. 
 
Figure 2 shows the chromatogram of EGFR-L2 using RP-HPLC with a C18 column. Gradient 
used is shown in Table 2.  
 
Table 5: Gradient for EGFR-L2 
# Time Flow % of H2O  % of ACN 
1  1.00 10 90 
2 1.00 1.00 10 90 
3 35.00 1.00 70 30 














Figure 3: HPLC chromatogram of EGFR-L1-GLY. 
 
Figure 3 shows the chromatogram of EGFR-L1-GLY using RP-HPLC with a C18 column. 
Gradient used is shown in Table 6.  
 
Table 6: Gradient for EGFR-L1-GLY 
# Time Flow % of H2O  % of ACN 
1  1.00 90 10 
2 1.00 1.00 90 10 
3 35.00 1.00 30 70 












Figure 4: HPLC chromatogram of EGFR-L2-GLY. 
 
Figure 4 shows the chromatogram of EGFR-L2-GLY using RP-HPLC with a C18 column. 
Gradient used is shown in Table 7.  
 
Table 7: Gradient for EGFR-L2-GLY 
# Time Flow % of H2O  % of ACN 
1  5.00 90 10 
2 1.00 5.00 90 10 
3 35.00 5.00 10 90 











Figure 5: HPLC chromatogram of EGFR-L1-D1. 
 
Figure 5 shows the chromatogram of EGFR-L1-D1 using RP-HPLC with a C18 column. 
Gradient used is shown in Table 8.  
 
Table 8: Gradient for EGFR-L1-D1 
# Time Flow % of H2O  % of ACN 
1  1.00 10 90 
2 1.00 1.00 10 90 
3 30.00 1.00 70 30 














Figure 6: HPLC chromatogram of EGFR-L2-D1. 
 
Figure 6 shows the chromatogram of EGFR-L2-D1 using RP-HPLC with a C18 column. 
Gradient used is shown in Table 9.  
 
Table 9: Gradient for EGFR-L2-D1 
# Time Flow % of H2O  % of ACN 
1  1.00 10 90 
2 1.00 1.00 10 90 
3 30.00 1.00 70 30 











Figure 7: HPLC chromatogram of EGFR-L2-SAR. 
 
Figure 7 shows the chromatogram of EGFR-L2-SAR using RP-HPLC with a C18 column. 
Gradient used is shown in Table 10.  
 
Table 10: Gradient for EGFR-L2-SAR 
# Time Flow % of H2O  % of ACN 
1  0.8 90 10 
2 1.00 0.8 90 10 
3 57.00 0.8 10 90 














Figure 8: HPLC chromatogram of EGFR-L1-3PEG-Fmoc. 
 
Figure 8 shows the chromatogram of EGFR-L1-3PEG-Fmoc using RP-HPLC with a C18 
column. The gradient used is shown in Table 11.  
 
Table 11: Gradient for EGFR-L1-3PEG-Fmoc 
# Time Flow % of H2O  % of ACN 
1  1.00 95 5 
2 1.00 1.00 95 5 
3 10.00 1.00 95 5 
4 19.00 1.00 5 95 












Figure 9: HPLC chromatogram of EGFR-L2-3PEG. 
 
Figure 9 shows the chromatogram of EGFR-L2-3PEG using RP-HPLC with a C18 column. 
Gradient used is shown in Table 12.  
 
Table 12: Gradient for EGFR-L1-3PEG 
# Time Flow % of H2O  % of ACN 
1  1.00 95 5 
2 1.00 1.00 95 5 
3 10.00 1.00 95 5 
4 19.00 1.00 5 95 











Figure 10: HPLC chromatogram of EGFR-L2-GLY-3PEG. 
 
Figure 10 shows the chromatogram of EGFR-L2-GLY-3PEG using RP-HPLC with a C18 
column. Gradient used is shown in Table 13.  
 
Table 13: Gradient for EGFR-L2-GLY-3PEG 
# Time Flow % of H2O  % of ACN 
1  1.00 100 0 
2 1.00 1.00 100 0 
3 24.00 1.00 0 100 
4 25.00 1.00 100 0 








ESI or MALDI of Peptides and Peptide-PEGs 
 




















































































































H NMR (400MHz) spectrum of EGFR-L1 in DMSO-d6.!
 
EGFR L1 1.1 DMSO.001.esp


















































































H NMR (400MHz) spectrum of EGFR-L2-SAR in DMSO-d6 
 
EGFR_L2_SAR_030712.001.esp



































































































































































H NMR (400MHz) spectrum of EGFR-L2-GLY-3PEG in DMSO-d6.!
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RP-HPLC of Peptide and Peptide-PEGs 
 
 
Figure 1: HPLC chromatogram of EGFR-L1-PEG-MesoPOR. 
 
 
Figure 1 shows the chromatogram of MesoPOR-(m)3PEG using RP-HPLC with a C18 column. 
Gradient used is shown in Table 1.  
 
Table 1: Gradient for EGFR-L1-3PEG-MesoPOR 
# Time Flow % A (H20)  % B (ACN) 
1  4.00 90 10 
2 1.00 4.00 90 10 
3 5.00 4.00 57 43 
4 60.00 4.00 10 90 








Figure 2: HPLC chromatogram of MesoPOR-(di)3PEG. 
 
 
Figure 2 shows the chromatogram of MesoPOR-(di)3PEG using RP-HPLC with a C18 column. 
Gradient used is shown in Table 2.  
 
Table 2: Gradient for MesoPOR-(di)3PEG 
# Time Flow % A (H20)  % B (ACN) 
1  1.00 90 10 
2 1.00 1.00 90 10 
3 10.00 1.00 40 60 
4 40.00 1.00 20 80 
5 43.00 1.00 10 90 











Figure 3: HPLC chromatogram of MesoPOR-(di)3PEG-(di)EGFR-L1. 
 
Figure 3 shows the chromatogram of MesoPOR-(di)3PEG-(di)EGFR-L1 using RP-HPLC with a 
C18 column. Gradient used is shown in Table 3.  
 
 
Table 3: Gradient for MesoPOR-(di)3PEG-(di)EGFR-L1 
# Time Flow % A (H20)  % B (ACN) 
1  1.00 90 10 
2 1.00 1.00 90 10 
3 5.00 1.00 50 50 
4 43.00 1.00 10 90 











Figure 4: HPLC chromatogram of MesoPOR-(m)EGFR-L1. 
 
Figure 4 shows the chromatogram of MesoPOR-(m)EGFR-L1 using RP-HPLC with a C18 
column. Gradient used is shown in Table 4.  
 
Table 4: Gradient for MesoPOR-EGFR-L1 
# Time Flow % of H2O  % of ACN 
1  0.60 90 10 
2 1.00 0.60 90 10 
3 5.00 0.60 50 50 
4 55.00 0.60 44 56 
5 57.00 0.60 10 90 











Figure 5: HPLC chromatogram of MesoPOR-(di)EGFR-L1. 
 
Figure 5 shows the chromatogram of MesoPOR-(di)EGFR-L1 using RP-HPLC with a C18 
column. Gradient used is shown in Table 5.  
 
Table 5: Gradient for MesoPOR-(di)EGFR-L1 
# Time Flow % of H2O  % of ACN 
1  0.60 90 10 
2 1.00 0.60 90 10 
3 5.00 0.60 50 50 
4 60.00 0.60 30 70 











 Figure 6: HPLC chromatogram of MesoPOR-EGFR-L2-SAR. 
 
 
Figure 6 shows the chromatogram of MesoPOR-EGFR-L2-SAR using RP-HPLC with a C18 
column. Gradient used is shown in Table 6.  
 
Table 6: Gradient for MesoPOR-EGFR-L2-SAR 
# Time Flow % B (ACN)  % D (Acetone) 
1  1.00 40 60 
2 1.00 1.00 40 10 






ESI or MALDI of Bioconjugates 
 
 













































































































































































































































































































H NMR (400MHz) spectrum of MesoPOR-(di)PEG-(di)EGFR-L1 in DMF-d7 
MesoPOR_diPEG_diEGFR_L1_030512.001.esp




















































































H NMR (400MHz) spectrum of MesoPOR-(di)PEG-(m)EGFR-L2-GLY in DMF-d7. 
MesoPOR_di3PEG_EGFR_L2_GLY_030312.001.esp
























































































H NMR (400MHz) spectrum of MesoPOR-(m)EGFR-L1 in DMF-d7.!
!
MesoPOR_(m)EGFR_L1.001.esp
























































H NMR (400MHz) spectrum of MesoPOR-(di)EGFR-L1 in DMF-d7.!
PORL1DI_DMF_1H_020911.esp












































































H NMR (400MHz) spectrum of MesoPOR-(m)EGFR-L2-GLY in DMF-d7
MesoPOR_EGFRL2_GLY_022912.001.esp













































































MALDI-MS/MS of Bioconjugates 
 
 
Figure 27 shows the LIFT-TOF/TOF spectrum of m/z 2551.27 and assignment of MesoPOR-
(di)PEG-(di)EGFR-L1 (MesoPOR-(di)PEG-(di)LARLLT) peptide sequence. !
 
Table 7: Ions generated for MesoPOR-(di)PEG-(di)EGFR-L1 
 Name a ions b ions y ions 
00 MesoPOR 928.75 955.77 1640.19 
1 LEU 1040.91 1068.80 683.60 
2 ALA 1111.94 1139.85 572.56 
3 ARG 1295.92 1295.92 501.47 
4 LEU - 1381.10 - 
5 LEU 1494.17 1522.13 - 





Figure 28 shows the LIFT-TOF/TOF spectrum of m/z 2551.27 and assignment of MesoPOR-









Table 8: Ions generated for MesoPOR-diPEG-EGFR-L2-GLY 
 Name a ions b ions y ions 
00 MesoPOR - 955.82 2551.55 
1 GLY - 1012.75 - 
2 TYR 1147.95 1175.79 - 
3 HIS 1285.05 1312.88 - 
4 TRP 1471.15 1498.80 - 
5 TYR 1634.24 1661.97 - 
6 GLY  1719.10 - 
7 TYR 1854.46 1882.10 - 
8 THR 1955.44 1982.10 - 
9 PRO - - - 
10 GLN 2180.57 2208.38 475.34 
11 ASN 2293.48 2322.09 - 
12 VAL 2393.56 2422.55 - 




Figure 29 shows the LIFT-TOF/TOF spectrum of m/z 1233.91 and assignment of MesoPOR-
EGFR-L1 peptide sequence. Both a and b ions confirms the sequence.!
 
Table 9: Ions generated for MesoPOR-EGFR-L1 
 Name a ions b ions y ions 
00 MesoPOR 523.26 - 1233.78 
1 LEU 637.94 549.84  
2 ALA 708.74 662.39 572.32 
3 ARG - 733.42 501.27 
4 LEU 974.69 889.57 - 
5 LEU -  - 







Figure 30 shows the LIFT-TOF/TOF spectrum of m/z 1900.39 and assignment of MesoPOR-
(di)EGFR-L1 (MesoPOR-LARLLT) peptide sequence. !
 
Table 10: Ions generated for MesoPOR-(di)EGFR-L1 
 Name a ions b ions y ions 
00 MesoPOR - - 1900.33 
1 LEU - 550.19 1352.78 
2 ALA - 662.39 1239.81 
3 ARG - - 501.19c 
4 LEU - - - 
5 LEU - 1783.07c - 







Figure 31 shows the LIFT-TOF/TOF spectrum of m/z 2145.23 and assignment of MesoPOR-
EGFR-L2-GLY (MesoPOR-GYHYWYTPGQNVI) peptide sequence. !
Table 11: Ions generated for MesoPOR-(m)EGFR-L2-GLY 
 Name a ions b ions y ions 
00 MesoPOR 522.19 549.24 2145.23 
1 GLY 578.27 606.27 - 
2 TYR 741.39 768.36 1537.79 
3 HIS 878.50 906.45 - 
4 TRP 1064.64 1092.57 - 
5 TYR 1227.74 1255.62 - 
6 GLY 1284.72 1312.68 892.43 
7 TYR 1447.82 1475.80 - 
8 THR 1548.92 1576.79 - 
9 PRO - 1673.89 567.22 
10 GLN 1773.87 1801.94 - 
11 ASN 1887.99 1915.98 - 
12 VAL 1987.05 2015.04 - 





Figure 32 shows the LIFT-TOF/TOF spectrum of m/z 2159.15 and assignment of MesoPOR-
EGFR-L2-SAR (MesoPOR-GYHYWYTPGQNVI) peptide sequence. !
 
Table 12: Ions generated for MesoPOR-EGFR-L2-SAR 
 Name a ions b ions y ions 
00 MesoPOR - 565.09 - 
1 GLY 594.16 620.15 - 
2 TYR 755.29 783.25 - 
3 HIS 892.39 920.35 - 
4 TYR 1078.52 1106.43 - 
5 TRP 1241.64 1269.54 - 
6 TYR 1298.68 1326.56 - 
7 THR 1461.77 1489.68 - 
8 PRO 1562.87 1590.72 - 
9 GLN 1789.85 - - 
10 ASN - 1816.01 - 
11 VAL - 1929.93 - 
12 ILE 2001.96 2028.03 - 
!
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This data is associated with the results of chapter 5 that includes HPLC and MALDI-MS. 
 
HPLC of AAMPs 
 
 
Figure 1: RP-HPLC chromatogram of AAMP11 with a RT of 14.093. 
 
Figure 1 shows the RP-HPLC chromatogram of AAMP11. AAMP11 has a retention time of 
14.09. Table 1 has the gradient conditions for AAMP11. 
 
Table 1: Gradient for AAMP11 
 Time Flow H2O ACN 
1  1.00 90 10 
2 20 1.00 60 40 
3 21 1.00 90 10 










Figure 2: RP-HPLC Chromatogram of AAMP12 with a RT of 7.178. 
 
Figure 2 shows the RP-HPLC chromatogram of AAMP12. AAMP12 has a retention time of 
7.17. Table 2 has the gradient conditions for AAMP12. 
 
Table 2: Gradient for AAMP12 
 Time Flow H2O ACN 
1  1.00 80 20 
2 20 1.00 60 40 
3 21 1.00 80 20 












Figure 3: RP-HPLC Chromatogram of AAMP13 with a RT of 11.62. 
 
Figure 3 shows the RP-HPLC chromatogram of AAMP13. AAMP13 has a retention time of 
11.62. Table 3 has the gradient conditions for AAMP13. 
 
Table 3: Gradient for AAMP13 
 Time Flow H2O ACN 
1  1.00 80 20 
2 20 1.00 60 40 
3 21 1.00 80 20 











Figure 4: RP-HPLC Chromatogram of AAMP14 with a RT of 12.24. 
 
Figure 4 shows the RP-HPLC chromatogram of AAMP14. AAMP14 has a retention time of 
12.24. Table 4 has the gradient conditions for AAMP14. 
 
Table 4: Gradient for AAMP14 
 Time Flow H2O ACN 
1  1.00 90 10 
2 20 1.00 60 40 
3 21 1.00 90 10 











Figure 5: RP-HPLC Chromatogram of AAMP15 with a RT of 10.93. 
 
Figure 5 shows the RP-HPLC chromatogram of AAMP15. AAMP15 has a retention time of 
10.93. Table 5 has the gradient conditions for AAMP15. 
 
Table 5: Gradient for AAMP15 
 Time Flow H2O ACN 
1  1.00 90 10 
2 20 1.00 60 40 
3 21 1.00 90 10 











Figure 6: RP-HPLC Chromatogram of AAMP16 with a RT of 14.63. 
 
Figure 6 shows the RP-HPLC chromatogram of AAMP6. AAMP16 has a retention time of 
14.63. Table 6 has the gradient conditions for AAMP16. 
 
Table 6: Gradient for AAMP16 
 Time Flow H2O ACN 
1  1.00 90 10 
2 20 1.00 60 40 
3 21 1.00 90 10 











Figure 7: RP-HPLC Chromatogram of AAMP18 with a RT of 24.55. 
 
Figure 7 shows the RP-HPLC chromatogram of AAMP18. AAMP18 has a retention time of 
24.55. Table 7 has the gradient conditions for AAMP18. 
 
Table 7: Gradient for AAMP18 
 Time Flow H2O ACN 
1  1.00 90 10 
2 1 1.00 90 10 
3 20 1.00 60 40 
4 30 1.00 60 40 
5 35 1.00 70 30 










Figure 8: RP-HPLC Chromatogram of AAMP19 with a RT of 23.84. 
 
Figure 8 shows the RP-HPLC chromatogram of AAMP19. AAMP19 has a retention time of 
23.843. Table 8 shows the gradient conditions for AAMP19. 
 
Table 8: Gradient for AAMP19 
 Time Flow H2O ACN 
1  1.00 90 10 
2 1 1.00 90 10 
3 20 1.00 60 40 
4 30 1.00 60 40 
5 35 1.00 70 30 










Figure 9: RP-HPLC Chromatogram of AAMP20 with a RT of 34.31. 
 
Figure 9 shows the RP-HPLC of AAMP20. AAMP20 has a retention time of 34.31. Table 9 has 
the gradient conditions for AAMP20. 
 
Table 9: Gradient for AAMP20 
 Time Flow H2O ACN 
1  1.10 90 10 
2 1 1.10 90 10 
3 60 1.10 30 70 











 Figure 10: RP-HPLC Chromatogram of AAMP23 with a RT of 22.11. 
 
Figure 10 shows the RP-HPLC chromatogram of AAMP23. AAMP23 has a retention time of 
22.11 Table 10 has the gradient conditions for AAMP23. 
 
Table 10: Gradient for AAMP23 
 Time Flow H2O ACN 
1  1.00 90 10 
2 1 1.00 90 10 
3 20 1.00 60 40 
4 30 1.00 60 40 
5 35 1.00 70 30 










Figure 11: RP-HPLC Chromatogram of AAMP25 with a RT of 21.84. 
 
Figure 11 shows the RP-HPLC spectrum chromatogram of AAMP25. AAMP25 has a retention 
time of 21.84. Table 11 has the gradient conditions for AAMP25. 
 
Table 11: Gradient for AAMP25 
 Time Flow H2O ACN 
1  1.00 90 10 
2 1 1.00 90 10 
3 20 1.00 60 40 
4 30 1.00 60 40 
5 35 1.00 70 30 
6 36 1.00 90 10 










Figure 12: RP-HPLC Chromatogram of AAMP17 with a RT of 24.65. 
 
Figure 12 shows the RP-HPLC chromatogram of AAMP17. AAMP17 has a retention time of 
24.65. Table 12 has the gradient conditions for AAMP17. 
 
Table 12: Gradient for AAMP14 
 Time Flow H2O ACN 
1  1.00 90 10 
2 20 1.00 60 40 
3 21 1.00 90 10 








ESI-MS or MALDI-MS of AAMPs 
 
 




























Figure 19: MALDI-MS spectrum of AAMP19. 
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